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ABSTRACT 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription 
factor, which, upon translocation into the nucleus, is capable of inducing a 
variety of cytoprotective genes, such as NAD(P)H:quinone oxidoreductase 1 
(Nqo1), glutamate-cysteine ligase, catalytic subunit (Gclc), glutathione-S-
transferases (Gsts), and multidrug-associated resistance proteins (Mrps).  
Because Nrf2 can induce many cytoprotective enzymes and transporters, it is 
a potential target for the prevention of liver injury, for which there are limited 
treatments.   Therefore, it was hypothesized that pharmacologic activation of 
Nrf2 would protect against acetaminophen (AA) hepatotoxicity, and that 
genetic ablation and enhancement of Nrf2 activation would alter 
pharmacokinetics of AA and sulfobromopthalein (BSP).  Pharmacokinetic 
analysis will provide insight into a potentially novel hepatoprotective role for 
Nrf2. 
It was determined whether the natural triterpenoid oleanolic acid and a 
synthetic derivative 2-cyano-3,12-dioxooleana-1,9-diene-28-imidazolide 
(CDDO-Im) could protect liver from AA toxicity through activation of Nrf2.   
  X 
Oleanolic acid increased mRNA expression of the Nrf2 target genes Nqo1, 
Gclc, and heme oxygenase-1 (Ho-1) in wild-type but not in Nrf2-null mice, and 
protected against acetaminophen hepatotoxicity in wild-type mice, but to a 
lesser extent in Nrf2-null mice.   The synthetic triterpenoid CDDO-Im also 
protected the liver from AA-induced injury and induced the Nrf2 target genes 
Nqo1, Gclc, and Ho-1 in a dose- and time-dependent manner.  In contrast, 
this protection and mRNA induction was ablated in Nrf2-null mice.   These 
studies demonstrate that oleanolic acid and CDDO-Im protect the liver from 
AA-induced injury by activating the antioxidant transcription factor Nrf2. 
A recently engineered mouse with knockdown of Keap1 (Keap1-kd 
mice), the cytosolic repressor of Nrf2, has a 55% decrease in Keap1 mRNA 
and a 200% increase in Nrf2 protein in liver.  Several experiments with Nrf2-
null mice have demonstrated the effects of a lack of Nrf2.  However, little is 
known about the biological effects of more Nrf2 activation.  Accordingly, the 
phenotype of Keap1-kd mice, as well as mRNA expression of detoxifying and 
antioxidant genes, were compared with Nrf2-null and wild-type mice.  The 
present study revealed three patterns of gene expression, which collectively 
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suggest that hepatic Nrf2 is more important for the detoxification and 
elimination of electrophiles rather than reactive oxygen species. 
Numerous studies have shown that Nrf2 protects against toxicity, 
which is frequently attributed to decreased toxicodynamic effects of chemical 
insults, as exemplified by increased expression of cytoprotective genes.  
However, the effects of Nrf2 on the kinetics of xenobiotics have not been 
examined.  It was found that Nrf2 increases biliary excretion of BSP by 
increasing glutathione (GSH) conjugation and biliary excretion of the BSP 
conjugate. In addition, lack of Nrf2 decreases AA glucuronidation, leading to 
increased NAPQI formation and hepatotoxicity, whereas activation of Nrf2 
enhances detoxification of NAPQI by Nqo1 and elimination of AA glucuronide 
conjugate via Mrp3.  Therefore, the effects of Nrf2 on the kinetics of 
xenobiotics should also be considered as a means of protection. 
Collectively, these studies have shown that liver can be protected by 
activation of Nrf2, either pharmacologically or genetically, as in the case of 
genetically-engineered Keap1-kd mice.  Nrf2 can also dramatically affect the 
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kinetics of xenobiotics because of its ability to transcriptionally control genes 
important in the biotransformation and excretion of chemicals. 
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GENERAL INTRODUCTION AND BACKGROUND 
  2 
Biotransformation 
Organisms are continually exposed to chemicals, either accidentally as 
in the case of toxic effects from pesticides or purposefully, such as in the 
therapeutic use of pharmaceutics.  Foreign compounds not produced by 
organisms are commonly referred to as xenobiotics.  Xenobiotics are often 
lipophilic and must be biotransformed to increase hydrophilicity and allow for 
excretion into urine or bile.  Thus, biotransformation is critical for maintaining 
homeostasis during xenobiotic exposure, the ultimate goal being to make 
xenobiotics more water soluble for enhanced excretion (Parkinson, 2008).  
Biotransformation chemically changes xenobiotics and has many effects, both 
desirable and undesirable.  The pharmacological effects of drugs are often 
terminated by biotransformation, which can be viewed as desirable for drugs 
for which one hopes to observe a short-term effect, or undesirable when 
drugs have to be administered chronically in order to maintain the preferred 
effect.  Also, some non-toxic xenobiotics can be biotransformed to toxic 
metabolites, which then cause cellular injury.  Finally and most importantly for 
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this dissertation, biotransformation can detoxify potentially harmful 
xenobiotics, which are typically the parent compound or a reactive metabolite.   
The liver is the primary organ where xenobiotics are biotransformed, 
as it is the organ most exposed to xenobiotics and the most abundant source 
for biotransformation enzymes.  Thus, the liver is paramount for protection of 
the whole organism against potentially toxic xenobiotics.  However, the liver 
can be overwhelmed by chemicals, which result in liver injury, dysrepair, or 
liver failure.  Increasing the ability of the liver to biotransform and eliminate 
xenobiotics has become an attractive mechanism for the prevention of liver 
injury. 
Oxidative and electrophilic stress. 
Oxidative stress (Fig 0.1, left side) is caused by increased production 
of reactive oxygen and nitrogen species, such as superoxide, hydroxyl 
radical, and peroxynitrite, or by depletion of protective antioxidants, such as 
reduced glutathione (GSH), ascorbate, and α-tocopherol.  Superoxide is 
formed, as in the case of diquat, when redox cycling occurs, and an electron 
is donated to molecular oxygen. More reactive peroxynitrite and hydroxyl 
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radicals are generated when superoxide is not adequately detoxified as 
discussed below.  Oxidative stress leads to oxidative damage to critical 
macromolecules, namely DNA, lipids, and proteins.  Detoxification of 
superoxide occurs enzymatically by first being converted to hydrogen 
peroxide and then to water by catalase (Cat), glutathione peroxidase (Gpx), 
or peroxiredoxin.   If hydrogen peroxide is not detoxified, it is converted to 
hydroxyl radical by the Fenton reaction.  Hydroxyl radical is almost impossible 
to detoxify because of its short half-life (10-9s), and thus prevention of its 
formation by the detoxification of its precursor hydrogen peroxide by Cat, 
Gpx, or Prx is necessary.  Detoxification of peroxynitrite to nitrite is carried out 
by Gpx and Prx; GSH may also be capable of reducing perxoxynitrite to nitrite 
(Harwood et al., 2006; Trujillo et al., 2008).  
An electrophile is a molecule that contains an electron-deficient atom 
with a partial or full positive charge that allows it to react by sharing electron 
pairs with electron-rich atoms (Parkinson, 2008).  Electrophilic stress (Fig 0.1, 
right side) results when electrophiles overwhelm the cell and cause injury by 
covalently binding to and damaging critical macromolecules.  Detoxification of 
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reactive intermediates or electrophiles occurs by biotransformation, such as 
conjugation with GSH catalyzed by glutathione-S-transferases (Gsts), 
reduction of quinones by NAD(P)H:quinone oxidoreductase 1 (Nqo1), or 
hydrolysis of epoxides by epoxide hydrolase-1 (Eh-1).  Nucleophilic 
conjugation mediated by UDP-glucuronosyltransferases (Ugts) or 
sulfotransferases (Sults) can also prevent the formation of electrophiles by 
increasing excretion of xenobiotics, limiting their availability for toxification by 
Cyps or peroxidases (Pods). 
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Fig 0.1. Illustration of oxidative and electrophilic stress.  Oxidative stress is 
represented in the left side and electrophilic stress on the right side. 
Xenobiotics can undergo redox cycling, such as in the case of paraquat, 
which generates superoxide in a reaction catalyzed by cytochrome p-450 
reductase (Cpr).   Detoxificaton of superoxide (O2-.) to hydrogen peroxide 
(HOOH) is mediated by superoxide dismutase (Sod).  HOOH is detoxified to 
H2O by catalase (Cat), peroxiredoxin (Prx), and glutathione peroxidase (Gpx).  
GSH is oxidized to glutathione disulfide (GSSG) in the Gpx-catalyzed 
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reaction.  If HOOH is not detoxified, it can undergo a Fenton reaction to 
generate hydroxyl radical (OH.).  O2-. can also react with nitric oxide (NO.) to 
form peroxynitrite (ONOO-), which can be detoxified by Gpx, Prx, or 
glutathione (GSH).  Biotransformaton of xenobiotics by cytochrome P-450s 
(Cyps) and peroxidases (Pod) can lead to the formation of nucleophiles or 
electrophiles.  Detoxification of electrophilic intermediates by 
NAD(P)H:quinone oxidoreductase 1 (Nqo1) or epoxide hydrolase-1 (Eh-1) 
creates nucleophiles, which can be conjugated with glucuronic acid via UDP-
glucuronosyltransferases (Ugts) or conjugated with sulfate via 
sulfotransferases (Sults) and excreted by multidrug resistance-associated 
proteins (Mrps).  Electrophiles can also be conjugated with GSH in a reaction 
catalyzed by glutathione-S-transferases (Gsts) and excreted via Mrps.  GSH 
and its synthesis play important roles in both superoxide and electrophile 
detoxification.  The rate limiting enzymes in GSH synthesis are glutamate-
cysteine ligase catalytic and modifier subunits (Gclc and Gclm, respectively). 
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Nuclear factor erythroid 2-related factor 2 (Nrf2) 
Over the past decade Nrf2 has emerged as an important 
transcriptional regulator of antioxidant cellular protection.   Upon cellular 
oxidative/electrophilic insult, Nrf2 initiates a response by up-regulating a 
battery of cytoprotective and biotransformation genes.  Moreover, inductive 
control over a broad array of genes that facilitate increased detoxification and 
clearance of reactive metabolites and xenobiotics has earned Nrf2 a crucial 
role in toxicology and xenobiotic metabolism. 
Under physiological conditions, Nrf2 (Fig 0.2) is bound in the cytosol by 
its repressor Kelch-like ECH associating protein 1 (Keap1).  Keap1 functions 
as an adapter for Cullin 3 (Cul3)-based E3 ligase, a scaffold protein that aids 
in the ubiquitination and subsequent degradation of Nrf2 (Cullinan et al., 
2004; Kobayashi et al., 2004a).   In fact, Nrf2 has a very rapid turnover, with a 
half-life of approximately 20 min, and thus Nrf2 is difficult to detect in 
unstressed conditions (Itoh et al., 2003; McMahon et al., 2003).  When an 
oxidative or electrophilic insult occurs, reactive cysteines of Keap1 are 
modified, and Keap1 is unable to target Nrf2 for proteasomal degradation 
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(Dinkova-Kostova et al., 2002).   Nrf2 then translocates into the nucleus, 
heterodimerizes with a small musculo-aponeurotic fibrosarcoma (Maf) protein, 
and binds to the antioxidant or electrophilic response element (ARE/EpRE) in 
the upstream promoter region of a variety of cytoprotective genes, promoting 
their transcription (Itoh et al., 1997; Venugopal and Jaiswal, 1998; He et al., 
2001). 
  10
 
 
 
 
 
 
 
Fig 0.2. Mechanism of Nrf2 activation.  Under basal conditions, Nrf2 (kNrf2 or 
bound Nrf2) is sequestered in the cytosol by Keap1, which acts as a scaffold 
protein to mediate ubiquitination and proteasomal degradation of Nrf2.  Upon 
exposure to oxidative or electrophilic stress, Keap1 is no longer able to target 
Nrf2 for proteasomal degradation and free Nrf2 (fNrf2) concentrations 
increase.  Free Nrf2 can then translocate to the nucleus, heterodimerize with 
a small Maf protein, bind to the electrophilic/antioxidant response element 
(ARE/EpRE), and initiate gene transcription.  ARE-mediated gene 
transcription increases cellular defenses against oxidative and electrophilic 
stress. 
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Genes regulated by Nrf2   
The Nrf2-Keap1 pathway regulates a wide variety of important 
antioxidant enzymes, including but not limited to Nqo1, Gsts, heme 
oxygenase-1 (Ho-1), and glutamate-cysteine ligase, catalytic subunit (Gclc), 
Eh-1, and Mrps (Fig 0.3).  It was shown through extensive analysis of these 
genes’ regulatory mechanisms that their inducible expression is attained at 
the transcriptional level through the antioxidant response element (Kobayashi 
et al., 2004b; Maher et al., 2007).   Therefore, the activation of Nrf2 will 
increase antioxidant genes, such as the ones mentioned above, and protect 
the organism against stress. 
Nqo1.  Nqo1 utilizes NAD(P)H as a reducing agent to reduce quinones 
in a single two-electron step.  This two-electron process detoxifies potentially 
toxic quinones by yielding substrates for conjugation reactions with 
glutathione, sulfate, or glucuronic acid and promoting excretion.  Reactive 
intermediates detoxified by Nqo1 include the reactive intermediate of 
acetaminophen metabolism, namely N-acetyl-p-benzoquinoneimine (NAPQI), 
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as well as benzo[a]pyrene quinone, and menadione (Jaiswal, 2000; Moffit et 
al., 2007). 
Gclc and Gclm.  Glutamate cysteine ligase (Gcl) is a heterodimer 
which can be dissociated under nondenaturing conditions into a catalytic, or 
heavy, subunit (Gclc) and a modulatory, or light, subunit (Gclm) (Dickinson et 
al., 2004).   It is the rate limiting enzyme in the synthesis of GSH.  GSH is 
found at millimolar concentrations in most cells, making it the most abundant 
nonprotein thiol. GSH is essential to antioxidant and electrophile defense, 
regulation of the cell cycle, and gene expression. The involvement of GSH in 
the protection of the cell against exposure to toxicants, and in the metabolism 
of xenobiotic compounds through formation of conjugates, is well established. 
GSH also interacts with glutaredoxin and protein disulfide isomerases to 
modulate the tertiary structure of proteins through thiol–disulfide exchange. In 
addition to the essential role in defense and metabolism, it has become clear 
in the past few years that GSH contributes to redox signaling mediated by 
reactive oxygen and nitrogen species (Dickinson et al., 2004). 
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Gsts.  Gsts are a family of detoxification enzymes that catalyze the 
nucleophilic attack of GSH sulfur to electrophilic substrates, resulting in a 
detoxified electrophile (Blanchette et al., 2007).  Given the fact that Gst 
substrates include an enormous array of electrophilic xenobiotics, its 
importance in detoxification cannot be overstated. 
Ho-1.  Ho-1 is the inducible form of the rate-limiting enzyme in the 
degradation of heme, converting heme to biliverdin, during which iron is 
released and carbon monoxide (CO) is emitted.  Biliverdin is subsequently 
converted to bilirubin by biliverdin reductase (Nath, 2006).  Bilirubin is an 
important antioxidant, capable of reducing ROS.  Ho-1 also facilitates the 
combining of free iron with ferritin, reducing free iron concentrations and 
oxidative stress that results when iron is involved in redox reactions.  
Furthermore, whereas the clinical toxicity of CO is clearly recognized, much 
smaller quantities of CO are remarkably cytoprotective, anti-apoptotic, 
vasorelaxant, and anti-inflammatory (Nath, 2006). 
Eh-1.  Eh-1 catalyzes the hydrolysis reaction in which potentially toxic 
electrophilic epoxides are converted to trans-dihydrodiols, which can be 
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conjugated and excreted from the body.  Important substrates for Eh-1 
include the epoxides formed in benz[a]pyrene and aflatoxin metabolism that 
unless detoxified are potent carcinogens (Omiecinski et al., 2000) .  
Mrps.  Once a xenobiotic has been conjugated by, for example, 
glucuronic acid, sulfate, or glutathione, it must be effluxed out of the 
hepatocyte or accumulation and toxicity can occur. One of the most important 
families of efflux transporters in liver are the Mrps.  Mrps are highly inducible, 
have a wide-variety of substrates, efflux xenobiotics both apically (Mrp2) and 
basolaterally (Mrp3 and Mrp4), and are induced via Nrf2 activation (Maher et 
al., 2007). 
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Figure 0.3.  Summary of the effects of Nrf2 activaiton on biotransformation in 
the liver.  In response to electrophilic or oxidative stress caused by 
xenobiotics, Nrf2 induces a variety of cytoprotective enzymes, including 
Nqo1, Eh-1, Gclc, Gclm, Gsts, Ugts, and Mrps in order to help restore the 
oxidative balance within the cell and prevent cell death. 
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 Nrf2 Activators 
Nrf2-activating chemicals which induce expression of ARE-containing 
genes have been categorized as cytoprotective agents.  These include 
phenolic antioxidants (β-naphthoflavone, β-NF; butylated hydroxyanisole, 
BHA; and tert-butyl-hydroquinone, tBHQ), synthetic antioxidants (ethoxyquin), 
derivatives of 1,2-dithiole-3-thiones (oltipraz, 3H-1,2-dithiol-3-thione, D3T), 
phorbol esters (phorbol 12-myristate 13-acetate, PMA), and isothiocyanates 
(sulforaphane from broccoli, phenethyl isothiocyanate) (Nguyen et al., 2003).  
These compounds have been used to identify Nrf2 target genes.   However, it 
is frequently overlooked that chemicals have many off-target effects and 
identifying Nrf2-target genes with absolute certainty is difficult and often 
impossible using chemicals. 
Nrf2-null and Keap1-kd mice. 
Nrf2-null mice have lower constitutive expression and an inability to 
induce many cytoprotective genes, such as Nqo1 and Gclc, upon 
oxidative/electrophlic insult.  Nrf2-null mice are extremely susceptible to 
chemical models of oxidative and electrophilic stress (Aleksunes and 
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Manautou, 2007), contributing to increased hepatotoxicity when administered 
acetaminophen (Enomoto et al., 2001), ethanol (Lamle et al., 2008), 
pentachlorophenol (Umemura et al., 2006), or a high-fat diet (Tanaka et al., 
2008b).   
In contrast to Nrf2-null mice, Keap1-null mice were engineered to 
investigate the effects of increased activation of Nrf2.  Unfortunately, even 
though Keap1-null mice have enhanced activation of Nrf2 and higher 
constitutive expression of Nrf2-target genes, the mice died at weaning due to 
malnutrition from hyperkeratosis of the esophagus and forestomach 
(Wakabayashi et al., 2003).  In an attempt to circumvent the post-natal 
lethality in Keap1-null mice, a hepatocyte-specific Keap1-null mouse was 
engineered, utilizing an Albumin-Cre loxP system.  This mouse is viable, has 
enhanced activation of Nrf2 and Nrf2-target genes in liver, and decreased 
susceptibility to acetaminophen hepatotoxicity (Okawa et al., 2006).  
However, later it was discovered that floxation of the Keap1 allele with loxP 
sites led to partial disruption of Keap1 expression, creating a whole-body 
knockdown phenotype (Okada et al., 2008).   The Keap1-kd mice is  an in 
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vivo model of increased Nrf2 activation without the off-target effects possible 
with chemical inducers of Nrf2, and should be useful in elucidating accurate 
effects of Nrf2 activation. 
Natural and synthetic triterpenoids 
Oleanolic acid (Fig 0.4, upper) is a natural triterpenoid that is a 
constituent of the leaves of Olea europaea, Viscum album L., and other 
plants, and is the aglycone of many saponins.  Oleanolic acid is used in 
Chinese medicine for the treatment of liver disorders, such as viral hepatitis, 
and has been shown to protect mice from various hepatotoxicants, including 
carbon tetrachloride, acetaminophen, bromobenzene, and thioacetamide.  In 
mice pretreated with oleanolic acid, and then exposed to one of the above 
chemical hepatotoxicants, serum alanine transaminase concentrations and 
centrilobular necrosis were diminished (Liu et al., 1993a; Liu et al., 1994a; Liu 
et al., 1994b; Liu et al., 1995b).  To partially explain the protective effects of 
oleanolic acid, a study on toxifying and detoxifying systems was performed.  
Oleanolic acid did not dramatically affect hepatic Cyp enzyme systems, but 
did increase hepatic GSH, metallothionein, and Gst activity. However, the 
  19
exact mechanism for oleanolic acid-mediated hepatoprotection has not been 
fully elucidated. 
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 Although, the limited efficacy of many naturally-occurring substances 
often precludes clinical use, natural compounds may serve as a critical 
foundation for drug development.  In an effort to make more potent and 
efficacious compounds with the beneficial effects of oleanolic acid, the 
Michael Sporn group at Dartmouth College synthesized many derivatives. 
Among them, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) was 
400-times more potent than previous compounds made as inhibitors of 
production of nitric oxide induced by interferon-γ in mouse macrophages 
(Honda et al., 1998).  In addition, an imidazole group was added (Fig 0.4, 
lower), making the compound 2- to 3-fold more potent than CDDO (Place et 
al., 2003).  
CDDO-Im was found to increase Ho-1 protein expression in vivo (Suh 
et al., 1999).  However, confirmation of activation of Nrf2 in vivo was missing 
from this study.  An even more recent study found that if one pretreated mice 
with CDDO-Im, and then exposed them to a dose of aflatoxin, the mice were 
protected from liver tumorigenesis (Thimmulappa et al., 2006). It was shown 
that micromole doses of CDDO-Im induced cytoprotective genes, inhibited 
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DNA-adduct formation, and dramatically blocked hepatic tumorigenesis.  The 
cytoprotective genes induced are known to have an antioxidant response 
element capable of binding Nrf2.  They were Eh-1, thioredoxin (Trx), Gclc, 
Gclm, and various isoforms of Gsts (Thimmulappa et al., 2006).  Taken 
collectively, all these results indicate that CDDO-Im is a potent 
chemopreventitive chemical, possibly acting through the Nrf2-Keap1 pathway 
and further study of this compound in vivo is needed, and of interest is 
whether CDDO-Im can protect against hepatotoxicants, particularly 
acetaminophen. 
Acetaminophen (AA) biotransformation. 
AA is a widely-used and effective antipyretic drug and is often used as 
a model hepatotoxicant.  A therapeutic dose of AA is primarility metabolized 
by glucuronidation and sulfation in liver (Fig 0.3).  However, when these 
systems become saturated, as in cases of overdose, larger amounts of the 
reactive intermediate N-acetyl-p-benzoquinoneimine (NAPQI) are formed via 
Cyps (Cyp2E1, Cyp3A4/11, and to a lesser extent Cyp1A2).  NAPQI is 
detoxified by GSH, however, when GSH stores are depleted, NAPQI 
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covalently binds to critical cellular macromolecules (namely proteins), 
inducing a cascade of reactive intermediates and free radicals that eventually 
lead to hepatotoxicity (Hinson et al., 2004). 
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STATEMENT OF PURPOSE 
Current therapeutic interventions for treating liver injury are limited; 
identification of a therapeutic target is a prerequisite for developing new drugs 
to treat liver injury.  Oxidative and electrophilic stresses play key roles in the 
pathogenesis of liver injury.  Nrf2 is a critical transcription factor in 
antioxidative responses. In quiescent hepatocytes, Nrf2 is sequestered in the 
cytosol by Keap1, which mediates Nrf2 proteasomal degradation.  Under 
oxidative or electrophilic stress, Keap1 becomes unable to mediate 
proteasomal degradation of Nrf2, and free Nrf2 accumulates in the cytosol, 
translocates into the nucleus, and activates gene transcription. The ability of 
Nrf2 to increase transcription of a large battery of cytoprotective genes is 
generally recognized. Nevertheless, whether activation of Nrf2 can prevent 
liver injury has not been thoroughly examined. 
The purpose of the first specific aim was to investigate the protective 
effects against AA hepatotoxicity of the natural triterpenoid oleanolic acid and 
a synthetic derivative, CDDO-Im, and to determine whether the two 
xenobiotics mediate such hepatoprotection through Nrf2. Over a decade ago, 
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our laboratory showed that pretreatment with the natural triterpenoid oleanolic 
acid protected mice from exposure to mechanistically diverse 
hepatotoxicants.  Mice pretreated with oleanolic acid and then administered 
bromobenzene, AA, carbon tetrachloride, thioacetamide, furosemide, 
phalloidin, colchicine, cadmium chloride, or D-
galactosamine/lipopolysaccharide had decreased hepatotoxicity.  Because 
electrophilic and/or oxidative stress play a role in the pathogenesis of toxicity 
from these hepatoxicants, it was hypothesized that oleanolic acid may be 
activating Nrf2.  CDDO-Im was synthesized in an attempt to generate a more 
potent and effective triterpenoid compound. Because CDDO-Im is structurally 
similar to oleanolic acid, CDDO-Im was also investigated as a possible Nrf2 
activator and alleviator of AA hepatotoxicity. 
A considerable amount of knowledge has accumulated regarding the 
effects of a lack of Nrf2 by performing experiments in the Nrf2-null mouse.  
However, very little is known about the biological effects of more Nrf2 
activation. Keap1-kd mice have increased nuclear accumulation of Nrf2 and 
present a novel in vivo model for investigating the activation of Nrf2 without 
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the added variable of off-target effects often observed with chemical 
treatments.  The availability of both Nrf2-null mice, which have no Nrf2, and 
Keap1-kd mice, which have enhanced activation of Nrf2, provide outstanding 
models to investigate the opposing effects of Nrf2 deficiency and Nrf2 
activation in liver.  Therefore, the purpose of the second aim was to determine 
the phenotype of Keap1-kd mice, and compare with Nrf2-null and wild-type 
mice the mRNAs of genes, which protect against oxidative and electrophilic 
stress.  A fundamental understanding of the mRNA expression of drug 
metabolizing and detoxification enzymes will provide a framework for future 
studies using both Nrf2-null mice and Keap1-kd mice. 
Numerous studies have shown that Nrf2-null mice have an increased 
sensitivity to hepatoxicants, and this is frequently attributed to decreased 
toxicodynamic effects, as exemplified by increased expression of 
cytoprotective genes, such as Nqo1 and Gsts, protecting against oxidative or 
electrophilic stress.  However, nothing is known about the influence of Nrf2 on 
the kinetics of xenobiotics.  Therefore, the purpose of the third aim was to 
investigate the effects Nrf2 has on the kinetics of sulfobromopthalein (BSP), a 
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xenobiotic used to study hepatobiliary function, as well as AA, a well known 
hepatotoxicant.  Both BSP and AA are biotransformed by enzymes under the 
transciriptional control of Nrf2. 
Overall, the data generated from these studies will 1) determine 
whether the natural triterpenoid oleanolic acid and its synthetic derivative, 
CDDO-Im, activate Nrf2 and protect against AA hepatotoxicity; 2) 
characterize the mRNA expression of oxidative stress and drug processing 
genes among wild-type, Nrf2-null, and Keap1-kd mice to lay a foundation for 
future studies; and 3) determine how Nrf2 effects the kinetics of BSP and AA. 
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PART I 
 
 
 
Pharmacologic Activation of Nrf2 and Induction of Target Genes by the 
Natural Triterpenoid Oleanolic Acid and a Synthetic Derivative CDDO-Im 
Protect the Liver from Acetaminophen Hepatotoxicity 
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CHAPTER ONE 
 
 
 
Oleanolic Acid Activates Nrf2 and Protects Against Acetaminophen 
Hepatotoxicity 
  30
ABSTRACT 
Oleanolic acid (OA) is a natural triterpenoid found in some plants, 
which protects against various hepatotoxicants.  In order to determine 
whether nuclear factor erythroid-2 related factor 2 (Nrf2), a transcription factor 
known to induce various antioxidant and cytoprotective genes, is activated by 
OA, wild-type and Nrf2-null mice were treated with OA (90 mg/kg, i.p.) once 
daily for three days.  OA increased nuclear accumulation of Nrf2 in wild-type 
but not Nrf2-null mice, as determined by Western blot and 
immunofluorescence.  OA-treated wild-type mice had increased hepatic 
mRNA expression of the Nrf2 target genes NAD(P)H:quinone oxidoreductase 
1 (Nqo1); glutamate-cysteine ligase, catalytic subunit (Gclc); heme 
oxygenase-1 (Ho-1); as well as Nrf2 itself.   In addition, OA increased protein 
expression and enzyme activity of the prototypical Nrf2 target gene, Nqo1, in 
wild-type, but not in Nrf2-null mice.  OA protected against acetaminophen 
(AA) hepatotoxicity in wild-type mice, but less so in Nrf2-null mice.  
Collectively, the present study demonstrates that OA facilitates Nrf2 nuclear 
accumulation, causing induction of Nrf2-dependent genes, which contributes 
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to protection from acetaminophen hepatotoxicity. 
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INTRODUCTION 
Oleanolic acid (OA) is a natural triterpenoid that is a constituent of the 
leaves of Olea europaea, Viscum album L., and other plants, and is an 
aglycone of many saponins.  OA is used in Chinese medicine for the 
treatment of liver disorders, such as viral hepatitis, and has been shown to 
protect mice from various hepatotoxicants that cause oxidative and 
electrophilic stress, including carbon tetrachloride, acetaminophen (AA), 
bromobenzene, and thioacetamide.  In mice pretreated with OA, and then 
exposed to one of the above chemical hepatotoxicants, serum alanine 
transaminase concentrations and centrilobular necrosis were diminished (Liu 
et al., 1993a; Liu et al., 1994a; Liu et al., 1994b; Liu et al., 1995b). 
The purpose of the present study was to determine whether OA 
activates the Nrf2-Keap1 pathway and whether this contributes to protection 
from AA hepatotoxicity.   Nuclear factor erythroid 2-related factor 2 (Nrf2), and 
its repressor kelch-like ECH-associated protein 1 (Keap1), have been 
characterized over the past decade as an important endogenous cellular 
mechanism for coping with oxidative stress (Kensler et al., 2007).  Nrf2 is a 
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transcription factor that binds to antioxidant response elements (AREs) in 
upstream promoter regions of various cytoprotective enzymes, the induction 
of which helps restore the intracellular balance between oxidants and 
antioxidants.  Under conditions when oxidative/electrophilic stress is low, 
Keap1 sequesters Nrf2 in the cytosol, by acting as an adaptor for Cul3-based 
E3 ligase, to target Nrf2 for proteasomal degradation (Tong et al., 2006).  
When oxidative/electrophilic stress is increased in the cell, Nrf2 is able to 
avoid Keap1-mediated proteasomal degradation by Cul3, and translocate into 
the nucleus (McMahon et al., 2003).  Once in the nucleus, Nrf2 
heterodimerizes with a small musculo-aponeurotic fibrosarcoma (Maf) protein 
and binds to AREs, promoting transcription of various cytoprotective genes 
(Itoh et al., 1997; Venugopal and Jaiswal, 1998; He et al., 2001).   
Nrf2 target genes include, but are not limited to, glutathione-S-
transferases (Gsts), NAD(P)H:quinone oxidoreductase 1 (Nqo1), UDP-
glucuronosyltransferases, glutamate-cysteine ligase catalytic subunit (Gclc), 
glutamate-cysteine ligase modifier subunit (Gclm), and heme oxygenase-1 
(Ho-1).  Such enzymes are referred to as the “Nrf2 regulon” and provide 
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antioxidative protection (Kobayashi and Yamamoto, 2006).   Nrf2-null mice 
have compromised antioxidant protection and are highly susceptible to target-
organ injury from AA (Enomoto et al., 2001), benzo[a]pyrene (Ramos-Gomez 
et al., 2001), diesel exhaust (Aoki et al., 2001), hyperoxia (Cho et al., 2002), 
hydrogen peroxide (Kraft et al., 2004), and many other oxidative-type 
pathologies.  In contrast, mice with a hepatocyte-specific deletion of Keap1 
have marked increases in Nrf2 target genes and protection from AA 
hepatotoxicity (Okawa et al., 2006).   
In wild-type mice, OA induces many cytoprotective genes, such as the 
Nrf2-dependent genes Nqo1, Gclc, and Ho-1 (3-fold to 5-fold over vehicle) 
(Liu et al., 2008).  However, in this study by Liu et al. nuclear translocation of 
Nrf2 protein was implied but not actually shown.  Furthermore, Nrf2-null mice 
were not used by Liu et al. to demonstrate definitively whether induction of 
Nqo1, Gclc, and Ho-1 was caused by Nrf2 activation, as other transcription 
factors and mechanisms are capable of inducing these genes (Dahl and 
Mulcahy, 2001; Okey et al., 2005; Ferrandiz and Devesa, 2008; Knight et al., 
2008).  The purpose of the present study was to investigate whether OA (90 
  35
mg/kg, i.p.), administered once daily for three days, as was used previously in 
hepatoprotection studies (Liu et al., 1995a), activates the Nrf2-Keap1 
pathway using wild-type and Nrf2-null mice, and whether activation of Nrf2 is 
responsible for OA-mediated protection against AA hepatotoxicity. 
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METHODS 
Reagents.  OA was a gift from Dr. Jie Liu (NIEHS, Research Triangle Park, 
NC).  Nqo1 and β-actin antibodies were purchased from Abcam (Ab2346, 
Ab8227, respectively, Cambridge, MA).  Nrf2 antibody was purchased from 
Santa Cruz Biotechnology (sc-30915, Santa Cruz, CA).  All other chemicals, 
unless otherwise specified, were purchased from Sigma-Aldrich (St. Louis, 
MO). 
Animals and Husbandry.  Eight-week-old male C57BL/6 mice were 
purchased from Charles River Laboratories, Inc (Wilmington, MA).  Nrf2-null 
mice on a mixed C57BL/6 and AKR background were obtained from Dr. 
Jefferson Chan (University of California, Irvine, Irvine, CA) and backcrossed 
seven generations into C57BL/6 mice to >99% congenicity, as was 
determined by Jackson Laboratories (Bar Harbor, ME).  Animals were housed 
in a temperature-, light-, and humidity-controlled environment and fed Teklad 
Rodent Diet #8604 (Harlan Laboratories, Madison, WI) ad libitum.   The 
housing facility is an American Animal Associations Laboratory Animal Care-
accredited facility at the University of Kansas Medical Center, and all 
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procedures were preapproved in accordance with the Institutional Animal 
Care and Use Committee guidelines. 
Animal Treatment.  Wild-type and Nrf2-null mice were dosed with OA (90 
mg/kg, i.p.) or vehicle (2% Tween 80, 10 mL/kg, i.p) in the morning, once 
daily for three days.  Livers were removed on the morning of the fourth day, 
frozen in liquid nitrogen, and stored at   -80ºC.  For the hepatoprotection 
study, wild-type and Nrf2-null mice were dosed with OA (90 mg/kg, i.p.) or 
vehicle (2% Tween 80, 10 mL/kg, i.p) in the morning, once daily for three 
days.  On the fourth day, mice were administered AA (500 mg/kg, i.p.) in 
saline (pH 8).  Blood and livers were collected 8 h later.  Consistent cross-
sections from the largest lobe of the liver were fixed in 10% zinc formalin for 
48 h. 
Total RNA Isolation. Total RNA was isolated using RNA-Bee reagent (Tel-
Test, Inc., Friendswood, TX) according to the manufacturer’s protocol. Total 
RNA concentrations were determined spectrophotometrically at 260 nm.  The 
RNA samples were diluted to 500 ng/µL with diethyl pyrocarbonate-treated 
deionized water. 
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Branched DNA Signal Amplification (bDNA) Analysis. The mRNA 
expression of Nqo1, Gclc, and Ho-1 in mouse livers was quantified using the 
bDNA assay (Quantigene 1.0 bDNA signal amplification kit; Panomics, Inc., 
Fremont, CA) with modifications.  Gene sequences of interest were accessed 
from GenBank. Target sequences were analyzed using ProbeDesigner 
software v1.0 (Chiron Diagnostics Corp., Walpole, MA) to design 
oligonucleotide probe sets (capture, label, and blocker probes).  All probes 
were designed with a melting temperature of 63ºC, enabling hybridization 
conditions to be held constant (i.e., 53ºC) during each hybridization step.  
Probe sets for Ho-1 and Nqo1 were previously described (Aleksunes et al., 
2005).   Probe sets for Gclc and metallothionein-1 (MT) are listed in Table 
1.1.  Because of sequence homology between MT and MT, the MT probe set 
may also detect MT.  Total RNA was added to each well of a 96-well plate 
containing 50 µL of each diluted probe set.  RNA was allowed to hybridize 
with the probe sets overnight at 53ºC.  Subsequent hybridization steps were 
carried out according to the manufacturer’s protocol, and luminescence was 
quantified with a Synergy 2 Multi-Detection Microplate Reader interfaced with 
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Gen5 Reader Control and Data Analysis Software (Biotek, Winoosky, VT).  
Data are presented as relative light units (RLU) normalized to control. 
Nrf2 and Nqo1 Protein Expression.  Livers were homogenized in sucrose-
Tris buffer (0.25 mol/L sucrose, 10 mmol/L Tris–HCl, pH 7.4) and centrifuged 
at 100,000 g for 60 min at 4°C. The resulting supern atant, containing the 
cytosolic fraction, was used to assay for Nqo1 protein.  Nuclear extracts were 
prepared with the NE-PER nuclear extraction kit according to the 
manufacturer's directions (Pierce Biotechnology, Rockford, IL).  Nuclear 
extracts were used for Nrf2 immunoblotting.  Protein concentrations were 
determined with BCA  Assay Kit from Pierce Biotechnology (Rockford, IL).  
Cytosolic and nuclear proteins (40 µg protein/lane) were 
electrophoretically resolved using polyacrylamide gels (4% stacking and 12% 
resolving for Nqo1; 4% stacking and 10% resolving for Nrf2).  Gels were 
transblotted overnight at 4ºC onto a nitrocellulose membrane for Nqo1, and a 
polyvinylidene fluoride membrane for Nrf2.  Membranes were then washed 
with PBS–buffered saline containing 0.05% Tween-20 (PBS-T).  Membranes 
were blocked for 1 h at room temperature with 5% non-fat milk in PBS–T.  
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Blots were then incubated with primary antibody (1:1000 dilution for both 
Nqo1 and Nrf2, in 2% non-fat milk in PBS-T) for 3 h at room temperature.  
Blots were then washed in PBS-T and incubated with secondary antibody 
conjugated with horseradish peroxidase (1:2000 dilution for Nqo1 and Nrf2) in 
2% non-fat milk in PBS-T buffer for 1 hr at room temperature.   Blots were 
then washed with PBS-T.  Protein-antibody complexes were detected using 
an enhanced chemiluminescent kit (Pierce Biotechnology, Rockford, IL) and 
exposed to X-ray film (Denville Scientific, Metuchen, NJ).  Intensity of protein 
bands was quantified using the Discovery Series Quantity One 1-D Analysis 
software (Bio-Rad Laboratories, Hercules, CA).  Intensity values were 
normalized to β-actin and expressed as relative protein expression. 
Immunofluorescence.  Nrf2 was detected as previously described (Slitt et 
al., 2006).  Briefly, cryosections were air-dried at room temperature for 5 min 
and fixed with 4% paraformaldehyde. The sections were blocked at room 
temperature for 30 min with 5% donkey serum/phosphate-buffered saline with 
0.2% Triton X-100 (PBS-Tx), and then incubated overnight with Nrf2 antibody 
diluted 1:50 in 5% donkey serum/PBS-Tx.  A fluorescein isothiocyanate-
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labeled secondary antibody (Jackson Immunoresearch Laboratories, West 
Grove, PA) diluted 1:200 was used, along with rhodamine-labeled phalloidin 
(Invitrogen, Carlsbad, CA) diluted 1:200 in 5% donkey serum/PBS-Tx.  4,6-
diamidino-2-phenylindole (Invitrogen, Carlsbad, CA) staining was performed 
to define nuclear regions.  Antibody solutions were filtered through 0.22 µm 
membrane syringe-driven filter units (Osmonics Inc., Minnetonka, MN) prior to 
use.  Frozen liver sections were stained and imaged under uniform conditions 
for each antibody.  Negative controls without primary antibody were also 
included in the analysis (data not shown).   Images were captured on an 
Olympus BX41 fluorescent microscope with a DP70 camera and DP 
Controller software (Olympus, Melville, NY). 
Nqo1 activity assay.  Cytosolic Nqo1 enzyme activity was determined by 
quantifying the reduction of 2,6-dichlorophenol-indophenol (DCPIP) as 
described previously (Ernster, 1967; Benson et al., 1980). 
Serum alanine transaminase (ALT) concentrations. Serum ALT 
concentrations were determined as a biochemical indicator of hepatocellular 
necrosis using Pointe Scientific Liquid ALT Reagent Set (Canton, MI) 
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according to the manufacturer's protocol. 
Histopathology.  Liver samples were fixed in 10% neutral-buffered zinc 
formalin prior to routine processing and paraffin embedding.  Liver sections (5 
µm) were stained with hematoxylin and eosin.  Liver sections were analyzed 
and assigned one of six scores of severity of necrosis: 0, none; 1, minimal (>2 
foci of single cell necrosis per section); 2, mild (at least 5 areas of focal 
necrosis per section); 3, moderate (at least five foci of zonal necrosis per 
section); 4, severe (lobular damage, with many viable lobules per section); 
and 5, global (severe lobular damage, few areas of viability per section).  A 
section was defined as a single viewpoint at low power (x100) magnification. 
Statistical Analysis.  All data but histological grading were analyzed using 
one-way analysis of variance (ANOVA) followed by Duncan's multiple range 
test (p ≤ 0.05).  Histopathological data were rank ordered prior to ANOVA 
analysis, which was followed by Newman-Keuls multiple range test (p ≤ 0.05). 
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RESULTS 
Nrf2 nuclear translocation in OA-treated wild-type and Nrf2-null mice.  
OA increased Nrf2 protein 432% in nuclear extracts from livers of wild-type 
mice (Fig 1.1, upper).   Nrf2-null mice treated with vehicle or OA did not have 
detectable levels of Nrf2 protein in the nuclear fractions.  Indirect 
immunofluorescent analysis revealed minimal Nrf2 staining (green) in frozen 
sections from wild-type mice (Fig 1.1, lower).   The actin cytoskeleton was 
stained in red.  Nrf2 staining of liver sections from OA-treated wild-type mice 
was strong and localized to the nucleus (blue).  No Nrf2 staining was 
observed in vehicle- or OA-treated Nrf2-null mice. 
Nrf2, Nqo1, Gclc, and Ho-1 mRNA expression in OA-treated wild-type 
and Nrf2-null mice.  OA increased mRNA expression of Nrf2 (347%), Nqo1 
(1108%), Gclc (521%), and Ho-1 (955%) in wild-type mice (Fig 1.2).  Nrf2-null 
mice treated with OA showed no increase in Nrf2, Nqo1, Gclc, or Ho-1 mRNA 
expression. 
Nqo1 protein expression and enzyme activity in OA-treated wild-type 
and Nrf2-null mice.  Because Nqo1 is considered the prototypical Nrf2-target 
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gene, Nqo1 protein and enzyme activity were evaluated.  Wild-type mice 
treated with OA had increased Nqo1 protein expression (79%) as determined 
by western blot (Fig 1.3, upper).  Nrf2-null mice had much lower Nqo1 protein 
expression (-73%) than wild-type mice.  Furthermore, OA did not change 
Nqo1 protein expression in Nrf2-null mice.  OA induced Nqo1 enzyme activity 
154% in wild-type mice (Fig 1.3, lower).  Basal Nqo1 activity is lower in Nrf2-
null mice (-47%) than in wild-type mice and is not induced by OA. 
OA-mediated protection against AA in wild-type and Nrf2-null mice.  OA 
did not alter serum ALTs or liver histology in wild-type or Nrf2-null mice (data 
not shown).  OA-pretreatment decreased AA-induced hepatotoxicity in wild-
type mice, as indicated by an 82% reduction in serum ALTs (Fig 1.4) and 
reduction in necrosis grade (Table 1.2).  AA produced more severe 
hepatotoxicity in Nrf2-null mice (increases in serum ALTs [250%] and 
necrosis grade) than in wild-type mice, similar to a previous report of 
increased sensitivity of Nrf2-null mice (Enomoto et al., 2001).   OA-
pretreatment of Nrf2-null mice protected against AA hepatotoxicity (reduction 
in serum ALTs [65%] and necrosis grade), but less so than in wild-type mice.  
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Of note, one Nrf2-null mouse pretreated with vehicle and challenged with AA 
died before completion of the study (8 h). 
MT mRNA expression in OA-treated wild-type and Nrf2-null mice.  
Because OA produced some protection from AA hepatotoxicity in Nrf2-null 
mice, mRNA expression of MT, a Nrf2-independent gene (Ohtsuji et al., 2008) 
that has been shown to protect against AA hepatotoxicity (Liu et al., 1999), 
was quantified in OA-treated wild-type and Nrf2-null mice (Fig 1.5).  OA 
induced hepatic MT mRNA expression in both wild-type (31-fold) and Nrf2-
null mice (22-fold). 
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Table 1.1.  Oligonucleotide probes used for analysis of mouse gene 
expression by bDNA signal amplification assay. 
 
Gene Accession # Targeta Functionb Probe Sequence 
Gclc NM_012815 1548-1566 CE atggctcggagctggtctgTTTTTctcttggaaagaaagt 
  1996-1724 CE cttaattagcttcaggtagttcagaataTTTTTctcttggaaagaaagt 
  1725-1749 CE tcattagttctccagatgctctcttTTTTTctcttggaaagaaagt 
  1848-1870 CE tcattagttctccagatgctctcttTTTTTctcttggaaagaaagt 
  1896-1917 CE acttcgcttttctaaagcctgaTTTTTctcttggaaagaaagt 
  1528-1547 LE ggccttgctacacccatccaTTTTTaggcataggacccgtgtct 
  1567-1588 LE atgagcgtgtactcctctgcagTTTTTaggcataggacccgtgtct 
  1589-1612 LE ccattgatgatggtgtctatgctcTTTTTaggcataggacccgtgtct 
  1656-1678 LE tcgacttccatgttttcaaggtaTTTTTaggcataggacccgtgtct 
  1679-1696 LE ctgcatcgggtgtccacgTTTTTaggcataggacccgtgtct 
  1750-1770 LE ctctcatccacctggcaacagTTTTTaggcataggacccgtgtct 
  1771-1794 LE agtcaggatggtttgcaataaactTTTTTaggcataggacccgtgtct 
  1822-1847 LE tttcaaaatgaggctatagttgatctTTTTTaggcataggacccgtgtct 
  1918-1939 LE gggtcgcttttacctccactgtTTTTTaggcataggacccgtgtct 
  1613-1632 BL caggaaacacgccttccttc 
  1633-1655 BL ggagttcagaatggggatgagtc 
  1795-1821 BL catcagttattacactgtcttgcttgt 
  1871-1895 BL tccaagtaactctggacattcacac 
MT NM_013602 72-92 CE ggtccattccgagatctggtgTTTTTctcttggaaagaaagt 
  170-190 CE ggagcagcagctcttcttgcaTTTTTctcttggaaagaaagt 
  130-147 LE caggcgcaggagctggtgTTTTTaggcataggacccgtgtct 
  191-207 LE cagcccacgggacagcaTTTTTaggcataggacccgtgtct 
  227-244 LE ggcgcctttgcagacacaTTTTTaggcataggacccgtgtct 
  245-262 LE gcacgtgcacttgtccgcTTTTTaggcataggacccgtgtct 
  263-283 LE ctgttcgtcacatcaggcacaTTTTTaggcataggacccgtgtct 
  284-302 LE tttacacgtggtggcagcgTTTTTaggcataggacccgtgtct 
  303-323 LE cgctgggttggtccgatactaTTTTTaggcataggacccgtgtct 
  93-112 BL ggtggagcaggagcagttgg 
  113-129 BL caagtgcaggagccgcc 
  148-169 BL ggaggtgcacttgcagttcttg 
  208-226 BL gccctgggcacatttggag 
aTarget refers to the sequence of the mRNA transcript as enumerated in the 
GenBank file. 
bFunction refers to the use of the oligonucleotide probe in the assay (CE, 
capture extender; LE, label extender; BL, blocker probe). 
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Table 1.2.  Histological analysis of livers from vehicle- and OA-
pretreated aild-type and Nrf2-null mice after AA challenge. 
 Histological Grade  
Treatment Group 0 1 2 3 4 5 p≤0.05 
Wild-type VC-AA 0 0 0 2 3 0  
Wild-type OA-AA  0 3 2 0 0 0 * 
Nrf2-null VC-AA  0 0 0 0 0 5 * 
Nrf2-null OA-AA  0 0 0 1 4 0 † 
Grade of liver injury in wild-type and Nrf2-null mice pretreated with OA (90 
mg/kg, i.p.) once daily for three days (n=5 for all groups except Nrf2-null mice 
receiving vehicle, n=4), administered acetaminophen (500 mg/kg, i.p.) on the 
fourth day, and sacrificed 8-h later.  Liver sections were analyzed at low 
power (x100) with six scores of severity: 0, none; 1, minimal (>2 foci of single 
cell necrosis per section); 2, mild (at least 5 areas of focal necrosis per 
section); 3, moderate (at least five foci of zonal necrosis per section); 4, 
severe (lobular damage, with many viable lobules per section); and 5, global 
(severe lobular damage, few areas of viability per section).  Values are 
expressed as mean ± S.E.M.  Abbreviations:  WT, wild-type; null, Nrf2-null.  
Asterisks (*) indicate a statistically significant difference from wild-type mice 
receiving vehicle (p ≤ 0.05). Daggers (†) indicate a statistically significant 
difference from Nrf2-null mice receiving vehicle (p ≤ 0.05).
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Fig 1.1.  Upper.  Western blot of liver nuclear fractions for Nrf2 after treatment 
with OA (90 mg/kg, i.p.) once daily for three days.  Also shown is the 
quantification of specific band intensity, normalized to β-actin, and expressed 
relative to control as mean ± S.E.M.  Abbreviations:  ND, Not Detected; Veh, 
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Vehicle; OA, OA; WT, wild-type; null, Nrf2-null.  Asterisks (*) indicate a 
statistically significant difference from wild-type mice treated with vehicle (p 
≤ 0.05).   Lower.  Immunofluorescent localization of Nrf2 in livers from wild-
type mice after vehicle or OA.  Indirect immunofluorescence to detect Nrf2 
(green) and actin (red) was performed on liver cryosections (5 µm) from wild-
type mice after OA (90 mg/kg, i.p.) treatment once daily for three days. 
Sections were mounted in Prolong Gold containing DAPI for nuclear staining 
(blue).  Representative images are shown at high-power magnification (x400).  
Bar represents 200 µm. 
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Fig 1.2.  Messenger RNA expression of Nqo1, Gclc, and Ho-1 in livers of 
wild-type and Nrf2-null mice after treatment with OA (90 mg/kg, i.p.) once 
daily for three days.  Messenger RNA was quantified by the bDNA assay.  
Data is expressed relative to wild-type controls as mean ± S.E.M.  
Abbreviations:  WT, wild-type; null, Nrf2-null.  Asterisks (*) indicate a 
statistically significant difference from wild-type mice receiving vehicle (p ≤ 
0.05). 
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Fig 1.3.  Upper.  Protein expression of Nqo1 determined by western blot in 
livers of wild-type and Nrf2-null mice after treatment with OA (90 mg/kg, i.p.) 
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once daily for three days.  Also shown is the quantification of specific band 
intensity, normalized to β-actin, and expressed relative to control as mean ± 
S.E.M.  Lower.  Nqo1 enzyme activity in livers of wild-type and Nrf2-null mice 
after treatment with OA (90 mg/kg, i.p.) once daily for three days.  Units are in 
nmole DCPIP reduced per min per mg of protein expressed as mean ± S.E.M.  
Abbreviations:  Veh, Vehicle; OA, OA; WT, wild-type; null, Nrf2-null.   
Asterisks (*) indicate a statistically significant difference from wild-type mice 
receiving vehicle (p ≤ 0.05). 
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Fig 1.4.  Serum alanine transaminase (ALT) levels in wild-type and Nrf2-null 
mice pretreated with OA (90 mg/kg, i.p.) once daily for three days (n=5 for all 
groups except Nrf2-null mice receiving vehicle, n=4), administered 
acetaminophen (500 mg/kg, i.p.) on the fourth day, and sacrificed 8-h later.  
Units are in International Units/Liter (IU/L) expressed as mean ± S.E.M.  
Asterisks (*) indicate a statistically significant difference from wild-type mice 
receiving vehicle (p ≤ 0.05).   Daggers (†) indicate a statistically significant 
difference from Nrf2-null mice receiving vehicle (p ≤ 0.05). 
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Fig 1.5.  Messenger RNA expression of MT from livers of wild-type and Nrf2-
null mice after treatment with OA (90 mg/kg, i.p.) once daily for three days.  
Messenger RNA was quantified by the bDNA assay.  Data is expressed 
relative to wild-type controls as mean ± S.E.M. Asterisks (*) indicate a 
statistically significant difference from wild-type mice receiving vehicle (p ≤ 
0.05). 
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DISCUSSION 
OA is a natural triterpenoid used for many years in the treatment of 
hepatitis in China.  In mice, OA can protect the liver from various xenobiotics, 
such as the classic hepatotoxicants carbon tetrachloride, AA, bromobenzene, 
thioacetamide, and cadmium (Liu et al., 1993a; Liu et al., 1993b; Liu et al., 
1994a; Liu et al., 1994b; Liu et al., 1995a).   These chemicals exert hepatic 
damage, in part, by generating hepatocellualar oxidative stress (Marzella et 
al., 1986). 
Nrf2 is a transcription factor capable of inducing the expression of a 
battery of cytoprotective and antioxidant proteins, including Nqo1, Gclc, and 
Ho-1.  Nqo1 catalyzes the reduction of quinones, protecting cells against 
redox cycling and oxidative stress (Riley and Workman, 1992).  More 
specifically for this study, Nqo1 can reduce the toxic metabolite of AA back to 
the parent compound in vitro (Moffit et al., 2007).  Gclc is the rate-limiting 
enzyme in the synthesis of glutathione, a major antioxidant molecule in cells, 
which is critical for the maintenance of cellular redox homeostasis and 
detoxification of electrophiles (Dalton et al., 2000).  Ho-1 catalyzes the 
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breakdown of heme into bilirubin, carbon monoxide, and iron.  Bilirubin is an 
antioxidant, and its generation following Ho-1 induction reduces cytotoxicity 
caused by oxidative stress (Clark et al., 2000).  In addition, small quantities of 
carbon monoxide are cytoprotective, anti-apoptotic, vasorelaxant, and anti-
inflammatory (Ryter and Otterbein, 2004).  Also, hemin-mediated induction of 
Ho-1 or pretreatment with biliverdin (a bilirubin precursor) protects rats 
against AA-induced hepatotoxicity (Chiu et al., 2002).  
Previous studies have suggested that OA is unable to activate the 
Nrf2-Keap1 pathway because OA is a natural compound and lacks necessary 
functional groups (Michael acceptors) possessed by its synthetic derivatives, 
including CDDO-Im (Dinkova-Kostova et al., 2005; Yates et al., 2007).  Nqo1 
is a prototypical target gene of Nrf2 activation; therefore, Nqo1 mRNA 
expression and enzyme activity are used as biomarkers of Nrf2 activation.  In 
previous studies, OA was unable to induce Nqo1 activity in vitro in 
Hepa1c1c7 murine hepatoma cells (Dinkova-Kostova et al., 2005).  In 
addition, a low, single, oral dose of OA (9 mg/kg) failed to induce hepatic 
Nqo1 mRNA expression in mice (Yates et al., 2007).   Thus, in these previous 
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studies, OA did not activate Nrf2 because both the dose and number of doses 
of OA were insufficient. 
 Because it has previously been shown that OA (90 mg/kg, i.p.) given 
once daily for three days is protective against various hepatotoxicants (Liu et 
al., 1995a), the present studies were undertaken to establish whether OA is 
an activator of the Nrf2-Keap1 pathway.  OA (90 mg/kg, i.p.), given once daily 
for three days, increases nuclear accumulation of Nrf2 in wild-type, but not in 
Nrf2-null mice, as determined by both western blot of nuclear fractions and 
immunofluorescence.   Also, the OA-dosing regimen used in the current 
studies, increases mRNA of  Nrf2, as well as three characteristic Nrf2-target 
genes (Nqo1, Gclc, and Ho-1) in wild-type, but not in Nrf2-null mice.  
In addition to mRNA expression, Nqo1 protein expression and activity 
were quantified because Nqo1 is a prototypical Nrf2-target gene (Venugopal 
and Jaiswal, 1996; Dhakshinamoorthy and Jaiswal, 2000; Jaiswal, 2000; 
Dhakshinamoorthy and Jaiswal, 2001).  OA increased protein expression of 
Nqo1 in wild-type mice (Fig 4). Nrf2-null mice have lower Nqo1 protein 
expression than their wild-type counterparts, as reported previously 
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(Aleksunes et al., 2006c).  OA was not able to increase Nqo1 protein 
expression in Nrf2-null mice, which correlates with the mRNA expression 
data.  In addition, OA increased Nqo1 enzyme activity in wild-type, but not 
Nrf2-null mice. 
The functional involvement of Nrf2 in OA-mediated hepatoprotection 
was investigated using AA as a model hepatotoxicant.  AA produced liver 
injury in both genotypes, but the injury was more severe in Nrf2-null mice.  
Enhanced susceptibility of Nrf2-null mice to AA is consistent with previous 
reports (Enomoto et al., 2001).  OA-pretreatment of wild-type mice decreased 
AA hepatotoxicity.  OA-pretreatment also decreased AA hepatotoxicity in 
Nrf2-null mice, although the reduction was less than in the wild-type mice. 
Because OA also had some hepatoprotective effects against AA 
toxicity in Nrf2-null mice, the possibility that OA might induce MT in Nrf2-null 
mice and produce protection by this mechanism was evaluated.  MT is a low-
molecular-weight, cysteine-rich, metal-binding protein that is suggested to be 
capable of trapping reactive oxygen and nitrogen species, as well as 
electrophiles (Klaassen et al., 1999), which all contribute to the pathogenesis 
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of AA hepatotoxicity (Michael et al., 1999).  MT has at least one ARE in its 
promoter region and is induced by Nrf1 (a transcription factor in the same 
family as Nrf2), but not Nrf2 (Ohtsuji et al., 2008).  OA induces MT in both 
mice and rats (Liu et al., 2008), and OA-mediated MT induction protects 
against cadmium toxicity (Liu et al., 1993b).  In addition, MT-null mice are 
more susceptible than wild-type mice to AA-mediated hepatotoxicity (Liu et 
al., 1993b).   OA induced hepatic MT mRNA expression in both wild-type and 
Nrf2-null mice (Fig 5), which suggests that that other mechanisms, especially 
MT induction, in addition to Nrf2 activation might contribute to protection from 
OA-mediated hepatoprotection from AA. 
Other genes that may contribute to Nrf2-independent hepatoprotection 
by OA include a 70 kDa heat shock protein (Hsp70) and the G protein-
coupled bile acid receptor 1 (Gpbar1 or Tgr5).  Hsp70 mRNA is induced by 
OA (Liu et al., 2008) and acts to protect cells by reducing the ability of 
oxidized proteins to aggregate, permitting them time to refold and return to a 
functional conformation.  Furthermore, Hsp70-null mice are more sensitive to 
AA hepatotoxicity (Tolson et al., 2006).   TGR5 mRNA is also induced by OA 
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(Sato et al., 2007) and is a bile acid responsive and cell surface G protein-
coupled receptor that when activated suppresses macrophage 
proinflammatory cytokine production, particularly interleukin-1α (IL-1α), IL-1β, 
and tumor necrosis factor α (TNFα)  (Kawamata et al., 2003; Keitel et al., 
2008).  Induction of IL-1 and TNFα lead to induction of inducible nitric oxide 
synthase (iNos) (Busse and Mulsch, 1990; Kilbourn et al., 1990).  iNos 
contributes to acetaminophen hepatotoxicity by leading to increased 
production of nitric oxide and subsequent peroxynitrite formation.  Thus, iNos 
suppression, possibly mediated by OA, may contribute to the observed 
hepatoprotection from AA in Nrf2-null mice (Bourdi et al., 2002; James et al., 
2003).  Thus, OA has Nrf2-dependent and Nrf2-independent effects, both of 
which likely contribute to OA-mediated hepatoprotection from AA. 
Collectively, increased nuclear accumulation of Nrf2, increased mRNA 
expression of Nrf2-target genes, and up-regulation of Nqo1 protein and 
activity provide strong evidence that OA activates the Nrf2-Keap1 pathway.  
In addition OA protected from AA hepatotoxicty in wild-type but less so in 
Nrf2-null mice, suggesting that OA also activates Nrf2-independent 
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cytoprotective mechanisms.  Thus, this study establishes OA as a Nrf2 
activator; however, Nrf2-independent mechanisms that contribute to OA-
mediated hepatoprotection from AA require further study. 
  62
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
 
 
 
 
CDDO-Im Protects from Acetaminophen Hepatotoxcity Through 
Induction of Nrf2-Dependent Genes 
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ABSTRACT 
CDDO-Im is a synthetic triterpenoid recently shown to induce cytoprotective 
genes through the Nrf2-Keap1 pathway, an important mechanism for the 
induction of cytoprotective genes in response to oxidative stress.  Upon 
oxidative or electrophilic insult, the transcription factor Nrf2 translocates to the 
nucleus, heterodimerizes with small Maf proteins, and binds to antioxidant 
response elements (AREs) in the upstream promoter regions of various 
cytoprotective genes.  To further elucidate the hepatoprotective effects of 
CDDO-Im, wild-type and Nrf2-null mice were pretreated with CDDO-Im (1 
mg/kg, i.p.) or vehicle (DMSO), and then administered acetaminophen (500 
mg/kg, i.p.).  Pretreatment of wild-type mice with CDDO-Im reduced liver 
injury caused by acetaminophen.  In contrast, hepatoprotection by CDDO-Im 
was not observed in Nrf2-null mice.  CDDO-Im increased Nrf2 protein 
expression and Nrf2-ARE binding in wild-type, but not Nrf2–null mice.  
Furthermore, CDDO-Im increased the mRNA expression of the Nrf2 target 
genes NAD(P)H: quinone oxidoreductase-1 (Nqo1); glutamate-cysteine 
ligase, catalytic subunit (Gclc); and heme-oxygenase-1 (Ho-1), in both a 
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dose- and time-dependent manner.  Conversely, CDDO-Im did not induce 
Nqo1, Gclc, and Ho-1 mRNA expression in Nrf2-null mice.  Collectively, the 
present study shows that CDDO-Im pretreatment induces Nrf2-dependent 
cytoprotective genes and protects the liver from acetaminophen-induced 
hepatic injury. 
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INTRODUCTION 
Oxidative stress is an injurious phenomenon that results from an 
imbalance in the ratio of pro-oxidant species to anti-oxidative defense 
mechanisms within a cell that ultimately damages three major critical 
macromolecules in cells: DNA, lipids, and proteins.  Oxidative damage can 
lead to a variety of pathologies, including cancer, Parkinson’s disease, 
atherosclerosis, diabetes, Alzheimer’s disease, and even the aging process 
(Valko et al., 2007).  One, or a combination of the following three factors, 
manifests oxidative stress.  The first factor is an increase in the amount of 
oxidants, which include any number of highly reactive species possessing a 
single unpaired electron, capable of damaging DNA, lipids, and proteins.  In 
addition to the amount of oxidants, there can be a decrease in the antioxidant 
status.  Antioxidants include free radical scavengers, such as glutathione 
(GSH), ascorbic acid, and α-tocopherol.  There are also detoxifying enzymes 
that contribute to antioxidant status, such as glutathione-S-transferases 
(Gsts); UDP-glucuronyl transferases (Ugts); NAD(P)H: quinone 
oxidoreductase 1 (Nqo1); catalytic and modifier subunits of γ-glutamyl 
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cysteine ligase (Gclc, Gclm), which synthesize GSH; and heme oxygenase-1 
(Ho-1), which catabolizes heme into iron, carbon monoxide, and the free 
radical scavenger bilirubin (Cho et al., 2006).  Finally, an inability to repair 
oxidized DNA, lipids, and proteins also may contribute to oxidative stress.  
Examples of macromolecule repair include DNA repair by base or nucleotide 
exclusion, and protein repair by thioredoxin and glutaredoxin. 
Over the past decade, the Nrf2-Keap1 pathway has been 
characterized as an important endogenous mechanism for combating 
oxidative stress.  Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a 
transcription factor that induces the expression of various cytoprotective 
enzymes possessing an antioxidant response element (ARE) in the promoter 
region.  Nrf2 activation and subsequent cytoprotective gene induction 
promotes the restoration of the balance between oxidants and antioxidants 
after oxidative insult.  Under conditions where oxidative stress is low, kelch-
like ECH-associated protein-1 (Keap1) sequesters Nrf2 in the cytosol and 
acts as an adaptor for Cul3-based E3 ligase to regulate proteasomal 
degradation of Nrf2 (Tong et al., 2006).  Increased oxidative stress promotes 
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Nrf2 avoidance of Keap1-mediated proteasomal degradation by Cul3 and 
subsequent translocation of Nrf2 into the nucleus. Once in the nucleus, Nrf2 
heterodimerizes with a small musculo-aponeurotic fibrosarcoma (Maf) protein 
and binds to the ARE, promoting transcription of various cytoprotective genes 
(Itoh et al., 1997).  Nrf2-target genes include, but are not limited to Gsts, 
Nqo1, Ugts, Gclc, Gclm, and Ho-1, collectively being referred to as the “Nrf2 
regulon” (Kobayashi and Yamamoto, 2006).  Furthermore, Nrf2-null mice are 
susceptible to injury from acetaminophen (Enomoto et al., 2001), 
benzo[a]pyrene (Ramos-Gomez et al., 2001), diesel exhaust (Aoki et al., 
2001), hyperoxia (Cho et al., 2002), hydrogen peroxide (Kraft et al., 2004), 
and other types of oxidative stress-induced injury. 
Oleanolic acid is a naturally-occurring triterpenoid used in China for the 
treatment of hepatitis and is protective against chemical-induced liver injury in 
mice (Liu et al., 1993; 1995a; 1995b).  Although, the limited efficacy of many 
naturally-occurring substances often precludes clinical use, but they may 
serve as a critical foundation for drug development.  In an effort to create a 
more efficacious and potent triterpenoid, 2-cyano-3,12 dioxooleana-1,9 diene-
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28-imidazolide (CDDO-Im) was synthesized (Honda et al., 1998).   CDDO-Im 
has been characterized as being effective in diminishing iNOS production in 
an in vivo model of inflammation (Place et al., 2003).  CDDO-Im also 
activates the Nrf2-Keap1 pathway in both in vitro and in vivo models (Liby et 
al., 2005).  Furthermore, pretreatment with CDDO-Im is protective against the 
LPS-inflammatory response and aflatoxin-induced liver tumorigenesis 
(Thimmulappa et al., 2006; Yates et al., 2006).  The ability of CDDO-Im to act 
as both an anti-inflammatory and antioxidant chemical renders this compound 
a prime candidate for chemoprevention. 
The purpose of the present study was to evaluate the protective effects 
of CDDO-Im in an acute chemical model of acetaminophen-induced 
hepatotoxicity.  Because oxidative stress is a main contributor to the 
hepatotoxic effects of acetaminophen (Knight et al., 2001; Jaeschke et al., 
2003), and CDDO-Im has been previously shown to activate Nrf2, the 
hepatoprotective effects of CDDO-Im against acetaminophen hepatotoxicity 
were evaluated in both wild-type and Nrf2-null mice. 
 
  69
METHODS 
Materials. Acetaminophen and DMSO were purchased from Sigma-Aldrich 
(St. Louis, MO).  CDDO-Im was a generous gift from Dr. Michael Sporn 
(Dartmouth College, Hanover, New Hampshire).  β-actin antibody was 
purchased from Abcam (Ab8227, Cambridge, MA).  Nrf2 antibody was 
purchased from Santa Cruz Biotechnology (sc-30915, Santa Cruz, CA). 
Animals and Husbandry.  Eight-week-old male C57BL/6 mice were 
purchased from Charles River Laboratories, Inc. (Wilmington, MA).  Nrf2-null 
mice on a mixed C57BL/6 and AKR background were obtained from Dr. 
Jefferson Chan (University of California-Irvine, Irvine, CA).  Nrf2-null mice 
were then backcrossed seven generations into C57BL/6 mice and >99% 
congenicity was determined by Jackson Laboratories (Bar Harbor, ME).   
Animals were housed in a temperature-, light-, and humidity-controlled 
environment and had access to Teklad Rodent Diet #8604 (Harlan 
Laboratories, Madison, WI) and water ad libitum.  The housing facility is an 
American Animal Associations Laboratory Animal Care-accredited facility at 
the University of Kansas Medical Center, and all procedures were 
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preapproved in accordance with Institutional Animal Care and Use Committee 
guidelines. 
Hepatotoxicity Study.  Mice were treated with CDDO-Im (1 mg/kg, i.p.) or 
vehicle (DMSO, 5 mL/kg, i.p.) once daily for three days.  On the fourth day, 
mice were administered acetaminophen (500 mg/kg, i.p.) or vehicle (saline, 
pH 8, 20 mL/kg, i.p.).   Six hours after acetaminophen administration, blood 
samples were taken for quantification of serum ALTs and liver samples were 
taken for histopathology. A sample of liver was also frozen in liquid nitrogen 
and stored at -80ºC. 
Serum alanine aminotransferase (ALT) concentrations.  Serum ALT 
concentrations were determined as a biochemical indicator of hepatocellular 
necrosis using Pointe Scientific Liquid ALT Reagent Set (Canton, MI) 
according to the manufacturer's protocol. 
Histopathology.  Samples were taken consistently as cross-sections of the 
largest lobe of the liver.  Liver sections, approximately 5 µm thick, were fixed 
in 10% neutral-buffered zinc formalin, processed, stained with hematoxylin 
and eosin, and analyzed by light microscopy for liver injury.  Samples were 
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blinded before analysis.  Grade of liver injury was analyzed semiquantitatively 
with six scores of severity: 0, none; 1, minimal (>2 foci of single cell necrosis 
per section); 2, mild (at least 5 areas of focal necrosis per section); 3, 
moderate (at least five foci of zonal necrosis per section); 4, severe (lobular 
damage, with many viable lobules per section); and 5, global (severe lobular 
damage, few areas of viability per section).  A section was defined as a single 
viewpoint at low power (x100) magnification. 
Nrf2 Protein Expression.  Nuclear extracts were prepared with the NE-PER 
nuclear extraction kit according to the manufacturer's directions (Pierce 
Biotechnology, Rockford, IL).  Protein concentrations were determined with 
the BCA Assay Kit from Pierce Biotechnology (Rockford, IL).   Nuclear 
proteins (60 µg protein/lane) were electrophoretically resolved using 
polyacrylamide gels (4% stacking and 7.5% resolving).  Gels were 
transblotted overnight at 4ºC onto a polyvinylidene fluoride membrane.  
Membranes were then washed with PBS–buffered saline containing 0.05% 
Tween-20 (PBS-T).  Membranes were blocked for 1 h at room temperature 
with 5% non-fat milk in PBS–T.  Blots were then incubated with primary 
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antibody (1:1000 dilution, in 2% non-fat milk in PBS-T) for 3 h at room 
temperature.  Blots were then washed in PBS-T and incubated with 
secondary antibody conjugated with horseradish peroxidase (1:2000 dilution, 
in 2% non-fat milk in PBS-T) for 1 hr at room temperature.   Blots were then 
washed with PBS-T.  Protein-antibody complexes were detected using an 
enhanced chemiluminescent kit (Pierce Biotechnology, Rockford, IL) and 
exposed to X-ray film (Denville Scientific, Metuchen, NJ).  Intensity of protein 
bands was quantified using the Discovery Series Quantity One 1-D Analysis 
software (Bio-Rad Laboratories, Hercules, CA).  Intensity values were 
expressed as protein expression relative to control.  β-actin was utilized as a 
loading control. 
Nrf2-ARE binding.  Nrf2-ARE binding was determined using the ELISA-
based TransAM™ Nrf2 Kit from Active Motif, according to manufacturer 
specifications (Carlsbad, CA).   Briefly, the kit contains a 96-well plate to 
which oligonucleotides containing the consensus ARE have been 
immobilized.  Nrf2 from nuclear extracts then binds to the oligonucleotide and 
is detected through use of an antibody against Nrf2.  A secondary antibody 
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conjugated to horseradish peroxidase is then added and allowed to bind to 
the primary antibody.   The signal is detected at 450 nm using a 
spectrophotomer.  The data is displayed as mean optical density (OD) at 450 
nm. 
Dose-Response Study.  Wild-type mice were dosed (i.p.) with CDDO-Im at 
0.1, 1.0, 3.0, or 10.0 mg/kg or vehicle (DMSO, 5 mL/kg).  Nrf2-null mice were 
dosed (i.p.) with CDDO-Im at 1.0 mg/kg or vehicle (DMSO, 5 mL/kg).  Livers 
were removed 6 hrs after dosing, frozen in liquid nitrogen, and stored at -80ºC 
until RNA isolation.  
Time-Course Study. Wild-type mice were dosed with CDDO-Im  (1 mg/kg, 
i.p.) or vehicle (DMSO, 5 mL/kg, i.p.).  Livers were removed 6, 12, 18, 24, 48, 
and 72 hrs after dosing, frozen in liquid nitrogen, and stored at -80ºC until 
RNA isolation.  
Total RNA Isolation. Total RNA was isolated using RNA-Bee reagent (Tel-
Test, Inc., 
Friendswood, TX) according to the manufacturer’s protocol.  Total RNA 
concentrations were determined spectrophotometrically at 260 nm.  Two 
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hundred ng/µl RNA solutions were prepared by dilution with diethyl 
pyrocarbonate-treated deionized water. 
Branched DNA Signal Amplification (bDNA) Analysis. Specific mRNAs 
were quantified using the bDNA assay (1.0 Quantigene bDNA signal 
amplification kit; Panomics, Inc., Fremont, CA).  Gene sequences of interest 
were accessed from GenBank.  Target sequences were analyzed using 
ProbeDesigner software v1.0 (Bayer Corp., Emeryville, CA) to design 
oligonucleotide probe sets (capture, label, and blocker probes).  All probes 
were designed with a melting temperature of 63ºC, enabling hybridization 
conditions to be held constant (i.e., 53ºC) during each hybridization step.  
Probe sets for Ho-1 and Nqo1 were developed as described previously 
(Aleksunes et al., 2005).   Probe sets for Gclc are listed in Table 1.1.  Total 
RNA was added to each well of a 96-well plate containing 50 µL of each 
diluted probe set.  RNA was allowed to hybridize at 53ºC with the probe sets 
overnight.  Subsequent hybridization steps were carried out according to the 
manufacturer’s protocol, and luminescence was quantified with a Quantiplex 
320 bDNA luminometer interfaced with Quantiplex Data Management 
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software v5.02.  Data are presented as relative light units (RLU) or as 
normalized to control. 
Statistical Analysis. All data were analyzed using one-way analysis of 
variance (ANOVA) followed by Duncan's multiple range test (p < 0.05).   ALT 
values were log transformed before statistical analysis.  Histopathological 
data were rank ordered prior to ANOVA analysis, which was followed by 
Newman-Keuls multiple range test (p ≤ 0.05). 
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RESULTS 
CDDO-Im pretreatment lowers serum ALT concentrations and necrosis 
in livers of wild-type but not Nrf2-null mice after acetaminophen 
administration. CDDO-Im or vehicle (DMSO) did not increase serum ALT 
concentrations in wild-type or Nrf2-null mice (data not shown).  Wild-type 
mice administered acetaminophen had elevated serum ALT concentrations 
(481 IU/L).  Acetaminophen administered to CDDO-Im pretreated wild-type 
mice resulted in less of an increase in serum ALT concentrations (110 IU/L) 
(Fig 2.1).  After acetaminophen administration, Nrf2-null mice had much 
higher serum ALT concentrations (2103 IU/L) than wild-type mice, as 
previously reported (Enomoto et al., 2001).  Acetaminophen administered to 
CDDO-Im pretreated Nrf2-null mice resulted in serum ALT concentrations 
similar to Nrf2-null mice not pretreated with CDDO-Im. 
CDDO-Im did not produce histologically observable abnormalities in 
either wild-type or Nrf2-null mice (data not shown).  Grading of liver necrosis 
after acetaminophen is shown in Table 2.2.  Acetaminophen produced 
moderate hepatic necrosis in wild-type mice, however, CDDO-Im 
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pretreatment reduced the acetaminophen-induced hepatic necrosis.  
Acetaminophen produced much more severe hepatotoxicity in the Nrf2-null 
mice, and CDDO-Im pretreatment did not protect Nrf2-null mice from 
acetaminophen-induced necrosis.  
Effect of CDDO-Im on translocation of Nrf2 to the nucleus and binding to 
the ARE.   CDDO-Im increased Nrf2 protein expression 380% in hepatic 
nuclear fractions from wild-type mice (Fig 2.2, upper).  No Nrf2 protein was 
detected in vehicle or CDDO-Im-administered Nrf2-null mice.   Activated Nrf2 
(or Nrf2 capable of binding to the ARE) in hepatic nuclear fractions was 
determined via ELISA (Fig 2.2, lower).  CDDO-Im activated Nrf2 in wild-type 
mice, whereas no activated Nrf2 was detected in vehicle or CDDO-Im treated 
Nrf2-null mice. 
Dose- and time- dependent effects of CDDO-Im on Ho-1, Nqo1, and Gclc 
induction in wild-type mice.  Wild-type mice were administered various 
doses of CDDO-Im from 0.1 to 10 mg/kg, i.p., and hepatic Ho-1, Nqo1, and 
Gclc mRNA expression were quantified (Fig 2.3, upper).  CDDO-Im induced 
Ho-1 mRNA expression at all dosages used, with a 125% increase after 0.1 
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mg/kg and 765% increase at 10 mg/kg.  CDDO-Im did not induce Nqo1 or 
Gclc at 0.1 mg/kg.  However, CDDO-Im did increase mRNA expression of 
both Nqo1 and Gclc at 1.0 mg/kg (58 and 156%, respectively) with much 
more induction observed after the highest dose of 10 mg/kg (199 and 408%, 
respectively). 
To determine the time-response effects of CDDO-Im, wild-type mice 
were administered CDDO-Im (1 mg/kg, i.p.), and livers removed at various 
times thereafter (6-72 hrs) (Fig 2.3, lower).  CDDO-Im induced Ho-1 mRNA 
expression, which was induced only at 6 hrs (224%).  Nqo1 peaked between 
18-24 hrs (323%) and returned back to control levels by 48 hrs, whereas Gclc 
mRNA induction peaked at 12 hrs (272%) and returned to control levels by 48 
hrs.   
Effect of CDDO-Im and acetaminophen on Ho-1, Nqo1, and Gclc-1 mRNA 
induction in wild-type and Nrf2-null mice.  CDDO-Im or vehicle was 
administered to wild-type and Nrf2-null mice.  CDDO-Im induced Ho-1 
(411%), Nqo1 (153%), and Gclc (248%) mRNA expression in wild-type mice 
(Fig 2.4).   Wild-type mice pretreated with CDDO-Im or vehicle and 
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administered acetaminophen had increased Gclc and Nqo1 mRNA 
expression compared to wild-type mice receiving CDDO-Im or vehicle only.   
Interestingly, wild-type mice pretreated with CDDO-Im and then administered 
acetaminophen had lower Ho-1 mRNA expression than wild-type mice 
pretreated with vehicle and administered acetaminophen.  Furthermore, 
CDDO-Im pretreatment had no effect on Nqo1 or Gclc mRNA expression 
when acetaminophen was also administered.   Neither CDDO-Im, 
acetaminophen, nor combination of the two induced Ho-1, Nqo1, or Gclc 
mRNA expression in Nrf2-null mice. 
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Table 2.1.  Histological analysis of livers from vehicle- and CDDO-Im-
pretreated wild-type and Nrf2-null mice after AA challenge. 
 
 Histological Grade  
Treatment Group 0 1 2 3 4 5 p≤0.05 
Wild-type VC-AA 0 0 1 4 0 0  
Wild-type CDDO-Im-AA 0 2 3 0 0 0 * 
Nrf2-null VC-AA 0 0 0 0 3 2 * 
Nrf2-null CDDO-Im-AA  0 0 0 2 1 2  
Grade of liver injury was analyzed at low power (x100) with six scores of 
severity: 0, none; 1, minimal (>2 foci of single cell necrosis per section); 2, 
mild (at least 5 areas of focal necrosis per section); 3, moderate (at least five 
foci of zonal necrosis per section); 4, severe (lobular damage, with many 
viable lobules per section); and 5, global (severe lobular damage, few areas 
of viability per section).  Asterisks (*) indicate a statistically significant 
difference from DMSO pretreated wild-type mice (p ≤ 0.05). 
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Figure 2.1.  Serum alanine transaminase (ALT) levels in wild-type and Nrf2-
null mice (n=5) pretreated with vehicle (DMSO) or CDDO-Im and then 
administered acetaminophen.  ALT concentrations are expressed as 
International Units/Liter.  Values are expressed as mean ± S.E.M.  ALT 
values were log transformed before statistical analysis.  Asterisks (*) indicate 
a statistically significant difference from DMSO pretreated wild-type mice (p ≤ 
0.05).  
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Figure 2.2.  Upper.  Protein expression of Nrf2 determined by western blot in 
livers of wild-type and Nrf2-null mice after treatment with CDDO-Im (1 mg/kg, 
i.p.) once daily for three days.  Also shown is the quantification of specific 
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band intensity, expressed relative to control as mean ± S.E.M.  Lower.  
Activated Nrf2 (or Nrf2 capable of binding to the ARE) in hepatic nuclear 
fractions was determined via.  Values are expressed as mean optical density 
(OD) at 450 nm ± S.E.M. 
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Figure 2.3.  Upper.  Hepatic mRNA expression of Nqo1, Gclc, and Ho-1 in 
wild-type mice after various doses of CDDO-Im.  Livers were removed 6 h 
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after dosing and mRNA quantified by the bDNA assay.  Lower. Hepatic 
mRNA expression of Nqo1, Gclc, and Ho-1 in wild-type mice at different time 
points after CDDO-Im (1 mg/kg, i.p.) administration. mRNA was quantified by 
the bDNA assay. Data is expressed as relative to control mean ± S.E.M.  
Asterisks (*) indicate statistically significant differences between CDDO-Im 
treated and control groups (p ≤ 0.05).  
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Figure 2.4.  Messenger RNA expression of Nqo1, Gclc, and Ho-1 in livers of 
wild-type and Nrf2-null mice after CDDO-Im (1 mg/kg, i.p.) or DMSO 
administration.  Also, shown is the combined effect of CDDO-Im and 
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acetaminophen in wild-type and Nrf2-null mice.  Messenger RNA was 
quantified by the bDNA assay.  Data is expressed as Relative Light Units 
(RLU) per 7.5 µg of total RNA.  Abbreviations: WT, wild-type; null, Nrf2-null.  
Values are expressed as mean ± S.E.M.  Asterisks (*) indicate statistically 
significant differences between treated and control groups (p ≤ 0.05). 
Daggers (†) indicate a statistically significant increase from CDDO-Im treated 
wild-type mice. 
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DISCUSSION 
CDDO-Im has emerged in recent years as a possible protective 
compound against oxidative stress.  CDDO-Im decreases the inflammatory 
response in a variety of in vitro and in vivo models.  For example, CDDO-Im 
decreases iNOS formation in vivo in primary mouse macrophages after 
interferon-g administration (Place et al., 2003).  Also, related triterpenoid 
compounds have been shown to decrease the inflammatory response 
through direct inactivation of IkBa-kinase, resulting in a decrease in NFkB 
activation (Shishodia et al., 2006).   
CDDO-Im activates the Nrf2-Keap1 pathway (Liby et al., 2005).  
Activation of the Nrf2-Keap1 pathway leads to a cytoprotective response 
through the up-regulation of genes containing an antioxidant response 
element in their promoter regions (Itoh et al., 1997).  Cytoprotective genes 
exert their effects by decreasing the amount of oxidative stress and restoring 
the balance between oxidants and antioxidants in the cell.   Pretreatment with 
CDDO-Im protects the liver from aflatoxin-induced tumorigenesis (Yates et 
al., 2006).  Furthermore, it has also been shown that CDDO-Im protects from 
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the LPS-inflammatory response via a Nrf2-dependent mechanism 
(Thimmulappa et al., 2006).         
Because liver is the major site of biotransformation for exogenous 
chemicals, a model of hepatotoxicity that involves electrophilic stress was 
utilized.  Acetaminophen is primarily metabolized in the liver by 
sulfotransferases (Sults) and Ugts.  High doses of acetaminophen saturate 
sulfation and glucuronidation detoxification pathways and result in a larger 
fraction of acetaminophen being biotransformed to the reactive intermediate, 
N-acetyl-p-benzoquinone imine (NAPQI), by cytochrome p450 2e1 (CYP2e1).  
NAPQI is detoxified by GSH conjugation, however, upon GSH depletion, 
NAPQI covalently binds to critical macromolecules and produces 
hepatotoxicity (Parkinson et. al, 2008).  NQO1 is not only capable of 
detoxifying NAPQI (Moffit et al., 2007), but is induced in livers of patients who 
died from acetaminophen overdose (Aleksunes et al., 2006), suggesting that 
NQO1 induction may be an adaptive response to acetaminophen 
hepatotoxicity.   Because Nrf2 target genes, such as Nqo1, are involved in 
detoxification of highly reactive intermediates, a chemical that activates Nrf2 
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might be a good cytoprotective compound, protecting from the hepatotoxicity 
of acetaminophen and other chemicals.   
The present study was aimed at characterizing the hepatoprotective 
effects of CDDO-Im against a well-known hepatotoxicant, acetaminophen.  
CDDO-Im pretreatment protected wild-type mice from acetaminophen-
induced hepatic injury, as determined by serum ALTs and histopathology.  In 
contrast, CDDO-Im pretreatment did not protect from acetaminophen 
hepatotoxicity in Nrf2-null mice. 
CDDO-Im facilitated Nrf2 translocation to the nucleus, which correlated 
with increased Nrf2 binding to consensus AREs (Fig 2.2).  Furthermore, the 
Nrf2-dependent genes Ho-1, Nqo1, and Gclc were induced in both a dose- 
and time- dependent manner by CDDO-Im.  Ho-1 mRNA expression was up-
requlated the most by CDDO-Im, followed by Gclc, and then Nqo1.  The 
induction of Ho-1, Nqo1, and Gclc in livers of wild-type mice by CDDO-Im was 
not observed in Nrf2-null mice, strongly suggesting the induction of 
cytoprotective genes and subsequent hepatoprotective effects of CDDO-Im 
are Nrf2-dependent.   
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Acetaminophen induced Ho-1, Nqo1, and Gclc in wild-type but not Nrf2 
–null mice, similar to a previous report (Aleksunes et al., 2008).  Pretreatment 
of wild-type mice with CDDO-Im did not further induce Nrf2 target genes in 
response to acetaminophen, suggesting that CDDO-Im-mediated 
hepatoprotection is not related to the adaptive response to acetaminophen 
injury.  Rather, CDDO-Im pretreatment enhanced Nrf2 cytoprotective gene 
expression prior to acetaminophen exposure, which likely contributed to 
detoxification of the reactive electrophilic intermediate NAPQI, as well as 
resulting oxidative stress, thereby protecting against hepatic damage.    In 
conclusion, CDDO-Im pretreatment induces Nrf2-dependent genes, in both a 
dose- and time-dependent manner, which protects from acetaminophen-
induced hepatotoxicity.  
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Characterization of Keap1-Knockdown Mice with Enhanced Activation 
of Nrf2 
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CHAPTER THREE 
 
 
 
 
Increased Nrf2 Activation in Livers from Keap1-Knockdown Mice 
Increases Expression of Cytoprotective Genes that Detoxify 
Electrophiles More Than Those That Detoxify Reactive Oxygen Species 
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ABSTRACT 
Nrf2 is a transcription factor critical for protection against electrophilic 
and oxidative stress.  In a recently engineered mouse with knockdown of 
Keap1 (Keap1-kd mice), the cytosolic repressor of Nrf2, there is a 55% 
decrease in Keap1 mRNA and a 200% increase in Nrf2 protein in liver.  
Experiments with Nrf2-null mice have demonstrated the effects of a lack of 
Nrf2.  However, little is known about the biological effects of more Nrf2 
activation.  Accordingly, the hepatic phenotype of Keap1-kd mice, as well as 
the hepatic mRNA expression of cytoprotective genes were compared among 
wild-type, Nrf2-null, and Keap1-kd mice.  Three distinct patterns of hepatic 
gene expression were identified among wild-type, Nrf2-null, and Keap1-kd 
mice.  The first pattern encompassed genes that were lower in Nrf2-null mice 
and considerably higher in Keap1-kd mice than wild-type mice, which 
included genes mainly responsible for the detoxification and elimination of 
electrophiles, such as NAD(P)H:quinone oxidoreductase 1 (Nqo1) and 
glutathione-S-transferases (Gst), and multidrug resistance-associated 
proteins (Mrps).  The second pattern encompassed genes that were lower in 
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Nrf2-null mice but not increased in Keap1-kd mice, and included genes, such 
as epoxide hydrolase-1, UDP-glucuronosyltransferases, aldehyde 
dehydrogenases, as well as genes important in the detoxification of reactive 
oxygen species, such as superoxide dismutase 1 and 2, catalase, and 
peroxiredoxin 1.  The third pattern encompassed genes that were not different 
among wild-type, Nrf2-null, and Keap1-kd mice and included genes such as 
glutathione peroxidase, microsomal Gsts, and uptake transporters.   In 
conclusion, the present study suggests that increased activation of hepatic 
Nrf2 is more important for the detoxification and elimination of electrophiles 
than reactive oxygen species. 
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INTRODUCTION 
Oxidative and electrophilic stresses are implicated in the development 
of numerous diseases.  Oxidative stress is caused by increased production of 
reactive oxygen and nitrogen species, such as superoxide, hydroxyl radical, 
and peroxynitrite, or by depletion of protective antioxidants, such as reduced 
glutathione (GSH), ascorbate, and α-tocopherol.  Oxidative stress leads to 
oxidative damage to critical macromolecules.  Superoxide is enzymatically 
detoxified by first being converted to hydrogen peroxide and then to water by 
catalase (Cat), GSH peroxidase (Gpx), or peroxiredoxin (Prx) (Fig 1, left 
side).   Detoxification of the hydroxyl radical is not usually possible because of 
its short half-life (10-9s), and thus prevention of its formation by detoxification 
of its precursor hydrogen peroxide by Cat, Gpx, or Prx is necessary.  
Detoxification of peroxynitrite to nitrite is carried out by Gpx and Prx; GSH 
may also be capable of reducing perxoxynitrite to nitrite (Harwood et al., 
2006; Trujillo et al., 2008).  
Electrophilic stress is caused by effects of reactive metabolites, such 
as the cytochrome p-450 (Cyp)-mediated formation of N-acetyl-p-benzo-
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quinoneimine (NAPQI) in acetaminophen hepatotoxicity, or the epoxide 
formed in benzo[a]pyrene-mediated carcinogenesis.  Electrophiles cause 
injury by covalently binding to and damaging critical macromolecules.  
Detoxification of reactive intermediates or electrophiles typically occurs 
through enzymatic processes, such as conjugation with GSH by glutathione-
S-transferases (Gsts), reduction of quinones by NAD(P)H:quinone 
oxidoreductase 1 (Nqo1), or hydrolysis of epoxides by epoxide hydrolase-1 
(Eh-1) (Fig 1, right side).  Nucleophilic conjugation mediated by UDP-
glucuronosyltransferases (Ugts) or sulfotransferases (Sults) can also prevent 
the formation of electrophiles by limiting xenobiotic availability for toxification 
by Cyps or peroxidases (Pods). 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is an important 
transcriptional regulator of antioxidative cellular protection.   Upon cellular 
oxidative/electrophilic insult, Nrf2 initiates a response by up-regulating a 
battery of cytoprotective genes, such as Nqo1, glutamate-cysteine ligase, 
catalytic and modifier subunits (Gclc and Gclm), heme oxygenase-1 (Ho-1), 
and drug processing genes, such Gsts, Ugts, and multidrug resistance-
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associated proteins (Mrps) (Venugopal and Jaiswal, 1996; Kobayashi and 
Yamamoto, 2006; Maher et al., 2007).  Moreover, inductive control over a 
broad array of genes that facilitate increased detoxification and clearance of 
reactive metabolites and xenobiotics has earned Nrf2 a crucial role in 
toxicology and xenobiotic metabolism. 
Under physiological conditions, Nrf2 is bound in the cytosol by its 
repressor Kelch-like ECH associating protein 1 (Keap1).  Keap1 functions as 
an adapter for Cullin 3 (Cul3)-based E3 ligase, a scaffold protein that aids in 
the ubiquitination and subsequent degradation of Nrf2 (Cullinan et al., 2004; 
Kobayashi et al., 2004).   In fact, Nrf2 has a very rapid turnover, with a half-
life of approximately 20 min, and thus Nrf2 protein is difficult to detect in 
unstressed conditions (Itoh et al., 2003; McMahon et al., 2003).  When an 
oxidative or electrophilic insult occurs, reactive cysteines of Keap1 are 
modified, and Keap1 is unable to target Nrf2 for proteasomal degradation 
(Dinkova-Kostova et al., 2002).   Nrf2 then translocates into the nucleus, 
heterodimerizes with a small musculo-aponeurotic fibrosarcoma (Maf) protein, 
and binds to antioxidant response elements (ARE) in the upstream promoter 
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region of a variety of cytoprotective genes, promoting their transcription (Itoh 
et al., 1997). 
Nrf2-null mice have lower constitutive expression and an inability to 
induce cytoprotective genes, such as Nqo1 and Gclc, upon 
oxidative/electrophlic insult.  Nrf2-null mice are extremely susceptible to 
chemical models of oxidative and electrophilic stress (Aleksunes and 
Manautou, 2007), contributing to increased hepatotoxicity when administered 
acetaminophen (Enomoto et al., 2001), ethanol (Lamle et al., 2008), 
pentacholorphenol (Umemura et al., 2006), or a high-fat diet (Tanaka et al., 
2008b). 
In contrast to Nrf2-null mice, Keap1-null mice were engineered to 
investigate the effects of increased activation of Nrf2.  Unfortunately, even 
though Keap1-null mice have enhanced activation of Nrf2 and higher 
constitutive expression of Nrf2-target genes, the mice died at weaning due to 
malnutrition from hyperkeratosis of the esophagus and forestomach 
(Wakabayashi et al., 2003).  In an attempt to circumvent the post-natal 
lethality in Keap1-null mice, a hepatocyte-specific Keap1-null mouse was 
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engineered, utilizing an Albumin-Cre loxP system.  This mouse is viable, has 
enhanced activation of Nrf2 and Nrf2-target genes in liver, and decreased 
susceptibility to acetaminophen hepatotoxicity (Okawa et al., 2006).  
However, later it was discovered that mice homozygous for Keap1 loxP sites 
(no Albumin-Cre transgene) have decreased or a “knockdown” of Keap1 
(Keap1-kd), leading to increased activation of Nrf2 in multiple organs (Okada 
et al., 2008).  
A considerable amount of knowledge has accumulated on the effect of 
a lack of Nrf2 by doing experiments in Nrf2-null mice.  However, very little is 
known about the biological effects of increased Nrf2 expression.  Therefore, 
the purpose of this study was to determine the hepatic phenotype of Keap1-
kd mice, as well as the mRNAs of genes whose protein products are thought 
to protect against oxidative and electrophilic stress, were compared with Nrf2-
null and wild-type mice.  The model used in the present study for increased 
activation of Nrf2 is the Keap1-knockdown (Keap1-kd) mouse.  Both mouse 
models, Nrf2-null and Keap1-kd, have been backcrossed into C57BL/6 mice 
to >99% congenicity, allowing for comparisons among wild-type, Nrf2-null, 
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and Keap1-kd mice without the added variable of strain differences. 
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METHODS 
Reagents.  Nrf2 antibody was purchased from Santa Cruz Biotechnology (sc-
30915, Santa Cruz, CA).  β-Actin antibody was purchased from Abcam 
(Ab8227, Cambrdige, MA).   PolyADP-ribose Polymerase (PARP) antibody, 
originally purchased from BD Pharmingen (cat. # 556362, San Jose, CA), 
was a gift from Dr. John Robertson (University of Kansas Medical Center, 
Kansas City, KS).  All other chemicals, unless otherwise specified, were 
purchased from Sigma-Aldrich (St. Louis, MO).  
Animals and Husbandry.  Eight-week-old male C57BL/6 mice were 
purchased from Charles River Laboratories Inc (Wilmington, MA).  Nrf2-null 
mice were obtained from Dr. Jefferson Chan (University of California, Irvine, 
Irvine, CA) (Chan et al., 1996).  Keap1-kd mice were supplied by Dr. 
Masayuki Yamamoto (Tohoku University, Aoba-ku, Sendai, Japan) (Okada et 
al., 2008).  In an attempt to make a hepatocyte-specific Keap1-null mouse, 
utilizing a loxP, Alb-Cre system (Okawa et al., 2006), a Keap1-kd mouse, in 
which Keap1 was decreased throughout the body, was engineered (Okada et 
al., 2008). 
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Nrf2-null and Keap1-kd mice were backcrossed into the C57BL/6 
background, and >99% congenicity was confirmed by the speed congenics 
group at Jackson Laboratories (Bar Harbor, ME).  Animals were housed in a 
temperature-, light-, and humidity-controlled environment and had access to 
Teklad Rodent Diet #8604 (Harlan Laboratories, Madison, WI) and water ad 
libitum.  The housing facility is an American Animal Associations Laboratory 
Animal Care-accredited facility at the University of Kansas Medical Center, 
and all procedures were preapproved in accordance with Institutional Animal 
Care and Use Committee guidelines. 
Bile Collection.  Wild-type, Nrf2-null, and Keap1-kd mice (n=5) were 
anesthetized by injection of ketamine/midazolam (100 mg/kg and 5 mg/kg, 
respectively, i.p.).  Body temperature was maintained at 37°C by rectal-probe 
controlled heating pads. Subsequently, the common bile duct was cannulated 
with the shaft of a 30-gauge needle attached to PE-10 tubing through a high 
abdominal incision.  Bile was collected for 15 min into pre-weighed 0.6-ml 
microcentrifuge tubes and immersed in ice.  The volumes of bile samples 
were determined gravimetrically, using 1.0 as specific gravity for bile.   
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Serum and bile enzyme analyses.  Glucose, alanine transaminase (ALT), 
triglycerides, cholesterol, phospholipids, and total bilirubin concentrations 
were quantified spectrophotometrically using commercially available kits 
(Pointe Scientific, Canton, MI). 
Hepatic enzyme analyses.  Livers were collected from wild-type, Nrf2-null, 
and Keap1-kd mice (n=5) in the morning (prior to 11:00 a.m.)  Livers were 
homogenized in ice-cold 10 mM sucrose- 250 mM Tris buffer (pH 7.5), and 
microsomal suspensions were prepared by differential centrifugation.  
Microsomal protein concentrations were determined by BCA Assay (Pierce 
Biotechnology, Rockford IL).  Microsomal cytochrome p450 (Cyp) activities 
were determined by XenoTech, LLC (Lenexa, KS) using established 
methods.  Briefly, Cyp1a1 and 2b1 activities were quantified by fluorimetric 
analysis of 7-ethoxyresorufin O-deethylation and 7-pentoxyresorufin O-
deethylation, respectively.  Cyp2e1 activity was determined by 
spectrophotometric analysis of 4-nitrophenol hydroxylation.  Lastly, Cyp3a11 
and 4a14 activities were measured by LC-MS/MS analysis of testosterone 6β-
hydroxylation and lauric acid 12-hydroxylation, respectively.   
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Cytosolic extracts were prepared with the NE-PER nuclear extraction 
kit according to the manufacturer's directions (Pierce Biotechnology, 
Rockford, IL).  Protein concentrations were determined by the BCA Assay 
(Pierce Biotechnology, Rockford IL).  Hepatic glutathione peroxidase (GPx) 
and catalase (Cat) activity in cytosolic fractions were quantified 
spectrophotometrically, as adapted from previously described methods (Luck, 
1963; Tappel, 1978; Flohe and Gunzler, 1984).  Superoxide dismutase (Sod) 
activity was quantified spectrophotometrically utilizing a commercially 
available kit (Cayman Chemical, Ann Arbor, MI). 
Glutathione (GSH) Qunatification.  Reduced GSH in livers was quantified 
utilizing the GSH –Glo™ Glutathione Assay from Promega (Madison, WI) 
according to their protocol. 
Nrf2 Protein Expression in Hepatic Nuclear Extracts.  Nuclear extracts 
were prepared with the NE-PER nuclear extraction kit according to their 
protocol (Pierce Biotechnology, Rockford, IL).  Protein concentrations were 
determined with the BCA Assay Kit from Pierce Biotechnology (Rockford, IL).  
Nuclear proteins (40 µg protein/lane) were electrophoretically resolved using 
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polyacrylamide gels (4% stacking and 10% resolving).  Gels were transblotted 
overnight at 4ºC onto PVDF membranes.  Membranes were then washed with 
PBS–buffered saline containing 0.05% Tween-20 (PBS-T).  Membranes were 
blocked for 1 h at room temperature with 5% non-fat milk in PBS–T.  Blots 
were then incubated with primary antibody (1:1000 dilution in 2% non-fat milk 
in PBS-T) for 3 h at room temperature.  Blots were washed in PBS-T and 
incubated with species-appropriate secondary antibody conjugated with 
horseradish peroxidase (1: 2000 dilution) in 2% non-fat milk in PBS-T buffer 
for 1 hr at room temperature.   Blots were then washed with PBS-T.  Protein-
antibody complexes were detected using an ECL chemiluminescent kit 
(Pierce Biotechnology, Rockford, IL) and exposed to X-ray film (Denville 
Scientific, Metuchen, NJ).  Equal protein loading was confirmed by β-actin 
and PARP.   Nrf2, β-actin, and PARP proteins migrated the same distance as 
proteins of approximately 110, 45, and 116 kDa, respectively.  Intensity of 
protein bands was quantified by Discovery Series Quantity One 1-D Analysis 
Software (Bio-Rad Laboratories, Hercules, CA).  Individual blot densities were 
normalized to that of wild-type mice. 
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Quantification of hepatic non-esterified fatty acids, free-cholesterol, and 
triglycerides.  Lipids were extracted from livers as described previously 
(Tanaka et al., 2008b).   In brief, 100 mg of liver was homogenized in 1 ml of 
buffer containing 18 mM Tris, pH 7.5, 300 mM mannitol, 50 mM EGTA, and 
0.1 mM phenylmethylsulfonyl fluoride.  Five hundred µL of homogenate was 
mixed with 4 ml of chloroform/methanol (2:1) and incubated overnight at room 
temperature with occasional shaking. The next day, 1 ml of H2O was added, 
vortexed, and centrifuged for 5 min at 3000 g. The lower lipid phase was 
collected and concentrated by vacuum. The lipid pellets were dissolved in 
PBS with 0.01% Triton X-100.  Liver lipid samples were analyzed 
spectrophotometrically for free-cholesterol (500 nm), nonesterified fatty acids 
(550 nm), and triglycerides (500 nm) using commercially available kits (Pointe 
Scientific, Canton, MI and Wako Diagnostics, Richmond, VA). 
Messenger RNA quantification.  Mouse liver mRNA expression was 
determined from liver tissue homogenates prepared as described by the 
manufacturer’s protocol utilizing Quantigene Plex 2.0 technology (Panomics, 
Fremont, CA).  Individual bead-based oligonucleotide probe sets, specific for 
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each gene examined, were developed by Panomics, Inc.  Genes and 
accession numbers are freely available at http://www.panomics.com.  
Samples were analyzed using a Bio-Plex 200 System Array reader with 
Luminex 100 X-MAP technology, and data were acquired using Bio-Plex Data 
Manager Software Version 5.0 (Bio-Rad, Hercules, CA).  Assays were 
performed according to the manufacturer’s protocol.  The mRNA of Cyp2b10 
and Mrp4 was quantified using liver tissue homogenates with Quantigene 1.0 
technology (Panomics, Fremont, CA), according to previously described 
methods (Maher et al., 2005; Petrick and Klaassen, 2007).  All data were 
standardized to the internal control Gapdh. 
Statistical Analysis. All data were analyzed using one-way analysis of 
variance (ANOVA) followed by Duncan's multiple range test (p ≤ 0.05).  
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RESULTS 
Nrf2 protein in hepatic nuclear fractions and hepatic mRNA expression 
of Nrf2 and Keap1.  Nrf2 protein in hepatic nuclear fractions of wild-type, 
Nrf2-null, and Keap1-kd mice was quantified using immunoblotting (Fig 3.1A).  
As expected, Nrf2 protein was not detected in Nrf2-null mice.  However, Nrf2 
protein in hepatic nuclear fractions from Keap1-kd mice was 200% higher 
than wild-type mice.  Both β-actin and PARP were used to confirm equal 
loading. 
 Nrf2 mRNA expression was not detected in Nrf2-null mice and was 
22% lower in Keap1-kd mice than in wild-type mice (Fig 3.1B).  Keap1 mRNA 
expression was lower in Nrf2-null (-24%) and Keap1-kd mice (-55%) than in 
wild-type mice.  
Serum, liver, and bile parameters. Various serum, liver, and bile 
parameters of hepatic function in the three genotypes of mice were quantified 
(Table 1).  Serum ALT, glucose, triglyceride, and cholesterol concentrations 
were not different among genotypes, neither were hepatic histology (data not 
shown), non-esterified fatty acids, free cholesterol, nor triglycerides.   Bile flow 
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tended to be lower in Nrf2-null mice and was higher in Keap1-kd mice.  The 
biliary excretion of total bilirubin was similar in the three genotypes.  There 
were no differences in the biliary excretion of cholesterol and phospholipids 
between Nrf2-null and wild-type mice.  In contrast, the biliary excretion of 
cholesterol and phospholipids was higher in Keap1-kd mice than wild-type 
mice. 
Hepatic GSH concentrations.  Gclc and Gclm are Nrf2-dependent genes 
important in the de novo synthesis of GSH (Moinova and Mulcahy, 1999).  
Therefore, reduced GSH content was quantified among the three genotypes 
(Fig 3.2).  Nrf2-null mice had 65% lower and Keap1-kd mice had 77% higher 
GSH concentrations in liver than wild-type mice. 
Hepatic mRNA expression of classical oxidative and electrophilic-stress 
genes.  Hepatic mRNA expression of prototypical Nrf2-target genes is 
depicted in Fig 3.3A.  The expression of mRNAs for Nqo1, Gclc, Gclm, and 
GSH reductase (Gsr) was lower in Nrf2-null mice (-88, -38, -16, and -23%, 
respectively) and higher in Keap1-kd mice (222, 63, 22, and 17%, 
respectively).  Epoxide hydrolase-1 (Eh-1) was 72% lower in Nrf2-null mice 
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and 18% lower in Keap1-kd mice.  Ho-1 mRNA expression was not different 
among the three genotypes. 
 Hepatic mRNA expression of superoxide and hydrogen peroxide 
metabolizing enzymes is shown in Fig 3.3B.  There was less than a 15% 
decrease in mRNA for Sod1, Sod2, and Cat in Nrf2-null mice, whereas there 
was no difference between Keap1-kd and wild-type mice.  Gpx mRNA was 
not different among the three genotypes.  In addition, there were no 
differences in Sod, Cat, or Gpx enzyme activities among the three genotypes 
(data not shown). 
 Hepatic mRNA expression of redoxins is shown in Fig 3.3C.  
Glutaredoxin 1 (Glrx1) and peroxiredoxin 1 (Prx1) mRNA were lower in Nrf2-
null mice (-27 and -20%, respectively), whereas there were no differences 
between wild-type mice and Keap1-kd mice.  Thioredoxin 1 (Txn1) and 
thioredoxin reductase 1 (Txnrd1) mRNA were lower in Nrf2-null mice (24 and 
41%, respectively) and higher in Keap1-kd mice (9 and 23%, respectively).   
Hepatic mRNA of malic enzyme 1 (Me1) and hexose-6-phosphate 
dehydrogenase (H6pdh), enzymes important in generating nicotinamide 
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adenine dinucleotide phosphate (NADPH), were quantified (Fig 3.3D).  
Messenger RNAs for both Me1 and H6pdh were lower in Nrf2-null mice (62 
and 16%, respectively), but were unchanged between Keap1-kd and wild-
type mice. 
Cytochrome P-450 and major transcription factor mRNA expression and 
Cyp activity of liver microsomes.  Hepatic mRNA expression and enzyme 
activity of major Cyps were quantified (Fig 3.4A).  Cyp1a1 mRNA was lower 
in both Nrf2-null (43%) and Keap1-kd (34%) mice than wild-type mice.  
Cyp2b10 mRNA was higher in both Nrf2-null (92%) and Keap1-kd (155%) 
mice than wild-type mice. The amounts of Cyp2e1 and 3a11 mRNAs were not 
different among the three genotypes.  Cyp4a14 mRNA tended to be higher in 
Nrf2-null and was much lower in Keap1-kd (85%) mice than wild-type mice.   
Enzyme activities of Cyp1a1, 2b1, 2e1, 3a11, and 4a14 were quantified (Fig 
3.4B).  There were no differences in Cyp1a1, 3a11, and 4a14 enzyme activity 
among genotypes.  Cyp2b1 and 2e1 enzyme activities were unchanged 
between Nrf2-null and wild-type mice, but increased 36 and 38%, 
respectively, in Keap1-kd mice.  Also, there were no differences in mRNA 
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expression of the transcription factors aryl hydrocarbon receptor (AhR), 
pregnane X receptor (PXR), and peroxisome proliferator-activated receptor-
alpha (PPARα) among genotypes (data not shown).  However, constitutive 
androstane receptor (CAR) mRNA was 59% lower in Nrf2-null mice, whereas 
there were no differences between Keap1-kd and wild-type mice (data not 
shown).  
Hepatic mRNA expression of the phase-I genes: aldehyde 
dehydrogenases and carboxylesterases.  Hepatic mRNAs of aldehyde 
dehydrogenase 1a1 (Aldh1a1), 1a7, 3a2, 6a1, and 7a1 were decreased in 
Nrf2-null mice (14-33%), whereas there were no differences between Keap1-
kd and wild-type mice (Fig 3.6A).  Aldh1b1, 2, 4a1, 8a1, and 9a1 mRNA were 
not different among the three genotypes (data not shown). 
Hepatic mRNAs of carboxylesterase 1b4 (Ces1b4), 1d1, and 1h1 were 
lower in Nrf2-null mice (14-46%), whereas there were no differences between 
Keap1-kd and wild-type mice (Fig 3.5B).  Ces1e1 and 2a6 mRNAs were 
markedly lower in Nrf2-null mice (94 and 85%, respectively) and higher in 
Keap1-kd mice (38 and 59%, respectively) than wild-type mice.  The 
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expression of paraoxonase 1 (Pon1) and 3 mRNAs were not different among 
the three genotypes (data not shown). 
Hepatic mRNA expression of the phase-II genes: Ugts, Gsts, and Sults.  
Messenger RNAs for Ugt1a9, 2b1, 2b34, 2b36, 3a2, and the uridine 5'-
diphospho-glucuronic acid (UDP-GA) synthesizing enzyme UDP-glucose 
pyrophosphorylase (Ugp2) were lower in Nrf2-null mice (28-66%), whereas 
there were no differences between wild-type and Keap1-kd mice (Fig 3.6A).  
Messenger RNAs of Ugt1a6, 2b35 and the UDP-GA synthesizing enzyme 
UDP-glucose dehydrogenase (Ugdh) were lower in Nrf2-null mice (45-78%) 
and higher in Keap1-kd mice (23-75%).  There were no differences in mRNA 
expression of Ugt1a1, 1a5, 2a3, or 2b35 among the three genotypes (data 
not shown). 
Hepatic mRNAs of Gsta1, a4, m1, m2, m3, m4, m6, and p2 were lower 
in Nrf2-null mice (40-84%) and higher in Keap1-kd mice (45-585%) than in 
wild-type mice (Fig 3.6B).  There were no differences in mRNA expression for 
microsomal Gst1 (mGst1), mGst2, mGst3, Gstt1, or Gstt2 among the three 
genotypes (data not shown). 
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Hepatic mRNAs of hepatic Sults were quantified (Alnouti and 
Klaassen, 2006).  There were no differences among the three genotypes for 
mRNAs of Sult1a1, 1d1, and the Sult co-substrate 3'-phosphoadenoside 5'-
phosphosulfate (PAPS) synthesizing enzyme, PAPS synthetase 1 (Papps1) 
(data not shown).   Sult5a1 mRNA expression was 10% higher in Keap1-kd 
mice, whereas its expression in Nrf2-null mice did not differ from wild-type 
mice (data not shown).  In addition, Papps2 mRNA was 25% higher in Nrf2-
null mice than wild-type mice, whereas its expression in Keap1-kd mice was 
not different from wild-type mice (data not shown). 
Hepatic mRNA expression of uptake and efflux transporters.   Hepatic 
mRNA expression of uptake transporters in livers of the three genotypes of 
mice was quantified (Fig 3.7A).  Hepatic mRNAs of organic anion transporting 
polypeptide 1a1 (Oatp1a1), 1b2, and organic cation transporter 1 (Oct1) were 
lower (17-25%) in Nrf2-null mice.  Surprisingly, in Keap1-kd mice, Oatp1a1 
mRNA was 35% lower, whereas there were no differences in Oatp1b2 and 
Oct1 mRNA expression between Keap1-kd and wild-type mice.  In addition, 
there were no differences in the mRNA expression among the three 
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genotypes for organic anion transporter 2 (Oat2), Oatp1a4, 2b1, equilibrative 
nucleoside transporter 1 (Ent1), or sodium taurocholate co-transporting 
polypeptide (Ntcp) (data not shown). 
 Hepatic mRNAs of various efflux transporters were also quantified (Fig 
3.7B).  The mRNA of Mrp2, Mrp3, breast cancer resistance protein (Bcrp), 
and the two cholesterol and plant sterol efflux ATP-binding cassette 
transporters, Abcg5 and Abcg8, were lower in Nrf2-null (17, 85, 27, 29, and 
20%, respectively) and higher in Keap1-kd mice (24, 111, 16, 45, and 40%, 
respectively).  Mrp4 mRNA was lowly and similarly expressed in both wild-
type and Nrf2-null mice, but increased 55% over wild-type mice in Keap1-kd 
mice.  Messenger RNA of multidrug and toxin extrusion 1 (Mate1) was 26% 
lower in Nrf2-null mice, whereas there was no difference between wild-type 
mice and Keap1-kd mice.  There were no differences in mRNA among 
genotypes for multidrug resistance protein 2 (Mdr2), Mrp6, ATP-binding 
cassette transporter a1 (Abca1), or bile salt export pump (Bsep) (data not 
shown). 
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Table 3.1. Serum, liver, and bile parameters of hepatic function in wild-
type, Nrf2-null, and Keap1-kd mice. 
 
Analyte (Units) Nrf2-null Wild-type Keap1-kd 
Serum    
ALTs (IU/L) 20.9 ± 1.3 19.5 ± 1.6 22.7 ± 3.9 
Glucose (mg/dL) 176 ± 6 185 ± 7 206 ± 10 
Triglycerides (mg/dL) 66.0 ± 8.9 56.7 ± 4.9 64.1 ± 4.0 
Cholesterol (mg/dL) 57.0 ± 1.5 65.8 ± 2.0 61.4 ± 5.4 
Liver    
Non-esterified Fatty Acids  
(mEq/g Liver) 
0.018 ± 0.002 0.025 ± 0.003 0.020 ± 0.003 
Free Cholesterol (mg/g Liver) 19.0 ± 4.2 23.0 ± 4.2 26.3 ± 3.9 
Triglycerides (mg/g Liver) 34.2 ± 1.3 40.2 ± 7.2 36.9 ± 10.7 
Bile    
Bile Flow (mL/min/kg) 106 ± 5 124 ± 1 167 ± 12 * 
Bilirubin (mg/min/kg) 7.57 ± 0.42 7.05 ± 0.52 6.65 ± 1.05 
Cholesterol (mg/min/kg) 35.5 ± 0.6 40.1 ± 1.7 54.3 ± 3.9 * 
Phospholipids (mg/min/kg) 37.0 ± 3.2 35.0 ± 2.6 54.34 ± 2.2 * 
 
Values are expressed as mean ± S.E.M.   Asterisks (*) indicate a statistically 
significant difference from wild-type mice (p ≤ 0.05). 
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Fig 3.1.  Nrf2 protein expression in hepatic nuclear fractions in wild-type, 
Nrf2-null, and Keap1-kd mice (A).  Intensity of protein bands was quantified, 
and individual blot densities were normalized to wild-type and expressed as 
mean ± S.E.M.  Messenger RNA expression of Nrf2 and Keap1 in wild-type, 
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Nrf2-null, and Keap1-kd mice (B).  Values are expressed as mean ± S.E.M.   
Asterisks (*) indicate a statistically significant difference from wild-type mice 
(p ≤ 0.05). 
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Fig 3.2.  Hepatic reduced liver glutathione content in wild-type, Nrf2-null, and 
Keap1-kd mice.  Values are expressed as mean ± S.E.M.   Asterisks (*) 
indicate a statistically significant difference from wild-type mice (p ≤ 0.05). 
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Fig 3.3.  Messenger RNA expression of prototypical Nrf2 targets (A), 
superoxide and hydrogen peroxide reducing enzymes (B), redoxins (C), and 
NADPH generating enzymes (D) in wild-type, Nrf2-null, and Keap1-kd mice.  
Values are expressed as mean ± S.E.M.   Asterisks (*) indicate a statistically 
significant difference from wild-type mice (p ≤ 0.05). 
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Fig 3.4.  Messenger RNA expression (A) and enzyme activity (B) of 
cytochrome p450s in wild-type, Nrf2-null, and Keap1-kd mice.  Values are 
expressed as mean ± S.E.M.   Asterisks (*) indicate a statistically significant 
difference from wild-type mice (p ≤ 0.05). 
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Fig 3.5.  Messenger RNA expression of aldehyde dehydrogenases (A) and 
carboxylesterases (B) in wild-type, Nrf2-null, and Keap1-kd mice.  Values are 
expressed as mean ± S.E.M.   Asterisks (*) indicate a statistically significant 
difference from wild-type mice (p ≤ 0.05). 
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Fig 3.6.  Messenger RNA expression of UDP-glucuronosyltransferases (A) 
and glutathione-S-transferases (B) in wild-type, Nrf2-null, and Keap1-kd mice.  
Values are expressed as mean ± S.E.M.   Asterisks (*) indicate a statistically 
significant difference from wild-type mice (p ≤ 0.05). 
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Fig 3.7.   Messenger RNA expression of uptake (A) and efflux (B) 
transporters in wild-type, Nrf2-null, and Keap1-kd mice.  Values are 
expressed as mean ± S.E.M.   Asterisks (*) indicate a statistically significant 
difference from wild-type mice (p ≤ 0.05). 
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DISCUSSION 
 Nrf2 is a transcription factor that upon activation by 
oxidative/electrophilic insult induces a battery of cytoprotective genes.  Nrf2-
null mice are highly susceptible to a variety of oxidative/electrophilic stress-
induced pathologies because of reduced basal and inducible expression of 
detoxification enzymes (Aleksunes and Manautou, 2007).   In contrast, 
chemicals that activate Nrf2 protect rodents from pathologies linked to or 
caused by oxidative/electrophilic stress, leading to the hypothesis that Nrf2 is 
a target for chemoprevention (Lee and Surh, 2005).   However, because 
chemical compounds typically have many off-target effects, it would be more 
informative to study activation of Nrf2 in a mouse model of increased Nrf2 
activation.   Therefore, the present study determined which genes have 
decreased mRNA expression with lack of Nrf2, and which genes have more 
mRNA expression when there is increased activation of Nrf2. 
 Upon activation, Nrf2 translocates into the nucleus, as reflected by the 
amount of Nrf2 protein in the nucleus in wild-type, Nrf2-null, and Keap1-kd 
mice.  As shown in Fig 2, wild-type mice have very little Nrf2 protein in the 
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nucleus, similar to previously published results (Kwak et al., 2001; Maher et 
al., 2007).  Low Nrf2 protein in the nucleus in wild-type mice is most likely due 
to the rapid turnover of Nrf2 under basal or unchallenged conditions 
(Kobayashi et al., 2004).  As expected, no hepatic Nrf2 mRNA or protein was 
detected in Nrf2-null mice, similar to previous results (Tanaka et al., 2008a).  
Nrf2-null mice also have lower Keap1 mRNA expression, most likely due to 
loss of Nrf2 binding to a functional ARE in the promoter region of Keap1 in a 
proposed negative feedback mechanism (Lee et al., 2007).  In contrast, 
Keap1-kd mice have 55% lower Keap1 mRNA expression, which is likely the 
mechanism for tripling the amount of Nrf2 protein in the nucleus of Keap1-kd 
mice.  Keap1-kd mice also have a modest decrease in Nrf2 mRNA 
expression, which suggests a possible negative feedback pathway for Nrf2 
mRNA expression when Nrf2 is over-activated. 
Most basal hepatic physiological parameters in serum, liver, and bile 
were not different among wild-type, Nrf2-null, and Keap1-kd mice (Table 1).  
However, bile flow tended to be lower in Nrf2-null mice and was significantly 
higher in Keap1-kd mice. Increased bile flow in Keap1-kd mice is due to 
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increased biliary excretion of GSH, as GSH excretion regulates bile acid-
independent bile flow (Ballatori and Truong, 1989).  The reason for the 
increased biliary excretion of GSH in Keap1-kd mice is the higher hepatic 
GSH concentrations, resulting from the increased expression of GSH 
synthetic enzymes (Gclc and Gclm) as discussed in detail below.  There were 
no differences in total biliary bile acids among genotypes (data not shown).  
Biliary excretion but not biliary concentrations of phospholipids and 
cholesterol were increased in Keap1-kd mice. 
 Hepatic concentrations of GSH in the three mouse genotypes were 
proportional to the amount of activated Nrf2.  GSH is a prominent cellular 
antioxidant that protects against oxidative/electrophilic stress by directly 
scavenging reactive oxygen species or acting as a co-substrate for Gst-
mediated detoxification of reactive electrophiles (Meister and Anderson, 
1983).  The rate-limiting enzymatic process in GSH synthesis is catalyzed by 
γ-glutamylcysteine synthetase, which is made up of the catalytic and modifier 
subunits, Gclc and Gclm, respectively.  Nrf2-null mice have lower, whereas 
Keap1-kd mice have higher hepatic mRNA expression of Gclc and Gclm, 
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genes positively regulated by Nrf2 (Moinova and Mulcahy, 1999; Wild et al., 
1999; Lee et al., 2007) (Fig 4A).  Furthermore, mRNA expression of Gsr, the 
enzyme responsible for the reduction of oxidized glutatihione (GSSG) to 
reduced GSH, is lower in Nrf2-null mice and higher in Keap1-kd mice.  
Because Gclc, Gclm, and Gsr mRNA expression is lower in Nrf2-null mice 
and higher in Keap1-kd mice, the amount of GSH in the liver was determined.  
Nrf2-null mice have less than half, whereas Keap1-kd mice have almost 
double the hepatic reduced GSH as wild-type mice (Fig 3).  Higher GSH 
concentrations in the Keap1-kd mouse should increase resistance to a variety 
of oxidative/electrophilic stress-induced pathologies, whereas lower reduced 
GSH concentrations render the Nrf2-null mice more susceptible to such 
pathologies. 
With few exceptions, typical Nrf2-target genes are lower in Nrf2-null 
mice and higher in Keap1-kd mice.  Nqo1 is a Nrf2-dependent flavoprotein 
that catalyzes the two-electron reduction and detoxification of electrophilic 
quinones and its derivatives (Jaiswal, 2000).  Nqo1 is a prototypical Nrf2 
target gene and is expressed lower in Nrf2-null mice and higher in Keap1-kd 
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mice (Fig 4A).  Eh-1 is induced by sulforophane and 3H-1,2-dithiole-3-thione 
(D3T) in wild-type but not Nrf2-null mice (Kwak et al., 2001; Thimmulappa et 
al., 2002).  However, Eh-1 mRNA is not increased in Keap1-kd mice, 
suggesting that other mechanisms aside from Nrf2 nuclear translocation are 
important for Eh-1 mRNA induction in the liver.  Ho-1 catalyzes the 
breakdown of heme into iron, carbon monoxide, and biliverdin.  Biliverdin is 
then reduced to bilirubin, an antioxidant, via biliverdin reductase.  Ho-1 is 
induced, in mice, by many Nrf2 activators or stressors, such as CDDO-Im 
(Liby et al., 2005), butylated hyroxyanisole (Keum et al., 2006), hyperoxia 
(Cho et al., 2002), and arsenite (Gong et al., 2002).  However, no difference 
in Ho-1 expression was observed among wild-type, Nrf2-null, and Keap1-kd 
mice, a result that is consistent with previous reports (Okawa et al., 2006).  
The lack of induction of Ho-1 in Keap1-kd mice is attributed to the presence of 
Bach1, a protein that suppresses the activity of Maf proteins, which are 
important heterodimers for Nrf2-ARE binding and subsequent Ho-1 gene 
transcription (Keum et al., 2006).   
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The superoxide and hydrogen peroxide detoxifying enzymes Sod1, 
Sod2, catalase, and Gpx are inducible in response to Nrf2 activators, such as 
3H-1,2-dithiole-3-thione (D3T) (Zhu et al., 2005), phenolic acids (Yeh and 
Yen, 2006), and shear stress (Jones et al., 2007).  In the present study, a 
minor decrease in hepatic mRNA expression of Sod1, Sod2, and catalase 
was observed in Nrf2-null mice (10-30%), whereas there was no increase in 
Keap1-kd mice.  Gpx mRNA expression was not different among the three 
genotypes (Fig 4B).  There were also no differences among the three 
genotypes in Sod, Cat, or Gpx enzyme activities.  The lack of induction of 
Sods, Cat, and Gpx in Keap1-kd mice suggests that nuclear translocation of 
Nrf2 does not induce enzymes capable of detoxifying superoxide and related 
reactive oxygen species in liver. 
Redoxins are important for protein repair, as they are responsible for 
the reduction of protein disulfide bonds that could disrupt proper protein 
folding and function.  Peroxiredoxins reduce hydrogen peroxide to water, 
protecting against hydroxyl radical formation.  Glrx1, Prx1, Txn1, and Txnrd1 
have lower hepatic mRNA expression in Nrf2-null mice, whereas only Txn1 
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and Txnrd1 are induced in Keap1-kd mice (Fig 4C).  NADPH is a cofactor for 
many oxidoreductase reactions that are important in detoxifying reactive 
oxygen species.  Me1 and H6pdh are enzymes that regenerate NADPH after 
it has been oxidized.   Both Me1 and H6pdh are lower in Nrf2-null mice but 
not increased in Keap1-kd mice (Fig 4D).   
Chemicals, such as acetaminophen, benzo[a]pyrene, carbon 
tetrachloride, and benzene, are activated to reactive intermediates by Cyps, 
which can result in toxicity.  Knowledge of Cyp activity in toxicity studies 
utilizing Nrf2-null and Keap1-kd mice is critical, because changes in Cyp 
activity could alter the amount of toxic metabolite generated, leading to an 
incorrect interpretation of results, i.e. less injury caused by decreased toxic 
metabolite formation and not increased detoxification of the metabolite. Even 
though there were differences among genotypes in mRNA expression of 
Cyp1a1, 2b10, and 4a14, minor differences, if any, were detected in the 
enzyme activity of major Cyps.  Thus, Cyps most likely will not play a role in 
the interpretation of results from toxicity studies involving Nrf2-null and 
Keap1-kd mice. 
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Aldhs catalyze the oxidation of a wide variety of electrophilic aliphatic 
and aromatic aldehydes to carboxylic acids (Parkinson, 2008).  Nrf2-null mice 
have lower expression of Aldh1a1, 1a7, 3a2, 6a1, and 7a1, whereas Keap1-
kd mice were not different from wild-type mice (Fig 6A).  The lack of induction 
of Aldhs in Keap1-kd mice suggests that Aldhs are not induced by Nrf2 in this 
mouse model. 
Carboxylesterases (Cess) catalyze the hydrolysis of ester- and amide-
containing chemicals and are important in the activation of prodrugs 
(Parkinson, 2008).  Produrg strategies allow for improvement of oral 
bioavailability of poorly absorbed drugs.  Expression of Ces1b4, 1d1, 1e1, 
1h1, and 2a6 were lower in Nrf2-null mice, wheras only Ces1e1 and 2a6 were 
higher in Keap1-kd mice (Fig 6B).  An increase in expression of Cess in 
Keap1-kd mice suggests that activation of Nrf2 increases expression of Cess 
and metabolism of xenobiotics by Cess.  An increase in Ces1e1 also might 
increase the amount of prodrug (i.e. the chemotherapeutics floxuridine and 
gemcitabine) converted to the active form, providing a more efficacious result 
(Marsh et al., 2004; Landowski et al., 2006; Taketani et al., 2007).   
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Hepatic mRNA expression of phase-II enzymes is also altered in Nrf2-
null and Keap1-kd mice.  Ugts catalyze the conjugation of a glucuronosyl 
group from UDP-GA to a variety of substrate molecules, making them more 
water soluble and readily excreted.  Increased excretion of xenobiotics 
decreases the amount of compound available for biotransformation to a toxic 
electrophilic metabolite.  In addition, Ugt-catalyzed reactions are responsible 
for approximately 35% of all drugs metabolized by phase-II enzymes (Evans 
and Relling, 1999).  In general, Ugt mRNA expression is lower in Nrf2-null 
mice, whereas Keap1-kd mice are not different from wild-type mice, with the 
exception of a minor increase in mRNA expression of Ugt1a6 and Ugt2b35 
(Fig 7A).  The availability of the co-substrate UDP-GA is required for the 
enzyme activity of Ugts.  Both Ugdh and Ugp2 mRNA expression were lower 
in Nrf2-null mice, whereas Ugdh was significantly higher and Ugp2 tended to 
be higher in Keap1-kd mice.  
Sults catalyze approximately 20-25% of phase-II reactions by 
transferring a sulfonic acid group from the co-substrate PAPS (Evans and 
Relling, 1999).  There are few differences in the amount of the various Sult 
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mRNAs among wild-type, Nrf2-null, and Keap1-kd mice, suggesting that Nrf2 
does not play a major transcriptional role in the expression of Sults. 
Gsts catalyze the conjugation of nucleophilic GSH with reactive and 
potentially damaging electrophiles (Parkinson, 2008).  Substrates for Gsts 
include hydroperoxides of fatty acids, phospholipids, cholesterol, and 
quinone-containing compounds (Hayes et al., 2005).  The expression of many 
Gsts is dependent on Nrf2, with most Gsts having 41-85% lower expression 
in Nrf2-null mice and 45-585% higher expression in Keap1-kd mice (Fig 7B).  
A decrease in hepatic GSH concentration and Gst mRNA expression 
contributes to Nrf2-null mice being highly susceptible to electrophilic stress.  
In contrast, Keap1-kd mice have increased hepatic GSH concentrations and 
Gst mRNA expression and most likely have an increased resistance against 
damaging electrophiles that can be neutralized via GSH conjugation.  The 
ability to produce and use more GSH appears to be one of the most important 
benefits of increased hepatic activated Nrf2, as observed in Keap1-kd mice. 
 Uptake transporters are important for the hepatic uptake and 
clearance of xenobiotics, an important process in the first-pass effect 
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(Klaassen and Lu, 2008).  In general, mRNA expression of hepatic uptake 
transporters was similar among genotypes, with the exception of Oatp1a1, 
1b2, and Oct1, which exhibit relatively minor differences (<25%) in expression 
(Fig 8A).  Of note, Oatp1a1 expression is lower in Keap1-kd mice, which is 
consistent with what has been observed upon administration of Nrf2 
activators (Cheng et al., 2005).  Furthermore, Oatp and Oct1 mRNA are 
generally not altered by Nrf2 activators or other microsomal enzyme inducers 
(Cheng et al., 2005).  Thus, this data suggests that uptake transporters in the 
liver are not activated by Nrf2. 
Hepatic efflux transporters are important for the elimination and overall 
clearance of xenobiotics from the liver.  Mrps are a group of ATP-dependent 
transporters that are important in cytoprotection, because Mrps can remove 
potentially toxic xenobiotics, metabolites, and endogenous substrates from 
cells (Maher et al., 2007).  Mrp2 and Mrp3 mRNA expression is lower in Nrf2-
null mice, but higher in Keap1-kd mice.  Mrp4 mRNA was lowly expressed 
and not different between Nrf2-null and wild-type mice, but was increased 
55% over wild-type in Keap1-kd mice (Fig 8B).  Bcrp is an efflux transporter 
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for substrates, such as mitoxantrone, anthracyclines, camptothecins, 
topotecan, and SN-38, the active metabolite of irinotecan (Doyle et al., 1998; 
Brangi et al., 1999; Miyake et al., 1999; Ross et al., 1999; Litman et al., 
2000).  Bcrp mRNA expression is 28% lower in Nrf2-null mice and 15% 
higher in Keap1-kd mice.  Mate1 effluxes organic cations, such as metformin 
and tetraethylammonium, from hepatocytes into bile (Hiasa et al., 2006; 
Terada et al., 2006).  Mate1 mRNA is expressed at a 27% lower level in Nrf2-
null mice.  There was no difference in Mate1 mRNA expression between 
Keap1-kd and wild-type mice, similar to a previous report in which Nrf2 
activators did not induce Mate1 mRNA expression (Lickteig et al., 2008).  
Abcg5 and Abcg8, transporters involved in the efflux of cholesterol and 
potentially toxic plant sterols from the liver into bile, were lower in Nrf2-null 
mice and higher in Keap1-kd mice.  The increase of mRNA expression of 
efflux transporters may provide Keap1-kd mice the ability to increase the 
clearance of potentially toxic xenobiotics, thereby decreasing time of 
exposure and toxicity. 
Table 2 categorizes mRNA expression of detoxifying and transporter 
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genes among wild-type, Nrf2-null, and Keap1-kd mice into three different 
patterns.  The first pattern encompasses genes that have decreased mRNA 
expression in Nrf2-null mice and increased expression in Keap1-kd mice 
compared to wild-type mice.  Pattern 1 genes include Nqo1, Gsts, and Mrps, 
which detoxify and eliminate electrophiles.  The second pattern consists of 
genes that have decreased mRNA expression in Nrf2-null mice but no 
difference between Keap1-kd and wild-type mice.  Prominent genes in pattern 
2 are the superoxide detoxifying enzymes Sod1, Sod2, Cat, and Prx1, as well 
as some Ugts and Aldhs.  The third pattern includes genes that were not 
different among wild-type, Nrf2-null, and Keap1-kd mice and includes genes 
such as some Ugts, Sults, some Aldhs, Gpx, Ho-1, and uptake transporters. 
In conclusion, this study has shown that whereas Nrf2-null and Keap1-
kd mice have normal livers under standard institutional animal care 
conditions, baseline defenses against electrophilic stress are lower in Nrf2-
null mice and higher in Keap1-kd mice.  In addition, classical reactive oxygen 
species reducing enzymes, such as Cat, Gpx, and Sods, were not induced in 
livers of Keap1-kd mice, whereas genes, such as Gsts, Nqo1, and Mrps, 
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important in detoxifying and eliminating electrophiles are markedly increased 
in Keap1-kd mice.  The major advantage Keap1-kd mice have against 
reactive oxygen and nitrogen species in the liver appears to be an increase in 
hepatic GSH concentrations. Collectively, these results suggest that hepatic 
Nrf2 is more important in the direct detoxification of highly reactive 
electrophilies formed from xenobiotic exposure than for detoxification of 
reactive oxygen species. 
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Table 3.2. Categorization of Antioxidant, Phase-I, Phase-II, and 
transporter mRNA expression.  Percent change from wild-type in Nrf2-null 
and Keap1-kd mice are presented.  The first pattern represents genes that 
Pattern 1 Pattern 2 Pattern 3 
Decrease in Nrf2-null Mice and 
Increase in  
Keap1-kd Mice 
Decrease in Nrf2-null Mice and 
Non-Significant Change in 
Keap1-kd Mice 
No Changes 
Among 
Genotypes 
Gene 
Nrf2-null 
% 
change 
Keap1-
kd % 
change 
Gene 
Nrf2-null 
% 
change 
Keap1-
kd % 
change 
Gene 
Gstp2* -40 586 Ugp2 -29 16 Ho-1 
Gsta1 -84 448 Ces1b4 -14 16 Gpx 
Gstm3 -81 336 Ugt2b36 -66 12 Pon1 
Nqo1 -88 222 Txn1 -23 9 Pon3 
Gstm1 -74 140 Aldh7a1 -13 8 Aldh1b1 
Mrp3 -85 111 Oct1 -25 8 Aldh2 
Gstm4 -67 102 H6pdh -16 7 Aldh4a1 
Ugdh -50 75 Prx1  -20 6 Aldh8a1 
Gstm2 -57 65 Ces1d1 -38 4 Aldh9a1 
Gclc -37 63 Cat  -15 4 Ugt1a1 
Ces1e1 -94 59 Oatp1b2 -25 1 Ugt1a5 
Mrp4* -3 55 Ugt2b34 -35 0 Ugt2a3 
Gsta4 -53 45 Ugt2b1 -32 -1 Ugt2b35 
Abcg5 -29 45 Glrx1 -27 -1 Gstt1 
Abcg8 -20 40 Sod1 -10 -2 Gstt2 
Ces2a6 -85 38 Ugt1a9 -47 -3 mGst1 
Ugt2b35 -79 32 Ces1h1 -54 -3 mGst2 
Mrp2 -17 24 Aldh6a1 -21 -3 mGst3 
Ugt1a6 -46 23 Aldh1a1 -32 -4 Sult1a1 
Txnrd1 -41 23 Aldh1a7 -23 -5 Sult1d1 
Gclm  -16 22 Aldh3a2 -25 -6 Papps1 
Gsr -23 17 Ugt3a2 -31 -11 Oat2 
Bcrp -27 16 Sod2 -32 -14 Oatp1a4  
   Mate1 -26 -15 Oatp2b1  
   Me1  -62 -18 Ent1 
   Eh-1 -72 -18 Ntcp 
   Oatp1a1 -17 -35 Mdr2 
      Mrp6 
      Abca1 
      Bsep 
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had significant decrease in Nrf2-null mice (p≤0.05) and a significant increase 
in Keap1-kd mice (p≤0.05).  The second pattern represents genes that had 
significant decrease in Nrf2-null mice (p≤0.05) and no change from wild-type 
in Keap1-kd mice (p>0.05).  The third pattern of gene expression represents 
genes that were not different among wild-type, Nrf2-null, and Keap1-kd mice.  
*No significant difference between Nrf2-null and wild-type mice (p>0.05). 
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In conclusion, this study has shown that whereas Nrf2-null and Keap1-
kd mice have normal livers under standard institutional animal care 
conditions, baseline defenses against electrophilic stress are lower in Nrf2-
null mice and higher in Keap1-kd mice.  In addition, classical reactive oxygen 
species reducing enzymes, such as Cat, Gpx, and Sods, were not induced in 
livers of Keap1-kd mice, whereas genes, such as Gsts, Nqo1, and Mrps, 
important in detoxifying and eliminating electrophiles are markedly increased 
in Keap1-kd mice.  The major advantage Keap1-kd mice have against 
reactive oxygen and nitrogen species in the liver appears to be an increase in 
hepatic GSH concentrations. Collectively, these results suggest that hepatic 
Nrf2 is more important in the direct detoxification of highly reactive 
electrophilies formed from xenobiotic exposure than for detoxification of 
reactive oxygen species. 
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Enhanced Activation of Nrf2 in Keap1-Knockdown Mice Increases the 
Biotransformation and Excretion of Sulfobromophthalein and 
Acetaminophen 
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CHAPTER FOUR 
 
 
 
 
Nrf2 Activation Enhances Biliary Excretion of Sulfobromophthalein by 
Inducing Glutathione-S-Transferase Activity 
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ABSTRACT 
Sulfobromophthalein (BSP) is used to study hepatobiliary excretory function.  
BSP is conjugated with glutathione (GSH), whereas its dibrominated analog 
disulfobromophthalein (DBSP) is not conjugated with GSH prior to biliary 
excretion.  In addition, both BSP and DBSP are transported into hepatocytes 
via organic anion transporting polypeptides (Oatps) and excreted into bile via 
multidrug resistance-associated protein 2 (Mrp2).  Nrf2 is a transcription 
factor that under basal conditions is tethered in the cytosol by Keap1.  
Oxidative stress facilitates Nrf2 nuclear translocation and subsequent 
induction of cytoprotective genes, including GSH-synthetic enzymes, GSH-S-
transferases (Gsts), and Mrp transporters. The current study determined 
whether varying the amount of Nrf2 activation would effect the elimination of 
BSP and DBSP.  Male wild-type (WT), Nrf2-null, and Keap1-knockdown 
(Keap1-kd) mice were administered BSP or DBSP.  Within 30 min, Nrf2-null 
mice excreted 25%, WT mice 52%, and Keap1-kd mice 80% of the injected 
BSP.   Liver GSH content was not altered by BSP.  The biliary excretion of 
GSH and mRNA expression of major Gsts were directly proportional to the 
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amount of Nrf2.  Moreover, BSP-GSH conjugation activity in the liver of Nrf2-
null and Keap1-kd mice was 42 and 237% of WT mice, respectively.   In 
contrast to BSP, there were no differences in biliary excretion or plasma 
disappearance of DBSP among the three genotypes, indicating that 
differences in transporter expression among genotypes do not affect BSP or 
DBSP biliary excretion.  Collectively, these results indicate that increased 
biliary excretion of BSP, and possibly other compounds, is due to Nrf2-
induced Gst mRNA expression and enzyme activity. 
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INTRODUCTION 
Sulfobromophthalein (BSP) is a prototypical compound used to assess 
hepatobiliary transport, biotransformation, and excretory mechanisms.   BSP 
is transported into hepatocytes via the organic anion transporting polypeptide 
(Oatp) family of uptake transporters (Kanai et al., 1996; Hagenbuch et al., 
2000; Cattori et al., 2001; van Montfoort et al., 2002).  BSP is conjugated with 
glutathione (GSH) in hepatocytes by glutathione-S-transferases (Gsts) 
(Brauer and Pessotti, 1949; Krebs and Brauer, 1958; Grodsky et al., 1959; 
Combes and Stakelum, 1960; Combes and Stakelum, 1961; Combes, 1965; 
Yalcin et al., 1983; Alin et al., 1985; Tahir et al., 1985) and then excreted from 
hepatocytes into the bile via the efflux transporter, multidrug resistance-
associated protein 2 (Mrp2) (Cui et al., 2001; Tanaka et al., 2003).   The 
dibrominated analog of BSP, disulfobromophthalein (DBSP), is also used to 
assess hepatobiliary function.  Similar to BSP, DBSP is transported into the 
liver via Oatps and exported by Mrp2 (Johnson and Klaassen, 2002).  In 
contrast to BSP, however, DBSP is not conjugated with GSH before biliary 
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excretion and therefore, is excreted into bile as the parent compound (Javitt, 
1964). 
 The Nrf2-Keap1 pathway has been characterized over the past decade 
as an important endogenous cellular mechanism for coping with oxidative 
stress.  Nuclear factor erythroid-2 related factor 2 (Nrf2) is a transcription 
factor that promotes transcription of a battery of cytoprotective genes via 
antioxidant response elements (AREs) in promoter regions, thus restoring the 
intracellular balance between oxidants and antioxidants.  Under conditions 
when oxidative stress is low, Keap1 (kelch-like ECH-associated protein-1) 
sequesters Nrf2 in the cytosol by acting as an adaptor for Cul3-based E3 
ligase to regulate proteasomal degradation of Nrf2 (Tong et al., 2006).  Upon 
increased oxidative stress within the cell, Nrf2 circumvents Keap1-mediated 
proteasomal degradation and translocates into the nucleus (Bloom and 
Jaiswal, 2003).  Once in the nucleus, Nrf2 heterodimerizes with a small 
musculo-aponeurotic fibrosarcoma (Maf) protein and promotes transcription 
of various cytoprotective genes through direct ARE binding (Itoh et al., 1997; 
Venugopal and Jaiswal, 1998; He et al., 2001).  Genes up-regulated by Nrf2 
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include, but are not limited to, Mrp2, which effluxes BSP and DBSP into bile; 
glutamate-cysteine ligase catalytic (Gclc) and modifier (Gclm) subunits, which 
are responsible for the rate limiting step in GSH synthesis; and Gsts (Ramos-
Gomez et al., 2001; Solis et al., 2002; Maher et al., 2007). 
Because activation of the Nrf2-Keap1 pathway results in induction of 
Mrp2 as well as genes responsible for both the synthesis and conjugation of 
GSH, the present study investigated whether changes in the amount of Nrf2 
in vivo (Nrf2-null, WT, and Keap1-kd mice) would alter the pharmacokinetics 
of BSP and DBSP.  Nrf2-null mice, which have no functional Nrf2 protein, are 
highly susceptible to tissue injury due to a decreased capability to induce 
cytoprotective genes upon oxidative stress (Aoki et al., 2001; Enomoto et al., 
2001; Ramos-Gomez et al., 2001; Kraft et al., 2004).   Keap1-kd mice have 
decreased functional Keap1 protein and therefore, have increased Nrf2 in the 
nucleus, resulting in constitutively expressed, higher levels of cytoprotective 
genes (Okada et al., 2008).  The current study investigates the functional 
importance of Nrf2 on the pharmacokinetics of BSP and DBSP in wild-type, 
Nrf2-null, and Keap1-kd mice. 
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METHODS 
Materials. Sulfobromophthalein was purchased from Sigma-Aldrich (St. 
Louis, MO). Disulfobromophthalein was purchased from SERB Laboratories 
(Paris, France).  All other chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO). 
Animals and husbandry. Eight-week-old male C57BL/6 mice were 
purchased from Charles River Laboratories Inc (Wilmington, MA).  Nrf2-null 
mice were obtained from Dr. Jefferson Chan (University of California, Irvine, 
Irvine, CA) (Chan et al., 1996).  Keap1-knockdown (Keap1-kd) mice were 
graciously supplied by Dr. Masayuki Yamamoto (Tohoku University, Aoba-ku, 
Sendai, Japan) (Okada et al., 2008). 
Both Nrf2-null and Keap1-kd mice were backcrossed into C57BL/6 
mice, and >99% congenicity was confirmed by the speed congenics group at 
Jackson Laboratories (Bar Harbor, ME).  Animals were housed in a 
temperature-, light-, and humidity-controlled environment and had free access 
to Teklad Rodent Diet #8604 (Harlan Laboratories, Madison, WI) and water 
ad libitum.  The housing facility is an American Animal Associations 
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Laboratory Animal Care-accredited facility at the University of Kansas Medical 
Center, and all procedures were preapproved in accordance with Institutional 
Animal Care and Use Committee guidelines. 
Determination of plasma concentration and biliary excretion of BSP and 
DBSP.   Wild type, Nrf2-null, and Keap1-kd mice (n=5, 8 weeks old) were 
anesthetized by injection of ketamine/midazolam (100 mg/kg and 5 mg/kg, 
respectively, i.p.).  Body temperature was maintained at 37°C by rectal-probe-
controlled heating pads. Subsequently, the right carotid artery was cannulated 
with PE-10 tubing, and the common bile duct cannulated with the shaft of a 
30-gauge needle attached to PE-10 tubing through a high abdominal incision.  
Depth of anesthesia was monitored by pinching the footpad before and 
throughout surgery, and if necessary, additional anesthetic drugs were 
administered during sample collection.  Bile samples were collected in 15-min 
periods into pre-weighed 0.6-ml microcentrifuge tubes for 5 periods.  The 
tubes into which bile was collected were immersed in ice.  After the first bile 
collection, BSP (80 µmol/kg/10 ml) or DBSP (120 µmol/kg/10 ml) was injected 
via the carotid cannula. Thirty-35 µl of blood were collected into heparinized 
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tubes at -2, 7.5, 22.5, 37.5, 52.5 min after BSP or DBSP injection.  The 
volumes of bile samples were determined gravimetrically, taking 1.0 as 
specific gravity.  Concentrations of BSP and DBSP in bile and plasma were 
quantified spectrophotometrically at 580 nm after an appropriate dilution of 
the samples with 0.1 M sodium hydroxide. 
Determination of hepatic GSH depletion by BSP.  In WT mice, the peak 
excretion rate of BSP was within 20 min after injection.  Therefore, WT mice 
were surgically prepared as described above, and after a 15-min bile 
collection, saline or BSP (80 µmol/kg/10 ml) was injected.  During these 
experiments, bile and plasma samples were collected at the same time points 
described above.  The livers were removed 20 min after saline or BSP 
administration, frozen in liquid nitrogen, and stored at –80ºC.  
Total GSH. Total GSH was quantified in bile and liver using a commercial 
glutathione assay kit (Sigma, St. Louis, MO).  Bile was diluted 60x in 5% 5-
sulfosalicylic acid (SSA) solution, whereas liver was homogenized (0.1 g/ml) 
in 5% SSA and further diluted 10x in 5% SSA.  Samples were pre-incubated 
in assay buffer, glutathione reductase, and 5,5’-dithiobis(2-nitrobenzoic acid) 
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(DTNB) at room temperature prior to adding NADPH.  In the presence of 
NADPH, the GSH-dependent production of 5-thio-2-nitrobenzoic acid (TNB) 
was quantified spectrophotometrically at 412nm. 
BSP-GSH conjugation. Optimal assay conditions were described previously 
(Goldstein and Combes, 1966; Klaassen and Plaa, 1967).  The BSP-GSH 
solution was prepared with 0.1 M (pH 8.4) sodium pyrophosphate buffer to 
achieve a final solution of 226 µM BSP, 21.1 mM GSH, at pH 8.0.  All 
components were incubated at 37°C and 546 µl of incubation medium (23 µl 
BSP + 68 µl GSH + 455 µl pyrophosphate buffer) was added to 1-ml cuvettes.   
Livers were homogenized (0.4 g/ml) in 250 mM sucrose-10 mM Tris buffer 
(pH 7.4) with protease inhibitors.  The cytosolic fraction was separated after 
two consecutive centrifugations (1000 g for 12 min; 100,000 g for 60 min at 
4°C).  Cytosols were diluted 50x in sodium pyrophospha te buffer, incubated 
at 37°C, and 454 µl of each sample was added to the BSP and GSH mixture 
in 1-ml cuvettes.  Glutathione conjugation of BSP was determined 
spectrophotometrically at 330 nm, and corrected for the amount of BSP per 
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cuvette, cytosolic dilution factor, protein content of sample, time in min of 
conjugation reaction, and non-enzymatic conjugation. 
Total RNA Isolation.  Total RNA was isolated using RNA-Bee reagent (Tel-
Test, Inc., Friendswood, TX) according to the manufacturer’s protocol. Total 
RNA concentrations were determined spectrophotometrically at 260 nm. One 
mg/ml solutions were prepared from the isolated RNA solutions by diluting 
with diethyl pyrocarbonate-treated deionized water.   Total liver RNA from 
each group of mice was then pooled and stored at -80°C.  
Multiplex suspension array.  Livers were collected from naïve, 8-week-old 
WT, Nrf2-null, and Keap1-kd male mice (n=5).  After RNA isolation and 
dilution to 1 mg/ml, samples were pooled.  Mouse liver Gst mRNA expression 
was determined by a multiplex suspension array assay (Quantigene Plex 1.0, 
Panomics, Fremont, CA).  Individual bead-based oligonucleotide probe sets 
specific for each mouse Gst isoform were developed by Panomics Inc., using 
gene accession numbers for mouse Gst isoforms.  The accession numbers 
for Gst mRNA are freely available on the Panomics website at 
http://www.panomics.com.  Gapdh mRNA expression was used as an internal 
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control for each sample.  Samples were analyzed using a Bio-Plex 200 
System Array reader with Luminex 100 X-MAP technology, and data were 
acquired using Bio-Plex Data Manager Software (Bio-Rad, Hercules, CA).  
Assays were performed according to the manufacturer’s protocol (Panomics, 
Inc., Fremont, CA).  Briefly, 10 µg mouse liver total RNA was incubated 
overnight at 54°C with X-MAP beads containing oligon ucleotide capture 
probes, label extenders, and blockers.  The next day, beads and bound target 
RNA were washed and subsequently incubated with bDNA amplifier at 46°C 
for 1 hr.  Samples were then washed and incubated with label (biotin) at 46°C 
for 1 hr.  Samples were washed and incubated with streptavidin-conjugated 
R-phycoerythrin (SAPE), which binds biotinylated probes, and incubated at 
room temperature for 30 min.  SAPE fluorescence was then detected for each 
specific mRNA within each sample.  All data were standardized to the internal 
control, Gapdh.  Data are expressed as the ratio of Gst mRNA to Gapdh 
mRNA per 10 µg of total RNA. 
Statistical analysis. All data were analyzed using one-way analysis of 
variance (ANOVA) followed by Duncan's multiple range test (p < 0.05). 
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RESULTS 
Bile flow and GSH excretion.  Bile flow tended to be lower in Nrf2-null mice, 
whereas it was higher (~30%) in Keap1-kd mice (Fig 4.1A).  Nrf2-null mice 
excreted GSH 30% slower, whereas Keap1-kd mice excreted GSH 30% 
faster than WT mice (Fig 4.1B). 
Plasma concentration and biliary excretion of BSP.   Nrf2-null mice had 
slower plasma disappearance of BSP than WT mice, whereas there was not 
a statistical difference in the plasma disappearance of BSP between Keap1-
kd and WT mice (Fig 4.2A).  After BSP injection, Nrf2-null mice continued to 
have a slower bile flow, whereas Keap1-kd mice had a higher bile flow than 
WT mice (Fig 4.2B).  Nrf2-null mice had slower biliary excretion of BSP and 
lower cumulative biliary excretion of BSP than WT mice (Fig 4.2C).  In 
contrast, Keap1-kd mice had faster biliary excretion of BSP and higher 
cumulative biliary excretion of BSP than do WT mice (Fig 4.2D).   Thirty min 
after BSP injection, Nrf2-null mice excreted 25%, WT mice 52%, and Keap1-
kd mice 80% of the injected BSP. 
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Plasma concentration and biliary excretion of DBSP.   There were no 
differences in plasma disappearance, biliary excretion, or cumulative biliary 
excretion of DBSP in WT, Nrf2-null, and Keap1-kd mice (Figs 4.3A, 4.3C, and 
4.3D).  However, after DBSP administration, Keap1-kd mice maintained 
higher bile flow (Figure 4.3B).  It should be noted that Keap1-kd mice also 
had a higher bile flow rate than WT mice before injection of DBSP (Fig 4.1A). 
Effect of BSP administration on Hepatic GSH concentration.  Twenty min 
after BSP (80 µmol/kg) administration, GSH concentrations were quantified in 
WT mice to determine whether GSH depletion after BSP administration might 
play a role in biliary excretion of BSP.  GSH concentrations in liver were not 
decreased by BSP (Fig 4.4). 
BSP-GSH conjugation activity.  BSP-GSH conjugation activity was 
determined in hepatic cytosol fractions.  Consistent with the biliary excretion 
of BSP, conjugation of BSP with GSH is 42% less than in WT mice, whereas 
Keap1-kd mice have 137% higher conjugation activity than WT mice (Fig 4.5). 
Gst mRNA expression.  In order to quantify various Gsts that could play a 
role in GSH conjugation, total liver RNA was pooled (n=5) from naïve WT, 
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Nrf2-null, and Keap1-kd mice.  The mRNA expression of various hepatic Gsts 
was quantified utilizing multiplex suspension array technology.  The mRNA 
expression of Gsta1, a4, m1, m2, m3, and p2 were 33-77% lower in Nrf2-null 
mice but 100-1600% higher in Keap1-kd mice (Fig 4.6).  The mRNA 
expression of Gstt1, Gstt2, MGst1, and Mgst3 was not different among the 
three genotypes (data not shown). 
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Figure 4.1. Basal bile flow  (A) and GSH excretion  (B) in wild-type, Nrf2-null, 
and Keap1-kd mice (n=5). Values are expressed as mean ± S.E.M.  Asterisks 
(*) indicate a statistically significant difference from wild-type mice (p ≤ 0.05). 
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Figure 4.2.  Plasma disappearance (A), bile flow (B), biliary excretion (C), 
and cumulative biliary excretion (D) of BSP (80 µmol/kg) in wild-type, Nrf2-
null, and Keap1-kd mice (n=5).  Values are expressed as mean ± S.E.M.  
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Asterisks (*) indicate a statistically significant difference from wild-type mice 
(p ≤ 0.05). 
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Figure 4.3.  Plasma disappearance (A), bile flow (B), biliary excretion (C), 
and cumulative biliary excretion (D) of DBSP (120 µmol/kg) in wild-type, Nrf2-
null, and Keap1-kd mice (n=5).  Values are expressed as mean ± S.E.M.  
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Asterisks (*) indicate a statistically significant difference from wild-type mice 
(p ≤ 0.05). 
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Figure 4.4.  Liver GSH concentration in wild-type mice 20 min after intra-
vascular injection of saline or BSP (80 µmol/kg, n=5).  No differences were 
observed between treated and untreated groups. 
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Figure 4.5.  BSP-GSH conjugation activity in wild-type, Nrf2-null, and Keap1-
kd mice (n=5).  Asterisks (*) indicate a statistically significant difference from 
wild-type mice (p ≤ 0.05). 
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Figure 4.6.  Messenger RNA expression of Gsta1, a4, m1, m2, m3, m4, m6, 
and p2 in wild-type, Nrf2-null, and Keap1-kd mice.  Total RNA from livers 
(n=5) was quantified using multiplex suspension array.  The data are 
expressed as relative light units (RLU) normalized to Gapdh. Values are 
expressed as mean ± S.E.M.   Asterisks (*) indicate a statistically significant 
difference from wild-type mice (p ≤ 0.05). 
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Figure 4.7.  Summary of Nrf2-dependent BSP excretion. Enhanced Nrf2 
activation increases BSP biliary excretion by increasing the mRNA expression 
and activity of glutathione-S-transferases (Gsts).  BSP excretion is not 
affected by uptake transporters (Oatps), the efflux transporter Mrp2, or GSH 
content in this model.  
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DISCUSSION 
BSP has been used for decades as a model compound to assess 
hepatobiliary function both clinically and experimentally.  In the present study, 
BSP was used to elucidate the role of Nrf2 in hepatobiliary function.  Nrf2 is a 
transcription factor that upon activation induces a wide variety of 
cytoprotective genes, such as GSH-synthesis enzymes, Gsts, and Mrps; all of 
which play a role in biliary excretion of xenobiotics.   
Basal bile flow tends to be lower in Nrf2-null mice, whereas it is higher 
in Keap1-kd mice.  These trends in bile flow correlate with the decreased and 
increased biliary excretion of GSH in Nrf2-null and Keap1-kd mice, 
respectively (Fig 4.1B).  GSH provides the osmotic force that drives bile acid-
independent bile flow (Ballatori and Truong, 1989; Ballatori and Truong, 
1992).   In addition, there were no differences in the biliary excretion of total 
bile acids (p>0.05, data not shown). 
Among wild-type, Nrf2-null, and Keap1-kd mice, Nrf2-null mice have 
the slowest disappearance of BSP from the plasma, slowest bile flow after 
BSP, slowest biliary excretion of BSP, and lowest cumulative excretion of 
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BSP (Fig 4.2).  The opposite is true when Nrf2 is more highly activated 
(Keap1-kd mice), thus there is a direct correlation with the amount of 
activated Nrf2 and plasma disappearance of BSP, bile flow, and biliary 
excretion of BSP. 
Clearly, Nrf2 influences bile flow and GSH biliary excretion; however, 
because Nrf2 affects multiple pathways that could affect BSP biliary 
excretion, additional experiments were performed to elucidate how Nrf2 alters 
BSP disposition.  To investigate the possible role of transporters, the 
dibrominated analog of BSP, namely DBSP, was used in experiments similar 
to those performed with BSP.  DBSP is transported into hepatocytes and 
effluxed into bile by the same transporters as BSP, but unlike BSP, DBSP is 
not conjugated with GSH.  Therefore, if BSP biliary excretion differences are 
due to a transporter-mediated phenomenon rather than a biotransformation 
phenomenon, then there should be differences in the biliary excretion of 
DBSP among the three genotypes.   However, no such differences in plasma 
disappearance and biliary excretion of DBSP were observed among the three 
  170
genotypes, demonstrating that transporter activity is not responsible for the 
changes observed in the biliary excretion of BSP (Fig 4.3). 
After parallel studies with DBSP failed to show differences in the biliary 
excretion among the genotypes, BSP metabolism was considered in more 
detail.  Because BSP is conjugated with GSH before biliary excretion, and 
GSH excretion is a determinant of bile acid-independent flow, experiments 
were conducted to determine whether the differences in biliary excretion of 
BSP were due to depletion of GSH after BSP administration.  The lack of 
decrease in GSH concentrations 20 min following BSP administration 
demonstrates that differences in biliary excretion of BSP are not due to 
depletion of the co-substrate, GSH (Fig 4.4).   
Because the aforementioned studies suggested Nrf2-dependent 
differences in BSP biliary excretion might be due to GSH conjugation, Gst 
activity and mRNA expression were quantified.  Interestingly, Nrf2-null mice 
have 42% less and Keap1-kd mice have 137% more enzyme activity to 
conjugate BSP with GSH, than do WT mice.  Furthermore, the mRNA 
expression of six Gst isoforms, namely Gsta1, a4, m1, m2, m3, and p2 was 
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33-77% lower in Nrf2-null mice and 100-1600% higher in Keap1-kd mice.  
The differences in expression of Gsts confirms that the differences in biliary 
excretion of BSP in WT, Nrf2-null, and Keap1-kd mice are due to differences 
in activity of liver to conjugate BSP with GSH.  The mechanism by which Nrf2 
modulates BSP biliary excretion is summarized in Fig 4.7. 
Numerous studies have shown that Nrf2 protects against toxicity, 
which is frequently attributed to decreased toxicodynamic effects, as 
exemplified by increased expression of cytoprotective genes, such as 
NAD(P)H:quinone oxidoreductase 1 (Nqo1), protecting against oxidative or 
electrophilic stress (Aleksunes and Manautou, 2007).  The present study 
emphasizes the importance of the Nrf2-Keap1 pathway on the toxicokinetics 
of chemicals.  Whereas activation of Nrf2 protects cells from electrophiles 
through induction of cytoprotective genes, Nrf2 also increases biliary 
excretion of potentially toxic xenobiotics, as exemplified by increased GSH 
conjugation and biliary excretion of BSP, which represents another important 
defense mechanism. 
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Altered Disposition of Acetaminophen in Nrf2-null and Keap1-
Knockdown Mice 
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ABSTRACT 
Acetaminophen (AA) is a widely-used antipyretic drug that causes 
hepatotoxicity at high doses.  Nuclear factor erythroid 2-related factor 2 (Nrf2) 
is a transcription factor that mitigates electrophilic stress from AA by inducing 
genes, such as NAD(P)H:quinone oxidoreductase 1 (Nqo1), multidrug 
resistance-associated proteins (Mrps), and glutathione (GSH) synthesis 
enzymes.  To determine whether Nrf2 activation alters the biotransformation, 
excretion, and in turn, the hepatotoxicity of AA, male wild-type, Nrf2-null, and 
Keap1-knockdown (Keap1-kd) mice (which have increased activation of Nrf2) 
were administered a single subtoxic dose of AA (50 mg/kg, iv), after which, 
AA and its metabolites (AA-glucuronide, AA-GLUC; AA-sulfate, AA-SULF; 
AA-glutathione, AA-GSH) were quantified in plasma, bile, and liver.  AA-
GLUC concentrations were reduced in plasma and elevated in livers of Nrf2-
null mice due to decreased glucuronidation activity and lower expression of 
the basolateral efflux transporter Mrp3.  In contrast, Keap1-kd mice had 
higher plasma and lower hepatic AA-GLUC concentrations, due to higher 
Mrp3 expression.  Lower glucuronidation activity of Nrf2-null mice increased 
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the proportion of AA available for sulfation, resulting in elevated AA-SULF 
concentrations in plasma, bile, and liver.  Decreased AA sulfation activity in 
Keap1-kd mice resulted in lower AA-SULF concentrations.  In general, GSH-
derived AA conjugates were increased in Nrf2-null mice and decreased in 
Keap1-kd mice.  Furthermore, Nqo1, an enzyme capable of detoxifying the 
reactive intermediate of AA metabolism, NAPQI, had 85% lower activity in 
Nrf2-null mice and 415% higher activity in Keap1-kd mice relative to wild-type.  
In addition, hepatotoxicity 6 h after AA (600 mg/kg, ip) was most severe in 
Nrf2-null mice and absent in Keap1-kd mice.  In conclusion, lack of Nrf2 
decreases AA glucuronidation, leading to increased NAPQI formation and 
hepatotoxicity, whereas activation of Nrf2, as in Keap1-kd mice, enhances 
detoxification of NAPQI by Nqo1 and elimination of AA-GLUC via Mrp3. 
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INTRODUCTION 
Nuclear factor erthyroid 2-related factor 2 (Nrf2) is a member of the 
family of basic leucine zipper transcription factors.  Under basal conditions, 
Kelch-like ECH-associated protein 1 (Keap1) sequesters Nrf2 in the cytosol 
(Itoh et al., 2003; McMahon et al., 2003).  During periods of 
oxidative/electrophilic stress, the Nrf2-Keap1 interaction is disrupted, 
permitting Nrf2 to translocate to the nucleus.  Once in the nucleus, Nrf2 
complexes with small musculo-aponeurotic fibrosarcoma (Maf) proteins, and 
the complex binds to antioxidant response elements (ARE), promoting 
transcription of a large battery of cytoprotective genes (Itoh et al., 1997; 
Venugopal and Jaiswal, 1998; He et al., 2001).  Nrf2-ARE-dependent genes 
include the prototypical target gene NAD(P)H: quinone oxidoreductase 1 
(Nqo1), and others such as glutamate-cysteine ligase, catalytic and modifiers 
subunits (Gclc and Gclm), glutathione-S-transferases (Gsts), UDP-
glucuronosyltransferases (Ugts), multidrug resistance-associated proteins 
(Mrp2-4), and many others (Venugopal and Jaiswal, 1996; Kobayashi and 
Yamamoto, 2006; Maher et al., 2007). 
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Acetaminophen is a widely-used analgesic and antipyretic drug that 
can produce hepatic injury with acute overdosing.  AA is conjugated with 
glucuronic acid and sulfate, reactions catalyzed by Ugts and sulfotransferases 
(Sults), respectively (Nelson, 1990).   In mice, AA-glucuronide (AA-GLUC) is 
excreted into bile via Mrp2 (Xiong et al., 2000).   However, the basolateral 
transporter Mrp3 has a higher affinity for AA-GLUC and effluxes AA-GLUC 
into blood (Manautou et al., 2005).  Furthermore, induction of rat Mrp3 by 
phenobarbital, trans-stilbene oxide, diallyl sulfide, or oltipraz increases efflux 
of AA-GLUC into blood (Gregus et al., 1990; Slitt et al., 2003).   AA-sulfate 
(AA-SULF) is excreted into bile primarily via Mrp2, and to a lesser extent by 
breast cancer resistance protein (Bcrp) (Zamek-Gliszczynski et al., 2005).  
AA-SULF can also be effluxed into blood via Mrp3 and Mrp4 (Zamek-
Gliszczynski et al., 2006).  Some AA is also bioactivated by cytochrome 
P450s (Cyps) to N-acetyl-p-benzoquinone imine (NAPQI), which can be 
reduced back to AA in vitro in a redox reaction catalyzed by Nqo1 (Moffit et 
al., 2007) or scavenged through conjugation with glutathione (GSH) in a 
reaction that mainly occurs nonenzymatically.  The resultant AA-GSH 
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conjugate is then excreted as AA-GSH or one of its hydrolysis products, AA-
cysteinylglycine (AA-Cys/Gly), AA-cysteine (AA-Cys), or the acetylated 
cysteine product, namely AA-mercapturate (AA-NAC).  AA-GSH and AA-NAC 
are then effluxed into bile via Mrp2 (Chen et al., 2003).   
The role of Nrf2 in AA hepatotoxicity has been previously investigated, 
but mainly with respect to the effects of Nrf2-dependent alterations in gene 
expression.  Enomoto et al. (Enomoto et al., 2001) concluded that Nrf2 
protects against acetaminophen-induced liver injury by up-regulating Ugt1a6, 
Gclc, and Gclm; however, their experiments were performed in Nrf2-null mice, 
demonstrating increased sensitivity to AA hepatotoxicity due to lower 
expression of cytoprotective enzymes, not protection from AA hepatotoxicity 
in a model of Nrf2 activation.  Okawa et al (Okawa et al., 2006), also basing 
conclusions mainly on mRNA expression data, deduced that hepatocyte-
specific Keap1-null mice are resistant to AA hepatotoxicity because of 
increased hepatic Nrf2 activation and higher constitutive mRNA expression of 
Nqo1, Gclc, and Gsts.  Unfortunately, these two studies (Enomoto et al., 2001 
and Okawa et al., 2006) relied heavily on mRNA expression data and did not 
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investigate the effect of Nrf2 on the disposition of AA. 
Keap1-knockdown (Keap1-kd) mice, in which Keap1 is expressed at 
low levels, resulting in increased Nrf2 activation, have recently been 
characterized (Reisman et al., Chapter Four; (Okada et al., 2008).  Keap1-kd 
mice have increased, whereas Nrf2-null mice have decreased hepatic mRNA 
expression of Nqo1, Gclc, Gclm, Bcrp, Mrp2, Mrp3, and Mrp4.  Nrf2-null mice 
have decreased hepatic Ugt mRNA expression levels, whereas Keap1-kd 
mice have Ugt mRNA expression unchanged from wild-type mice, with the 
exception of increases in Ugt1a6 and Ugt2b35.  Also, Sult mRNA expression 
levels and Cyp enzyme activities generally do not differ among livers from 
wild-type, Nrf2-null, and Keap1-kd mice (Reisman et al., Chapter Four).   
Because Nrf2 can transcriptionally regulate genes important in the 
biotransformation and excretion of AA, namely Ugts, Gclc, Gclm, Nqo1, and 
Mrps, the purpose of this study was to investigate the disposition of AA and 
susceptibility to AA hepatotoxicity in Nrf2-null and Keap1-kd mice.  Ugt and 
Sult activities, as well as protein levels of Bcrp, Mrp2, Mrp3, and Mrp4, were 
examined in livers from wild-type, Nrf2-null, and Keap1-kd mice to determine 
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whether changes in mRNA expression, as previously observed, functionally 
affect AA disposition and susceptibility to AA hepatotoxicity. 
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METHODS 
Reagents.  All chemicals, unless otherwise specified, were purchased from 
Sigma-Aldrich (St. Louis, MO).  Mrp3 (M5II-2), Mrp4 (M4I-10), and Bcrp (BXP-
53) antibodies were provided by Dr. George Scheffer (VU Medical Center, 
Amsterdam, Netherlands).  Mrp2 antibody was provided by Bruno Steiger 
(University Hospital, Zurich, Switzerland). 
Male albino guinea-pig microsomes were purchased from Xenotech, LLC 
(Lenexa, KS). 3-hydroxy benzo[a]pyrene was purchased from the National 
Cancer Institute's Chemical Carcinogen Reference Standards Repository 
operated under contract by Midwest Research Institute (Kansas City, MO). 
Animals and Husbandry. Eight-week-old male C57BL/6 mice were 
purchased from Charles River Laboratories Inc (Wilmington, MA).  Nrf2-null 
mice were obtained from Dr. Jefferson Chan (University of California, Irvine, 
Irvine, CA) (Chan et al., 1996).  Keap1-knockdown (Keap1-kd) mice were 
supplied by Dr. Masayuki Yamamoto (Tohoku University, Aoba-ku, Sendai, 
Japan) (Okada et al., 2008). 
Both Nrf2-null and Keap1-kd mice were backcrossed into C57BL/6 
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mice, and >99% congenicity was confirmed by the speed congenics group at 
Jackson Laboratories (Bar Harbor, ME).  Animals were housed in a 
temperature-, light-, and humidity-controlled environment and had access to 
Teklad Rodent Diet #8604 (Harlan Laboratories, Madison, WI) and water ad 
libitum.  The housing facility is an American Animal Associations Laboratory 
Animal Care-accredited facility at the University of Kansas Medical Center, 
and all procedures were preapproved in accordance with Institutional Animal 
Care and Use Committee guidelines. 
Determination of hepatobiliary disposition of acetaminophen.   Wild type, 
Nrf2-null, and Keap1-kd (n=5) mice were anesthetized by injection of 
ketamine/midazolam (100 mg/kg and 5 mg/kg, respectively, i.p.).  Body 
temperature was maintained at 37°C by rectal-probe-con trolled heating pads. 
Subsequently, the right carotid artery was cannulated with PE-10 tubing, and 
the common bile duct was cannulated with the shaft of a 30-gauge needle 
attached to PE-10 tubing through a high abdominal incision.  Depth of 
anesthesia was monitored by pinching the footpad before and throughout 
surgery, and if necessary, additional anesthetic drugs were administered to 
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mice.  Bile samples were collected in 15-min periods into pre-weighed 0.6 ml 
microcentrifuge tubes for 5 periods.  The bile collection tubes were immersed 
in ice.  After the first bile collection, AA (330 µmol/kg, 20% propylene glycol in 
saline, 5 mL/kg) was injected into the right femoral vein.  Blood (30-35 µl) was 
collected into heparinized tubes at 2, 7.5, 22.5, 37.5, and 52.5 min after AA 
injection.  Volume of bile was quantified gravimetrically, using 1.0 for specific 
gravity.  Bile and plasma were stored at -80°C.  Livers were removed at 1 h, 
frozen in liquid nitrogen, and stored at -80°C. 
Analysis of acetaminophen and its metabolites.  Liver, plasma, and bile 
samples were prepared as described previously (Manautou et al., 2005).  
Liver samples (1:3 wt/vol) were homogenized in ice-cold HPLC-grade 
methanol.  Homogenates were centrifuged at 1200 g for 30 min at 4ºC, and 
the supernatents were diluted further (1:2) in 12.5% methanol/1% acetic acid 
in water (mobile phase A).  Bile and plasma samples were diluted (1:1) with 
ice-cold methanol and then centrifuged at 1200 g for 30 min at 4ºC.  
Supernatants were further diluted (1:1 for bile and 1:1.5 for plasma) with 
mobile phase A.  Further dilutions in mobile phase A were made where 
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appropriate to be within the limits of the standard curve.  HPLC-UV detection 
was performed as previously described with modifications (Howie et al., 
1977).   Mobile phase A consisted of 12.5% methanol/1% acetic acid in water, 
and mobile phase B consisted of 50% methanol in water.  The mobile phase 
was first maintained at 8% for mobile phase B for 5 min, followed by a linear 
gradient of 10 min, ending at 25% mobile phase B.  Flow rate was kept 
constant at 1 ml/min, and peaks were detected at 254 nm.  The 
concentrations of AA and its metabolites were calculated using an AA 
standard curve.  Retention times of AA and its metabolites were determined 
using authentic standards provided by McNeil-PPC, Inc. (Fort Washington, 
PA). 
Hepatic microsomal preparation and in vitro biochemical assays.  Liver 
was dounce homogenized in 0.1 M potassium phosphate buffer containing 
20% glycerol and 10 mM dithiothreitol (1:10 w/v, pH 7.8).  Homogenates were 
centrifuged at 10,000 g at 4ºC for 20 min, and the supernatant was 
centrifuged at 100,000 g for 1 h.  The cytosolic supernatant was stored at -
80°C.  The microsomal pellet was resuspended in 0.1 M sodium phosphate 
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buffer (pH 7.8) and used immediately.   
Hepatic bioactivation of AA to NAPQI was determined in vitro, using a 
method described previously with modifications (Manautou et al., 1994).  
Briefly, 0.1 M sodium phosphate buffer (pH 7.8), 0.83 mM NADP, 15 mM 
MgCl2, 20 mM glucose-6-phosphate, 4 IU glucose-6-phosphate 
dehydrogenase, 1 mM N-acetylcysteine (NAC, as the trapping agent for 
NAPQI), and microsomes (1-2 mg protein) were preincubated at 37ºC in glass 
test tubes in a total volume of 200 µL.  After 10 min, 100 µL of AA (20 mM, 
incubation concentration) in sodium phosphate buffer (pH 7.8) was added and 
incubated for 20 min at 37ºC. The reaction was stopped after 30 min by 
addition of 300 µL of ice-cold HPLC-grade methanol.  The tubes were then 
centrifuged at 3200 g for 30 min at 4°C.  The supernatant was filtered (45-µm 
nylon filters) and analyzed by HPLC, as described above.  Control 
incubations were similarly prepared without NAC, AA, or microsomes, and 
upon HPLC analsys, no AA- NAC peaks were detected.  Activity was 
expressed as nmoles AA-NAC/min/mg protein. 
 Hepatic Ugt activity was determined using a modified method 
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(Manautou et al., 1996).  Briefly, 0.1 M sodium phosphate buffer (pH 7.8), 10 
mM MgCl2, 2.5 mM UDP-glucuronic acid (UDP-GA), 0.5% Brij 58 (microsomal 
activator), and microsomes (1-2 mg protein) were preincubated for 10 min in 
glass test tubes in a total reaction volume of 250 µL.  After 10 min, 100 µL of 
AA (5 mM incubation concentration) in 0.1 M sodium phosphate buffer (pH 
7.8) was added to the preincubation mixture.  The reaction was stopped after 
30 min by addition of 300 µL of ice-cold HPLC-grade methanol.  The tubes 
were then centrifuged at 3200 g for 30 min at 4°C.  The supernatant was 
filtered (45 µm nylon filters) and analyzed by HPLC, as described above.  
Control incubations were similarly prepared without either UDP-GA, AA, or 
microsomes, and upon HPLC analsys, no AA-GLUC peaks were detected.  
Activity was expressed as nmoles AA-UDP-GA/min/mg protein.   
 Hepatic Sult activity was quantified using cytosolic extracts (Mizuma et 
al., 1984; Liu and Klaassen, 1996).   Briefly, cytosols were preincubated at 
37°C for 10 min.  Then 0.5 mM AA and 0.1 mM 3'-phosphoadenosine 5'-
phosphosulfate (PAPS) in 0.1 M sodium phosphate buffer were added, and 
the mixture was incubated at 37°C.  After 20 min, 25 µL of 25% (v/v) HClO4 
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was added to stop the reaction.    Fifty microliters of 0.8 M BaCl2 was added 
to the incubation mixture, and the mixture was centrifuged at 3000 g for 10 
min at 4ºC.  The supernatant was transferred to a clean test tube, and 300 µL 
of ice-cold HPLC-grade methanol was added.  The mixture was centrifuged a 
second time at 3000 g for 10 min at 4ºC.  The supernatant was filtered (45-
µm nylon filters) and analyzed by HPLC, as described above.  Control 
incubations were similarly prepared without PAPS, acetaminophen, or 
cytosols, and upon HPLC analysis, no AA-SULF peaks were detected.  
Activity was expressed as nmoles AA-SULF/min/mg protein. 
Cytosolic Nqo1 enzyme activity was determined by quantifying the 
reduction of 2,6-dichlorophenol-indophenol (DCPIP), as described previously 
(Ernster, 1967; Benson et al., 1980) and modified (Aleksunes et al., 2006a). 
UPD-GA determination.  Hepatic concentrations of UDP-GA were 
determined using the method of formation of benzo[a]pyrene 3-glucuronide, 
as described previously (Singh et al., 1980).  Briefly, approximately 50 mg of 
liver was boiled for 3 min in 5 mL of water.  After cooling, liver was dounce 
homogenized and centrifuged at 3000 g for 10 min at 4ºC.  The supernatant 
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was further diluted to a final concentration of 5 mg wet weight of liver/ml of 
water.  The reaction mixture (200 µl) contained 20 µmol Tris-HCl buffer, pH 
7.6; 1 µmol MgCl2; 0.01% Brij-58 (w/v); 10 nmol 3-hydroxybenzo[a]pyrene in 
10 µl of methanol; 50 µl liver tissue homogenate; and 50 µg male albino 
guinea-pig liver microsomal protein in 0.25 M sucrose.  The mixture was 
incubated for 30 min at 37ºC with mild shaking.  Six ml of 
chloroform/methanol (2:1, v/v) and 0.8 ml of water were added to the mixture, 
and tubes were shaken.  Tubes were centrifuged at 1000 g for 1 min at room 
temperature, and 200 µl of the supernatant was transferred to an opaque 96-
well plate.  Fluorescence of the benzo[a]pyrene 3-glucuronide was quantified 
at 378 excitation/425 emission.  Concentrations of UDP-GA in unknown liver 
samples were calculated using a standard curve of known concentrations of 
UDP-GA. 
Immunofluorescence staining.  Immunofluorescence of Mrp2, Mrp3, Mrp4, 
and Bcrp was performed similarly as described previously (Aleksunes et al., 
2006b).  Cryostat cut tissue sections (5 µm) were fixed with 4% 
paraformaldehyde for 5 min.  All antibody solutions were filtered through 0.22 
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µm membrane syringe-driven filter units (Millipore, Billerica, MA). Sections 
were blocked with 5% goat serum/phosphate-buffered saline with 0.1% Triton 
X (PBS-Tx) for 1 h and then incubated with Mrp2, Mrp3, Mrp4, or Bcrp 
primary antibody diluted 1:100 in 5% goat serum/PBS-Tx for 2 h at room 
temperature.  After incubation with primary antibody, the sections were 
washed three times in PBS-Tx and incubated for 1 h with goat anti-rat IgG 
Alexa 488 for Mrp3, Mrp4, and Bcrp and with goat anti-rabbit IgG Alexa 488 
for Mrp2 (Invitrogen Corporation, Carlsbad, CA) diluted 1:200 in 5% goat 
serum/PBS-Tx.  The sections were air-dried and mounted in Prolong Gold 
with 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen Corp.).  Frozen liver 
sections were stained and imaged under uniform conditions for each 
antibody.  Negative controls without primary antibody were also included in 
the analysis (data not shown).   Images were captured on an Olympus BX41 
fluorescent microscope with a DP70 camera and DP Controller software 
(Olympus, Center Valley, PA). 
Hepatotoxicity Studies.  Wild-type, Nrf2-null, and Keap1-kd mice were 
administered AA (4 mmol/kg, i.p., 20% propylene glycol in saline, 10 mL/kg).  
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Six h later blood was collected by cardiac puncture under pentobarbital 
anesthesia, and livers were removed.  A portion of the largest lobe of the liver 
was placed in 10% phosphate-buffered zinc formalin to fix for 24 h.  Tissues 
were processed and sectioned according to standard histological techniques.  
Tissue sections were scored using a scale from 0 to 5 according to the 
severity of necrosis as described previously (Manautou et al., 1994). 
Histopathology scoring was as follows: no injury = grade 0; minimal injury 
involving single to few hepatocytes = grade 1; mild injury affecting 10–25% of 
hepatocytes = grade 2; moderate injury affecting 26–40% of hepatocytes = 
grade 3; marked injury affecting 41–50% of hepatocytes = grade 4; or severe 
injury affecting more than 50% of hepatocytes = grade 5.  Sections with 
scores higher than 2 are considered to exhibit significant liver injury.  Serum 
ALTs were quantified using a commercially available kit according to 
manufacturer’s protocol (Pointe Scientific, Canton, MI). 
Statistical Analysis. All data but histophathological data were analyzed 
using a one-way analysis of variance (ANOVA) followed by Duncan's multiple 
range test (p ≤ 0.05) utilizing SigmaStat Software (Systat Software Inc., San 
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Jose, CA).  N=5 for all groups, and values are expressed as mean ± S.E.M.  
Histopathological data were rank ordered prior to ANOVA analysis, which was 
followed by Newman-Keuls multiple range test (p ≤ 0.05). 
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RESULTS 
Plasma disposition of AA and its conjugates.   One h after AA (330 
µmol/kg, i.v.) administration, serum ALT concentrations ranged from 35-65 
IU/L with no differences among genotypes, indicating that there was no 
apparent hepatotoxicity at this dose during the 1 h of bile collection (data not 
shown).  Plasma disappearance of AA was decreased in Nrf2-null mice and 
increased in Keap1-kd mice (Fig 1A).  AA-GLUC was the most abundant AA-
metabolite detected in plasma.  The plasma appearance of AA-GLUC was 
decreased in Nrf2-null mice and increased in Keap1-kd mice at 7.5 and 22 
min (Fig 1B).  Plasma AA-GLUC concentrations in Nrf2-null mice did not 
approach the plasma concentrations of wild-type mice during the 1 h 
timeframe, reaching a maximum concentration that was only 48% of wild-type 
mice.  Plasma AA-GLUC concentrations were 45-62% higher in Keap1-kd 
mice for the first 22.5 min, but were comparable to wild-type mice at 
subsequent time points.  Plasma AA-SULF was 61-82% higher in the Nrf2-
null mice, whereas it was markedly reduced 85-96% in Keap1-kd mice (Fig 
1C).  AA-GSH conjugates in plasma were not different among genotypes, and 
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AA-Cys and AA-NAC conjugates were not detected in plasma (data not 
shown). 
Biliary disposition of AA and its conjugates.   Even though only a small 
portion of AA is excreted non-biotransformed into bile, Nrf2-null mice had 
higher, and Keap1-kd mice had lower, cumulative biliary excretion of AA (Fig 
2A).  There were no differences in the biliary excretion of AA-GLUC among 
genotypes (Fig 2B).   Cumulative biliary excretion of AA-SULF was increased 
40-43% in Nrf2-null mice at 45 and 60 min, and decreased 35-40% at 30, 45, 
and 60 min in Keap1-kd mice (Fig 2C).  AA-GSH was the most abundant 
metabolite excreted into bile.  Cumulative biliary excretion of AA-GSH was 
increased 54-76% in Nrf2-null mice (Fig 2D, values at 30 and 45 min tended 
to be higher than wild-type, p≤0.06).  There was no difference in cumulative 
biliary excretion of AA-GSH between Keap1-kd and wild-type mice.  AA-Cys 
was not detected in bile, and biliary excretion of AA-NAC was low and not 
different among genotypes (data not shown).  
Acetaminophen and its metabolites in liver.  Fig 3 shows the hepatic 
concentrations of AA and its metabolites in wild-type, Nrf2-null, and Keap1-kd 
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mice at 1 h after administration.  Accumulation of AA in livers of Nrf2-null and 
wild-type mice was similar after 1 h.  However, the hepatic concentration of 
AA after 1 h was 71% lower in Keap1-kd mice than wild-type mice.  Higher 
liver concentrations of AA-GLUC, AA-SULF, and AA-GSH accumulated in 
Nrf2-null mice, whereas these conjugates were reduced (AA-GLUC and AA-
SULF) or unchanged (AA-GSH) in Keap1-kd mice.  There was no difference 
in hepatic concentrations of AA-NAC between Nrf2-null and wild-type mice; 
however, Keap1-kd mice had 79% lower hepatic concentrations of AA-NAC.  
There were no differences in AA-Cys in the liver after 1 hr among the three 
genotypes (data not shown). 
In vitro bioactivation, glucuronidation, and sulfation activity.   Hepatic 
microsomes were used to quantify AA bioactivation and Ugt activity, whereas 
cytosols were used to determine Sult activity.  In vitro bioactivation activity of 
AA was not different among genotypes (Fig 4A).  In comparison to wild-type 
mice, in vitro glucuronidation activity of AA was 40% lower in Nrf2-null mice, 
whereas there was no increase in Keap1-kd mice (Fig 4B).  In vitro sulfation 
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activity of AA was unchanged in Nrf2-null mice and 29% lower in Keap1-kd 
mice than wild-type mice (Fig 4C). 
Hepatic UDP-GA determination.  UDP-GA concentrations in livers from 
wild-type, Nrf2-null, and Keap1-kd mice were determined because Ugt 
enzyme activity depends on availability of UDP-GA (Singh and Schwarz, 
1981; Gregus et al., 1983).   There were no differences in hepatic UDP-GA 
concentrations among the three genotypes (Fig 5). 
Nqo1 enzyme activity.  Enzyme activity of the Nrf2 prototypical target gene 
Nqo1 was quantified in wild-type, Nrf2-null, and Keap1-kd mice (Fig 6).  Nqo1 
activity was reduced 85% in Nrf2-null mice but elevated 514% in Keap1-kd 
mice. 
 Immunofluorescence of Bcrp, Mrp2, Mrp3, and Mrp4.  Hepatic expression 
of Bcrp, Mrp2, Mrp3, and Mrp4 proteins was assessed in frozen liver sections 
from wild-type, Nrf2-null, and Keap1-kd mice using indirect 
immunofluorescence (Fig 7).  The immunofluorescence of Bcrp and Mrp2 was 
consistent with localization to canalicular junctions between adjacent 
hepatocytes and was similar among all three genotypes.  Mrp3 and Mrp4 
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proteins were localized to basolateral hepatocyte membranes. 
Immunofluorescence of Mrp3 was difficult to detect on the plasma membrane 
in Nrf2-null mice, moderately expressed in all hepatocytes in wild-type mice, 
and enhanced in all hepatocytes in Keap1-kd mice.  Staining of Mrp4 was low 
in livers from wild-type and Nrf2-null mice, whereas Keap1-kd mice had 
enhanced immunostaining of Mrp4 predominantly on centrilobular 
hepatocytes. 
Hepatotoxic effects of AA.  Vehicle-administered wild-type, Nrf2-null, and 
Keap1-kd mice had no differences in serum ALT concentrations or necrosis 
grading (ALT values below 60 IU/L) and no apparent histopathological 
damage (data not shown).  AA-admininistered (4 mmol/kg, i.p.)  wild-type 
mice had serum ALT concentrations indicative of hepatic injury (Fig 8).  AA-
administered Nrf2-null mice had elevated (550%) serum ALT concentrations, 
whereas Keap1-kd mice had 57% lower serum ALT concentrations (62 IU/L) 
when compared to wild-type mice.   AA administration caused moderate 
hepatocellular necrosis in wild-type mice, severe hepatocellular necrosis in 
Nrf2-null mice, and no hepatocellular damage in Keap1-kd mice (Table 1). 
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Table 5.1.  Histological analysis of livers from wild-type, Nrf2-null, and 
Keap1-kd mice after AA challenge. 
 
 Histological Grade  
Treatment Group 0 1 2 3 4 5 P≤0.05 
Nrf2-null 0 0 0 0 3 2 * 
Wild-type 0 0 3 2 0 0  
Keap1-kd 3 2 0 0 0 0 * 
 
Necrosis grading in wild-type, Nrf2-null, and Keap1-kd mice 6 h after AA (600 
mg/kg, i.p.) administration.  There were no differences in necrosis grading in 
vehicle-treated wild-type, Nrf2-null, and Keap1-kd mice with necrosis grades 
of 0 (data not shown).  Histopathology scoring was as follows: no injury = 
grade 0; minimal injury involving single to few hepatocytes = grade 1; mild 
injury affecting 10–25% of hepatocytes = grade 2; moderate injury affecting 
25–40% of hepatocytes = grade 3; marked injury affecting 40–50% of 
hepatocytes = grade 4 or severe injury affecting more than 50% of 
hepatocytes = grade 5.  Asterisks (*) indicate a statistically significant 
difference from wild-type mice (p ≤ 0.05). 
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Fig 5.1.   Plasma concentrations of AA (A), AA-GLUC (B), and AA-SULF (C) 
in wild-type, Nrf2-null, and Keap1-kd mice administered AA (330 µmol/kg, 
i.v.). Values are expressed as mean ± S.E.M.   Asterisks (*) indicate a 
statistically significant difference from wild-type mice (p ≤ 0.05). 
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Fig 5.2.   Cumulative biliary excretion of AA (A), AA-GLUC (B), AA-SULF (C), 
and AA-GSH (D) in wild-type, Nrf2-null, and Keap1-kd mice administered AA 
(330 µmol/kg, i.v.).  Values are expressed as mean ± S.E.M.   Asterisks (*) 
indicate a statistically significant difference from wild-type mice (p ≤ 0.05).
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Fig 5.3.  Hepatic concentrations remaining 1 h after administration of AA (330 
µmol/kg, i.v.) for AA, AA-GLUC, AA-SULF, AA-GSH, and AA-NAC in wild-
type, Nrf2-null, and Keap1-kd mice.   Values are expressed as mean ± S.E.M.   
Asterisks (*) indicate a statistically significant difference from wild-type mice 
(p ≤ 0.05). 
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Fig 5.4.  In vitro enzyme activities of AA bioactivation (A), glucuronidation (B), 
and sulfation (C).  Values are expressed as mean ± S.E.M.   Asterisks (*) 
indicate a statistically significant difference from wild-type mice (p ≤ 0.05). 
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Fig 5.5.  Hepatic UDP-GA concentrations in wild-type, Nrf2-null, and Keap1-
kd mice. Values are expressed as mean ± S.E.M. 
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Fig 5.6.  Hepatic Nqo1 enzyme activity in wild-type, Nrf2-null, and Keap1-kd 
mice. Values are expressed as mean ± S.E.M.   Asterisks (*) indicate a 
statistically significant difference from wild-type mice (p ≤ 0.05). 
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Fig 5.7. Immunofluorescent analysis of Bcrp, Mrp2, Mrp3, and Mrp4 protein in 
wild-type, Nrf2-null, and Keap1-kd mice.  Indirect immunofluorescence 
against Bcrp, Mrp2, Mrp3, and Mrp4 (green) was performed on liver 
cryosections. Representative regions are shown. The bar represents 200 µm. 
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Fig 5.8.  Serum ALT concentrations in wild-type, Nrf2-null, and Keap1-kd 
mice 6 h after AA (600 mg/kg, i.p.) administration.  There were no differences 
in serum ALT concentrations in vehicle-treated wild-type, Nrf2-null, and 
Keap1-kd mice with values all below 60 IU/L (data not shown).  Values are 
expressed as mean ± S.E.M.   Asterisks (*) indicate a statistically significant 
difference from wild-type mice (p ≤ 0.05). 
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DISCUSSION 
 The increased susceptibility of Nrf2-null mice to AA hepatotoxicity has 
been attributed to decreased Ugt1a6 mRNA expression and reduced GSH 
concentrations in liver (Chan et al., 2001; Enomoto et al., 2001).  In contrast, 
the increased resistance of hepatocyte-specific Keap1-null mice to AA 
hepatotoxicity, where there is increased activation of Nrf2, is suggested to be 
due to increased mRNA expression of Ugt1a6 and the GSH synthesizing 
enzyme, Gclc (Okawa et al., 2006).  These previous studies using Nrf2-null 
and hepatocyte Keap1-null mice drew conclusions about sensitivity to AA 
hepatotoxicity mainly on gene expression data.  Because the 
biotransformation of AA is paramount in determining the severity of 
hepatotoxicity, the effects of differences in Nrf2 activation in in vivo mouse 
models were also determined in the present study.  Herein, the 
pharmacokinetics of AA were investigated in Nrf2-null mice, which lack Nrf2, 
and Keap1-kd mice, which have enhanced activation of Nrf2. 
The concentration of AA in plasma decreased more slowly in Nrf2-null 
mice and faster in Keap1-kd mice than in wild-type mice.  Generally, changes 
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in plasma disappearance of xenobiotics are due to alterations in uptake into 
liver, biotransformation, and/or excretion from liver into bile or plasma.  
Uptake transporters, such as organic anion transporting polypeptides, 
mediate the entrance of a large number of xenobiotics into hepatocytes 
(Klaassen and Lu, 2008).   However, AA is generally not considered a 
substrate for uptake transporters, but instead is thought to enter hepatocytes 
by diffusion, indicating that uptake of AA does not likely play a role in the 
altered plasma disappearance of AA among wild-type, Nrf2-null, and Keap1-
kd mice (McPhail et al., 1993). 
In mice, glucuronidation accounts for approximately 50% of AA 
excreted into urine and bile, significantly influencing the amount of AA 
available for other pathways of biotransformation, such as sulfation and 
bioactivation (Gregus et al., 1988).  Plasma concentrations of AA-GLUC are 
lower in Nrf2-null mice and higher in Keap1-kd mice (first 22.5 min) after AA 
administration (Fig 1B).  Reduced efflux of AA-GLUC into plasma of Nrf2-null 
mice is attributed to lower microsomal AA glucuronidation activity (Fig 4C) 
and Mrp3 expression (Fig 7).  Ugt1a6 mRNA expression is increased in 
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Keap1-kd mice (Reisman et al., Chapter Four); however, there was no 
change in AA glucuronidation activity from livers of Keap1-kd mice (Fig 4C).  
Therefore, increased hepatic efflux of AA-GLUC into plasma in Keap1-kd 
mice reflects the pronounced up-regulation of Mrp3 mRNA and protein (Fig 7) 
(Okada et al., 2008).   Efflux of AA-GLUC into bile is similar among 
genotypes, most likely due to comparable amounts of Mrp2 protein among 
the three genotypes (Fig 7).  There is more AA-GLUC remaining in liver 1 h 
after AA administration in Nrf2-null mice, but less in Keap1-kd mice, which 
correlates inversely with the plasma appearance of AA-GLUC and Mrp3 
protein.  Glucuronidation is also influenced by the availability of the co-
substrate UDP-GA. However, there were no differences in hepatic UDP-GA 
concentrations among genotypes, which suggests that differences in AA-
GLUC among genotypes are not due to availability of UDP-GA (Singh and 
Schwarz, 1981; Gregus et al., 1983). Therefore, lack of Nrf2 results in lower 
AA-GLUC in the plasma and higher amounts of AA-GLUC remaining in the 
liver, due to reduced AA-glucuronidation activity and Mrp3-mediated efflux 
from liver to plasma.  In contrast, enhanced activation of Nrf2 in Keap1-kd 
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mice increases AA-GLUC in the plasma and decreases AA-GLUC remaining 
in the liver 1 h after AA administration, which is attributed to elevated Mrp3 
expression. 
In mice, sulfation accounts for approximately 5% of the AA excreted 
into urine and bile, and any change in glucuronidation or bioactivation of AA 
could influence the quantity of AA available for sulfation (Gregus et al., 1988).  
Sulfation in rats is limited by the availability of PAPS; however, in mice, 
sulfation of AA is limited by sulfotransferase activity (Kim et al., 1995; Liu and 
Klaassen, 1996).  AA-SULF concentrations in plasma, liver, and bile are 
inversely proportional to Nrf2 activation (i.e., increased AA-SULF in Nrf2-null 
mice and decreased AA-SULF in Keap1-kd mice).  Expression of transporters 
capable of effluxing AA-SULF (Mrp2, Mrp3, Mrp4, and Bcrp) is either similar 
among all three genotypes or lower in Nrf2-null mice, suggesting that efflux is 
unlikely to be responsible for the differences, as no change or a decrease in 
efflux transporter expression should not result in an increase in hepatic efflux 
of AA-SULF (Nrf2-null mice).  In addition, in vitro AA-sulfation activity was 
similar between Nrf2-null and wild-type mice.  Taken together, the decrease 
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in AA-GLUC activity and increase in formation and excretion of AA-SULF in 
Nrf2-null mice suggests a metabolic shift to sulfation to compensate for the 
decrease in the amount of AA undergoing glucuronidation.  Keap1-kd mice 
have lower in vitro sulfation activity (Fig 4B), resulting in reduced AA-SULF 
concentrations in plasma, liver, and bile.  Phenol sulfotransferases in rat liver 
have higher activity when in a partially oxidized state, as the fully reduced 
state gives rise to a ternary complex that impedes binding of the co-substrate 
PAPS (Marshall et al., 2000).  It is possible that the more reduced 
environment caused by increased expression of cytoprotective genes in 
Keap1-kd mice liver results in lower Sult activity.  Therefore, Nrf2-null mice 
have increased AA-SULF in plasma, liver, and bile because of decreased 
glucuronidation activity, which leaves more AA available for sulfation, but 
Keap1-kd mice have decreased AA-SULF directly due to decreased AA-
sulfation activity. 
Ultimately, AA hepatotoxicity depends on the quantity of AA 
bioactivated by Cyps and the ability to detoxify NAPQI through GSH 
conjugation or Nqo1-mediated quinone reduction.  In general, Cyp2e1, 1a1, 
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and 3a11 enzyme activities are not different among genotypes (Reisman et 
al., Chapter Four).  Therefore, it was not surprising that the in vitro ability to 
generate NAPQI was not different among the three genotypes (Fig 4A).  
However, Nrf2-null mice generate more AA-GSH in vivo, as evident by more 
AA-GSH excreted into bile and remaining in liver (Fig 2D and 3).  The 
decreased ability to form AA-GLUC in Nrf2-null mice increases the availability 
of AA for bioactivation to the reactive metabolite NAPQI.  Decreased 
microsomal AA glucuronidation and Nqo1 activity (Fig 6) likely contribute to 
increased AA-GSH formation in Nrf2-null mice.  In turn, increased AA-GSH 
formation further decreases already reduced concentrations of GSH in Nrf2-
null mice (Reisman et al., Chapter Four) and increases sensitivity to AA 
hepatotoxicity.   Keap1-kd mice excrete similar quantities of AA-GSH into bile 
as wild-type mice (Fig 2).  Keap1-kd mice also have similar concentrations of 
AA-GSH as wild-type mice remaining in their livers 1 h after administration of 
AA.   However, increased Nqo1 enzyme activity (Fig 6) explains the decrease 
in the combined total of AA-GSH and its breakdown product AA-NAC 
remaining in the liver after 1 h.  The absence of Nrf2 decreases 
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glucuronidation of AA, and therefore increases the availability of AA for Cyp 
metabolism and subsequent AA-GSH synthesis.  In contrast, enhanced Nrf2 
activation does not affect glucuronidation activity but does increase the ability 
of hepatic Nqo1 to detoxify NAPQI. 
Nrf2 plays a crucial role in the pharmacokinetics and metabolism of 
AA, and, in turn, hepatotoxicity.  Decreased ability of Nrf2-null mice to 
conjugate and excrete the parent compound and to detoxify NAPQI results in 
increased sensitivity to hepatotoxicity (Fig 8 and Table 1).  In contrast, Keap1-
kd mice, with increased activation of Nrf2, have an enhanced ability to 
detoxify and excrete AA, resulting in decreased sensitivity to AA 
hepatotoxicity.  In fact, Keap1-kd mice do not display any hepatotoxicity at a 
relatively high dose of AA (4 mmol/kg, i.p.). 
 In conclusion, previous studies have shown that Nrf2 protects against 
hepatotoxicity, and the proposed explanation has been that the protection is 
due to an increase in genes that protect against electrophilic stress 
(Aleksunes and Manautou, 2007).  Whereas there is little doubt that the 
induction of cytoprotective genes, via Nrf2, is important in the prevention of 
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hepatic injury, the present study emphasizes the importance of the Nrf2-
Keap1 pathway on the pharmacokinetics of AA.  Collectively, the results 
presented herein have shown that lack of Nrf2 decreases AA glucuronidation 
and increases AA available for Cyp-mediated NAPQI formation and 
hepatotoxicity, whereas activation of Nrf2 enhances the detoxification of 
NAPQI by Nqo1 and the elimination of AA-GLUC via Mrp3. 
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 Mammals are frequently exposed to electrophilic and oxidative 
stressors and in turn, have developed highly efficient cytoprotective 
mechanisms (Li and Kong, 2008).  When exposed to electrophilic/oxidative 
stress, cells counter with induction of detoxification enzymes, antioxidants, 
and efflux transporters, allowing them to reduce an oxidative environment and 
return to homeostasis.  A homeostatic balance between oxidants and 
antioxidants in cells is required for normal cellular functions and the 
prevention of diseases, such as cancer and liver injury.   A key transcription 
factor regulating the antioxidative system response is Nrf2.  Many studies 
have demonstrated increased sensitivity to oxidative and electrophilic stress 
in mice lacking Nrf2 (Aleksunes and Manautou, 2007).  However, few have 
investigated whether there are protective effects when Nrf2 is activated and 
target genes induced, especially in the liver of whole animals.  Therefore, the 
purpose of this study was to investigate the pharmacologic (triterpenoids) and 
genetic effects (Keap1-kd mice) of increased Nrf2 on AA-induced liver injury, 
expression of hepatic drug processing genes, and the pharmacokinetics of 
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two compounds whose biotransformation occurs primarily in the liver, BSP 
and AA. 
 The experiments in Chapter One investigated the mechanism of action 
of oleanolic acid, a natural triterpenoid compound, shown previously to 
protect the liver from a wide-variety of chemicals with diverse mechanisms for 
producing liver toxicity (Liu et al., 1995a).  Daily injection of oleanolic acid (3 
days) activated Nrf2, indicated by an increase in Nrf2 nuclear accumulation.  
Oleanolic acid also increased mRNA expression of Nrf2-target genes (Nqo1, 
Gclc, and Ho-1), as well as protein expression and enzyme activity of the 
prototypical Nrf2-target gene Nqo1 in wild-type, but not in Nrf2-null mice.   
Furthermore, oleanolic acid pretreatment protected wild-type mice more than 
Nrf2-null mice from AA-induced hepatotoxicity. 
 Oleanolic acid also demonstrated mild hepatoprotection from AA in 
Nrf2-null mice, indicating a Nrf2-independent mechanism of action.   A 
possible explanation for this is that oleanolic acid induces cytoprotective 
enzymes in a manner independent of Nrf2.  Two such cytoprotective proteins 
induced by oleanolic acid include metallothionein (MT), a low-molecular-
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weight protein rich in cysteine residues, and a 70 kDa heat shock protein 
(Hsp70) (Liu et al., 2008).  Because of the high sulfhydryl content in Mt, it has 
been suggested to react with and detoxify reactive oxygen species and 
electrophiles (Klaassen and Cagen, 1981).  MT can be induced by Nrf2-
independent stress mechanisms, including the transcription factors Nrf1 and 
the metal-responsive-element-binding transcription factor-1 (Mtf-1) (Laity and 
Andrews, 2007; Ohtsuji et al., 2008).  Also, MT-null mice are more sensitive 
to AA toxicity (Liu et al., 1999).  Hsp70 acts to protect cells by reducing the 
ability of oxidized proteins to aggregate, permitting them time to refold and 
return to a functional conformation. Hsp70-null mice are more sensitive to AA 
hepatotoxicity (Tolson et al., 2006).  Collectively, the ability of oleanolic acid 
to induce cytoprotective genes independent of Nrf2 provides a possible 
explanation for part of the protection observed from AA hepatoxicity in 
oleanolic acid-pretreated Nrf2-null mice. 
 The experiments in Chapter Two investigated whether CDDO-Im, a 
synthetic triterpenoid, could also activate Nrf2 and protect from AA-
hepatotoxicity.  Indeed, CDDO-Im induced Nrf2-target genes in both a time- 
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and dose-dependent manner in wild-type mice, whereas no induction of Nrf2-
target genes was detected in Nrf2-null mice.  Also, the dramatic 
hepatoprotection CDDO-Im had in AA-administered wild-type mice was not 
observed in Nrf2-null mice.  To summarize Chapters One and Two, both 
oleanolic acid and CDDO-Im protected the liver from AA-induced injury, at 
least partially, by activating the cytoprotective transcription factor Nrf2. 
 Oleanolic acid has an oral bioavailability of approximate 0.7% (Jeong 
et al., 2007).  Therefore, alternative compounds were synthesized in order to 
not only take advantage of the positive effects of oleanolic acid, but also to 
increase its bioavailability.  Because CDDO-Im and related synthetic 
triterpenoids (CDDO and CDDO-Me) have much higher oral bioavailability 
and efficacy than the natural triterpenoid oleanolic acid, they are currently in 
Phase II clinical testing (Reata Pharmaceuticals, Inc.).  The synthetic 
triterpenoids are being tested as oral drugs for the treatment of autoimmune, 
cardiovascular, and renal diseases because of their ability to restore redox 
homeostasis.  This restoration of redox homeostasis inhibits the production of 
inflammatory cytokines, and reduces inflammation and cellular damage from 
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pro-oxidant species.  Perhaps the synthetic triterpenoids could also be 
developed for the treatment and prevention of liver diseases, as few therapies 
for treating hepatotoxicity currently exist. 
Because chemicals can have many off-target effects, a genetic model 
of Nrf2 activation would be extremely useful in determining the specific gene 
patterns induced by Nrf2.  Keap1-kd mice have a 55% decrease in Keap1 
mRNA and a 200% increase in Nrf2 protein in liver.  Therefore, the purpose of 
the second aim was to determine the phenotype of Keap1-kd mice and 
compare the patterns of gene expression among wild-type, Nrf2-null and 
Keap1-kd mice. A fundamental understanding of the mRNA expression of 
drug metabolizing and detoxification enzymes will provide a framework for 
future studies using both Nrf2-null mice and Keap1-kd mice.  Indeed, three 
patterns of gene expression were observed among wild-type, Nrf2-null, and 
Keap1-kd mice. The first pattern encompassed genes that were lower in Nrf2-
null mice and considerably higher in Keap1-kd mice than wild-type mice, and 
included genes mainly responsible for the detoxification and elimination of 
electrophiles, such as Nqo1 and Gsts, as well as Mrps.  The second pattern 
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encompassed genes that were lower in Nrf2-null mice, not increased in 
Keap1-kd mice, and included genes important in the detoxification of reactive 
oxygen species, such as Sod1, Sod2, catalase, and Prx1.  The third pattern 
encompassed genes that were not different among wild-type, Nrf2-null, and 
Keap1-kd mice and included genes such as Gpx1, microsomal Gsts, Ho-1, 
and uptake transporters.   In conclusion, the study presented in the third 
chapter suggests that hepatic Nrf2 is more important for the detoxification and 
elimination of electrophiles than reactive oxygen species.   This study 
provides a framework and foundation for future studies involving Keap1-kd 
mice in order to explore the effects of increased activation of Nrf2. 
In studies that have investigated the increased sensitivity to the toxicity 
as a result of a loss of Nrf2 or the increased resistance to toxicity due to 
activation of Nrf2, none have investigated the effects of Nrf2 on the kinetics of 
a xenobiotic.  The conclusions from many of these studies are often based 
exclusively on gene expression data.  Therefore, the purpose of Chapters 
Three and Four was to determine whether Nrf2 alters the kinetics of two well-
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known and well-studied compounds biotransformed in the liver, namely BSP 
(Chapter Three) and AA (Chapter Five).    
The elimination of BSP was most affected by the activity of Gsts, which 
is decreased in Nrf2-null mice and increased in Keap1-kd mice.  In addition, 
the elimination of BSP was not effected by differential Nrf2-dependent 
transporter expression among wild-type, Nrf2-null, and Keap1-kd mice.  For 
the kinetics of AA, a lack of Nrf2 (Nrf2-null mice) decreased AA 
biotransformation and elimination, leading to increased formation of the toxic 
intermediate and hepatotoxicity, whereas activation of Nrf2 (Keap1-kd mice) 
enhanced detoxification of the reactive metabolite of AA and elimination of 
conjugated AA via efflux transporters.  Therefore, it is important to note that 
the toxicokinetics of a xenobiotic due to increased Nrf2 activation must be 
investigated not just toxicodynamics.  This will allow one to determine 
whether the elimination of the toxicant is being affected by increased 
biotransformation and/or efflux transport. 
With activation or blocking of any target in pharmacology with a 
chemical, there are often unintended adverse effects, which are sometimes 
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overlooked because one is often only interested in and evaluating the desired 
effects. Indeed, Nrf2 does have and could have more adverse effects, which 
will be discussed here.  Occasionally mentioned in the literature, are the 
beneficial and adverse effects of Nrf2 activaiton (Hayes and McMahon, 2006). 
Nrf2 has a beneficial cytoprotective effects in healthy cells under stress, 
whereas Nrf2 activation can also result in cancer cell persistence and growth. 
Some human lung, gallbladder, breast, cancers have mutations in Keap1, 
which result in enhanced activation of Nrf2, which most likely would increase 
protection of the cancer cells from conventional chemotherapies (Singh et al., 
2006; Nioi and Nguyen, 2007; Ohta et al., 2008; Shibata et al., 2008a; 
Shibata et al., 2008b).  In contrast, RNAi-mediated silencing of Nrf2 gene 
expression in non-small cell lung cancer inhibited tumor growth and increased 
efficacy of chemotherapy (Singh et al., 2006; Nioi and Nguyen, 2007; Ohta et 
al., 2008; Shibata et al., 2008a; Shibata et al., 2008b).  Therefore, a 
compound that activates Nrf2 could allow a cancer cell that would normally be 
eliminated by the body to progress to malignancy. 
One of the major detoxifying pathways induced by Nrf2 activation is the 
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ability to synthesize and use GSH.  Compounds that are bioactivated to a 
toxic metabolite by GSH could have increased toxic effects because of 
increased reactive metabolite formation, due to activation of Nrf2 and 
subsequent induction of GSH synthesis genes and Gsts.  For example, 
hexachlorobutadiene, a halogenated alkene used as an industrial solvent, is 
conjugated with glutathione in the liver and then sent to the kidney for 
processing to mercapaturic acids (Dekant, 1996).   After removal of the 
glutamic acid and glycine residues by peptidases, b-lyase produces a reactive 
metabolite, which leads to nephrotoxicity (Dekant, 1996).  It is plausible that 
increased GSH concentrations and Gst activity due to Nrf2 activation could 
lead to increased nephrotoxicity from hexachlorobutadiene, as well as 
increased toxicity for other compounds activated by GSH (dichloromethane, 
dichloroethane, bromobenzene).  In contrast, inducing Nrf2 and subsequently 
Gsts in cancer cells could lead to the ability to more readily activate 
chemotherapies, such as canfosfamide, to the reactive metabolite that kills 
cancer cells.  Canfosfamide is metabolized into two fragments by Gstp1, a 
Nrf2-dependent gene. The cytotoxic fragment reacts with RNA, DNA and 
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protein in the cancer cell leading to apoptosis.  The glutathione analogue 
fragment remains bound to Gstp1 and prevents it from causing chemotherapy 
resistance. So, canfosfamide not only kills cancer cells directly, but also helps 
other chemotherapy drugs work more efficiently (McIntyre and Castaner, 
2004).   
The first two studies showed that Nrf2, when activated 
pharmacologically, protects from chemical-induced liver injury by up-
regulating cytoprotective genes.  Further studies in a genetic mouse model of 
Nrf2 activation showed that hepatic Nrf2 induces genes mainly responsible for 
the detoxification of electrophiles and not genes that detoxify reactive oxygen 
species.   In addition, the increase of Nrf2-regulated cytoprotective genes 
resulted in more favorable kinetic profiles of AA and BSP for their 
detoxification and elimination.  Overall, inductive control over a broad array of 
genes that facilitate increased detoxification and clearance of reactive 
metabolites and xenobiotics has earned Nrf2 a crucial role in toxicology and 
xenobiotic metabolism.  For toxicology, Nrf2 must be considered as a means 
of protection and a potential target for treatment after poisoning. For 
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pharmacology, Nrf2 must be considered in drug development especially for 
drugs that are biotransformed by Ugts and/or Gsts or transported by Mrps as 
kinetics could be drastically and unfavorably altered.  
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